<SEC-DOCUMENT>0001564590-17-006306.txt : 20170410
<SEC-HEADER>0001564590-17-006306.hdr.sgml : 20170410
<ACCEPTANCE-DATETIME>20170410171113
ACCESSION NUMBER:		0001564590-17-006306
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20170522
FILED AS OF DATE:		20170410
EFFECTIVENESS DATE:		20170410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		17754227

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>cytx-def14a_20170522.htm
<DESCRIPTION>DEF 14A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cytx-def14a_20170522.htm
</title>
</head>
<!-- NG Converter v4.0.6.19 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:16pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /><font style="font-size:12pt;">Washington, D.C. 20549</font></p>
<p style="text-align:center;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:28.57%;margin-right:28.57%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:16pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 14A<br /><br /><font style="font-size:12pt;">Proxy Statement Pursuant to Section 14(a) of the <br /></font><font style="font-size:14pt;">Securities Exchange Act of 1934</font></p>
<p style="text-align:center;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:28.57%;margin-right:28.57%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed by the Registrant <font style="font-family:MS Gothic;">&#9746;</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed by a Party other than the Registrant <font style="font-family:MS Gothic;">&#9744;</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box:</p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Preliminary Proxy Statement</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Definitive Proxy Statement</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Definitive Additional Materials</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CYTORI THERAPEUTICS, INC.<br /><font style="font-weight:normal;font-size:10pt;">(Name of Registrant as Specified In Its Charter)</font></p>
<p style="border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:14.29%;margin-right:14.29%;text-indent:0%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of Filing Fee (Check the appropriate box):</p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;<font style="font-family:Times New Roman;">&nbsp;&nbsp;No fee required</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Title of each class of securities to which transaction applies:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Aggregate number of securities to which transaction applies:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Proposed maximum aggregate value of transaction:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Total fee paid:</p></td></tr></table></div>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Fee paid previously with preliminary materials.</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:3.57%;text-indent:-3.57%;font-family:MS Gothic;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&nbsp;&nbsp;Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Amount Previously Paid:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Form, Schedule or Registration Statement No.:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Filing Party:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Date Filed:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g20170410210543884557.jpg" title="" alt="" style="width:221px;height:98px;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTICE OF 2017 ANNUAL MEETING OF STOCKHOLDERS </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />TO BE HELD ON MAY 22, 2017</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.01%;"></td>
<td style="width:49.99%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br />CYTORI THERAPEUTICS, INC.<br />Headquarters<br /><font style="font-weight:normal;">3020 CALLAN RD<br />SAN DIEGO, CALIFORNIA 92121</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meeting Location<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:44.25pt;;text-indent:-44.25pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CYTORI THERAPEUTICS, INC<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3020 CALLAN RD<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN DIEGO, CALIFORNIA 92121</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Cytori Therapeutics, Inc. Stockholder:</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You are cordially invited to attend the 2017 Annual Meeting of the stockholders of Cytori Therapeutics, Inc. (the &#8220;Annual Meeting&#8221;).&nbsp;&nbsp;The Annual Meeting will be held on May 22, 2017, commencing at 9:00 a.m., San Diego local time, at the Cytori Therapeutics, Inc. corporate offices, located at 3020 Callan Rd., San Diego, California 92121.</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The meeting will be webcast live for those who are unable to attend in person. To access the webcast of the meeting, please visit the Investor Relations section of our corporate website at ir.cytori.com. To vote online, please see the instructions on the accompanying proxy card.</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The items of business for the meeting are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Election of members of our Board of Directors for a one-year term;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2017 fiscal year;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Approval of the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:4pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.</p></td></tr></table></div>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors recommends the approval of each of these proposals.</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have attached a Proxy Statement that contains more information about these items and the Annual Meeting.&nbsp;&nbsp;Only stockholders that own stock at the close of business on March 23, 2017, the record date, can vote at the Annual Meeting.&nbsp;&nbsp;A list of our stockholders entitled to vote will be available for inspection by any stockholder at our offices in San Diego, during normal business hours for ten business days prior to the Annual Meeting. This list will also be available during the Annual Meeting.</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted by rules adopted by the U.S. Securities and Exchange Commission, we are using the Internet as our primary means of furnishing proxy materials to our stockholders. We will send our stockholders a notice with instructions for accessing the proxy materials and voting electronically over the Internet or by telephone.&nbsp;&nbsp;The notice also provides information on how stockholders may request paper copies of our proxy materials.&nbsp;&nbsp;For those stockholders who elect to receive their proxy materials in the mail, please review the Proxy Statement and Annual Report and vote using the enclosed proxy card.</p>
<p style="margin-bottom:4pt;margin-top:0pt;text-indent:7.69%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hope that you will find it convenient to attend the Annual Meeting in person.&nbsp;&nbsp;Whether or not you expect to attend, please <font style="color:#000000;">vote electronically over the Internet or by telephone, or if you receive a proxy card in the mail, by mailing the completed proxy card to us </font>to ensure your representation at the Annual Meeting and the presence of a quorum.&nbsp;&nbsp;If you decide to attend the meeting and wish to change your proxy vote, you may do so by voting in person at the Annual Meeting.&nbsp;&nbsp;If your shares are held in the name of a bank or broker, however, you must obtain a legal proxy from the bank or broker to attend the Annual Meeting and vote in person.</p>
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Order of the Board of Directors,</p>
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g20170410210544195557.jpg" title="" alt="" style="width:254px;height:68px;"></p>
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MARC H. HEDRICK</p>
<p style="margin-bottom:4pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-style:italic;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President &amp; Chief Executive Officer</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California, USA<br />April 10, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">YOUR VOTE IS IMPORTANT!</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALL STOCKHOLDERS ARE INVITED TO ATTEND THE ANNUAL MEETING IN PERSON. WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, WE ENCOURAGE YOU TO READ THIS PROXY STATEMENT AND SUBMIT YOUR PROXY OR VOTING INSTRUCTIONS AS SOON AS POSSIBLE. THIS WILL ENSURE THE PRESENCE OF A QUORUM AT THE MEETING. FOR SPECIFIC INSTRUCTIONS ON HOW TO VOTE YOUR SHARES, PLEASE REFER TO THE INSTRUCTIONS ON THE NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS (THE &#8220;NOTICE&#8221; ) YOU RECEIVED IN THE MAIL, THE QUESTION &#8220;WHAT DIFFERENT METHODS CAN I USE TO VOTE?&#8221; IN THIS PROXY STATEMENT, OR, IF YOU REQUESTED PRINTED PROXY MATERIALS, YOUR ENCLOSED PROXY CARD. IF YOU ATTEND THE MEETING, YOU MAY VOTE IN PERSON IF YOU WISH TO DO SO EVEN IF YOU HAVE PREVIOUSLY SUBMITTED YOUR PROXY OR VOTING INSTRUCTIONS<font style="font-weight:normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cytori Therapeutics, Inc.<br />3020 Callan Road<br />San Diego, CA 92121<br />(858) 458-0900</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROXY STATEMENT</p>
<p style="text-align:center;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MAY 22, 2017</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">This Proxy Statement and the Company&#8217;s 2016 Annual Report are both available at www.proxyvote.com.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cytori </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics, Inc.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />3020 Callan Road</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />San Diego, CA 92121</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />(858) 458-0900</font></p>
<p style="margin-bottom:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROXY STATEMENT</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017 ANNUAL MEETING OF STOCKHOLDERS</p>
<p style="margin-bottom:10pt;text-align:center;margin-top:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The 2016 Annual Report to Stockholders, including financial statements, is being made available to stockholders together with these proxy materials on or about April 10, 2017.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Proxy Statement is being furnished in connection with the solicitation of proxies by and on behalf of our Board of Directors (&#8220;Board&#8221;) to be used at our Annual Meeting of Stockholders to be held on May 22, 2017 at 9:00 a.m., San Diego local time (&#8220;Annual Meeting&#8221;), and at any adjournment or postponement of the Annual Meeting, for the purposes set forth in the accompanying notice of Annual Meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have fixed the close of business on March 23, 2017 as the record date for the determination of the stockholders entitled to notice of and to vote at the Annual Meeting. Only holders of record of shares of our common stock on that date are entitled to notice of and to vote at the Annual Meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Questions and Answers about the Meeting and Voting</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q: What is a Proxy Statement and why has this Proxy Statement been provided to me?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;A Proxy Statement is a document that the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regulations require us to give you when we ask you to sign a proxy card with regard to voting on proposals at the Annual Meeting.&nbsp;&nbsp;Among other things, a Proxy Statement describes those proposals and provides information about us.&nbsp;&nbsp;Our Board is soliciting your proxy to vote at the Annual Meeting and at any adjournment or postponement of the Annual Meeting.&nbsp;&nbsp;The Annual Meeting will be held at the Cytori Therapeutics, Inc. corporate offices, located at 3020 Callan Road, San Diego, California 92121. We will use the proxies received in connection with proposals to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Elect members of our Board for a one-year term;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2017 fiscal year;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Approve the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.</p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;Why did I receive a notice in the mail regarding Internet availability of proxy materials this year instead of a full set of proxy materials?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>A:&nbsp;&nbsp;We provide access to our proxy materials on the Internet.&nbsp;&nbsp;Some stockholders (those who hold in &#8220;street name&#8221;) will not receive printed copies of the proxy materials unless requested. Instead, these stockholders will receive a Notice of Internet Availability of Proxy Materials (the &#8220;Notice&#8221;) that will instruct you as to how you may access and review the proxy materials on the Internet. The Notice explains how you may vote your proxy. If you </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received a Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting printed materia</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls included in the Notice.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What is a proxy?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;A proxy is your legal designation of another person to vote the stock you own.&nbsp;&nbsp;That designee is referred to as a proxy holder. Designation of a particular proxy holder can be effected by completion of a written proxy card, or by voting via the Internet or by telephone.&nbsp;&nbsp;Our President, Chief Executive Officer and Director, Marc H. Hedrick, M.D., our Chief Financial Officer, Tiago M. Gir&#227;o, and our General Counsel, Jeremy B. Hayden, have each been designated as the proxy holders for the Annual Meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What is the difference between a stockholder of record and a beneficial owner who holds stock in street name?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;You are a stockholder of record, or a &#8220;registered holder&#8221;, if your shares are registered in your own name through our transfer agent. <font style="color:#000000;">You are a beneficial owner of our stock in street name if you hold your shares through a broker, bank or other third party institution (in this situation, the banks, brokers, etc. are the stockholders of record).The vast majority of our stockholders are represented on our share register in the name of a bank, broker or other third party institution and not in their own name. If you have elected to hold your shares in certificate form, your name will appear directly on our register as a stockholder of record.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp; What different methods can I use to vote?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;If you are a registered holder and you are viewing this proxy over the Internet, you may vote electronically over the Internet. For those stockholders who receive a paper proxy in the mail, you may also vote electronically over the Internet or by telephone or by completing and mailing the proxy card provided. The website identified in our Notice provides specific instructions on how to vote electronically over the Internet. Those stockholders who receive a paper proxy by mail, and who elect to vote by mail, should complete and return the mailed proxy card in the prepaid and addressed envelope that was enclosed with the proxy materials.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are the beneficial owner of stock in street name, that is, your shares are held in the name of a brokerage firm, bank or other nominee, you will receive instructions from your broker, bank or other nominee that must be followed in order for you to vote your shares. Your broker will be sending you a Notice which contains instructions on how to access the website and to vote your shares. If, however, you have elected to receive paper copies of our proxy materials from your brokerage firm, bank or other nominee, you will receive a voting instruction form.&nbsp;&nbsp;Please complete and return the enclosed voting instruction form in the addressed, postage paid envelope provided.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders who have previously elected to access our proxy materials and annual report electronically over the Internet will continue to receive an email, referred to in this Proxy Statement as an email notice, with information on how to access the proxy information and voting instructions.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only proxy cards and voting instruction forms that have been signed, dated and timely returned and only proxies that have been timely voted electronically or by telephone will be counted in the quorum and voted.&nbsp;&nbsp;<font style="font-style:italic;">The Internet and telephone voting facilities will close at 11:59 p.m. Eastern Time, May 21, 2017.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders who vote over the Internet or by telephone need not return a proxy card or voting instruction form by mail, but may incur costs, such as usage charges, from telephone companies or Internet service providers.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may also vote your shares in person at the Annual Meeting. If you are a registered holder, you may request a ballot at the Annual Meeting. If your shares are held in street name and you wish to vote in person at the meeting, you must obtain a proxy issued in your name from your broker, bank or other nominee and bring it with you to the Annual Meeting. We recommend that you vote your shares in advance as described above so that your vote will be counted if you later decide not to attend the Annual Meeting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you receive more than one Notice, email notice, proxy card or voting instruction form because your shares are held in multiple accounts or registered in different names or addresses, please vote your shares held in </font><font style="font-style:italic;">each account </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ensure that all of your shares will be voted.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What is the record date and what does it mean?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;The record date for the 2017 Annual Meeting is March 23, 2017. The record date is established by our Board as required by Delaware General Corporation Law.&nbsp;&nbsp;Owners of our common stock at the close of business on the record date are entitled to receive notice of the meeting and to vote at the meeting and any adjournment or postponement of the meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;How can I change my vote?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;You may revoke your proxy and change your vote at any time before the final vote at the meeting.&nbsp;&nbsp;You can revoke a proxy by giving written notice or revocation to our Corporate Secretary, following the Internet voting instructions, delivering a later dated proxy, or voting in person at the meeting. However, your attendance at the Annual Meeting will not automatically revoke your proxy unless you vote again at the meeting or specifically request in writing that your proxy be revoked.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What are my voting choices when voting for director nominees and what vote is needed to elect directors?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;In voting on the election of director nominees to serve until the 2018 Annual Meeting, stockholders may vote in favor of each nominee, or may withhold votes as to each nominee. In addition, if any other candidates are properly nominated at the meeting, stockholders of record who attend the meeting could vote for the other candidates. Directors will be elected by the affirmative vote of a majority of the shares of common stock present in person or represented by proxy and entitled to vote at the meeting, provided a quorum is present.&nbsp;&nbsp;Stockholders are not entitled to cumulative voting rights with respect to the election of directors.&nbsp;&nbsp;Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes &#8220;AGAINST&#8221; this proposal. Broker non-votes with respect to this proposal will not be considered as present and entitled to vote on this proposal, which will therefore reduce the number of affirmative votes needed to approve this proposal.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Board recommends a vote &#8220;FOR&#8221; each of the director nominees identified in this Proxy Statement.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What are my voting choices when voting to ratify the appointment of our independent registered public accounting firm, and what vote is needed to ratify the appointment?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;In voting on the ratification of the appointment our independent registered public accounting firm, stockholders may vote in favor of or against the appointment, or may abstain from voting on the appointment. The affirmative vote of a majority of the shares of common stock present in person or represented by proxy and voting at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the effect of a vote &#8220;AGAINST&#8221; this proposal. Brokers have discretionary authority to vote on this proposal; broker non-votes will have no effect on this proposal.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Board recommends a vote &#8220;FOR&#8221; ratification</font>.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What are my voting choices when voting to approve the amendment and restatement of our 2014 Equity Incentive Plan?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>A:&nbsp;&nbsp;In voting on the approval of the amendment and restatement of our 2014 Equity Incentive Plan, stockholders may vote in favor of the approval or against the approval, or may abstain from voting. The affirmative vote of a majority of the shares present in person or represented by proxy at the meeting and entitled to vote on such proposal is required to approve this proposal. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes &#8220;AGAINST&#8221; this proposal. Broker non-votes with respect to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this proposal will not be considered as present and entitled to vote on this proposal, which will therefore reduce the number of affirmative votes needed to approve this proposal.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Board recommends a vote &#8220;FOR&#8221; approval of an amendment to our 2014 Equity Incentive Plan</font>.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;What are my voting choices when voting, on an advisory basis, on the frequency of holding future non-binding advisory votes on executive officer compensation?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;In voting, on an advisory basis, on the frequency of holding non-binding advisory votes on executive officer compensation, or &#8220;say-on-pay,&#8221; stockholders may vote to have the say-on-pay vote every year, every two years, or every three years, or may abstain from voting. The option of every year, every two years or every three years that receives the affirmative vote of holders of a majority of shares present in person or by proxy and entitled to vote on the proposal will be the frequency recommended by stockholders for the advisory vote on the compensation of our executive officers, unless none of the frequency options receives a majority vote, in which case the option that receives the highest number of votes will be considered to be the frequency recommended by stockholders. Abstentions have the same effect as a vote against each of the frequency options. Broker non-votes are not counted for any purpose in determining which frequency option has been recommended by stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Board recommends that stockholders vote to hold future non-binding stockholder advisory votes on executive officer compensation, or &#8220;say-on-pay&#8221; votes, &#8220;EVERY YEAR</font><font style="font-weight:normal;">.&#8221; </font>Stockholders are not voting to approve or disapprove the Board&#8217;s recommendation. Stockholders may choose among the four choices (every year, every two years, every three years or abstain from voting) set forth above.&nbsp;&nbsp;The Board will consider any significant vote in favor of one frequency over the other options and will evaluate the appropriate next step<font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;How will a proxy get voted?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;If you properly complete and return a proxy card or vote by Internet or by telephone, the designated proxy holders will vote your shares as you have directed. If you sign a proxy card but do not make specific choices or if you vote by Internet or telephone but do not make specific choices, the designated proxy holders will vote your shares as recommended by the Board as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;">FOR</font><font style="font-family:Times New Roman;">&#8221; the election of each listed nominee for director;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;">FOR</font><font style="font-family:Times New Roman;">&#8221; ratification of BDO USA, LLP as our independent registered public accounting firm for the 2017 fiscal year;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">&#8220;FOR&#8221; </font><font style="font-family:Times New Roman;">approval of the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">for approval of the frequency of holding future non-binding advisory votes on executive officer compensation </font><font style="font-weight:bold;font-family:Times New Roman;">EVERY YEAR</font><font style="font-family:Times New Roman;">.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp; How are abstentions and broker non-votes counted?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;Abstentions and broker non-votes will be counted as present for purposes of determining a quorum.&nbsp;&nbsp;&nbsp;&nbsp;An abstention occurs when a stockholder withholds his or her vote by checking the &#8220;abstain&#8221; box on the proxy card or (if present and voting at the meeting) a ballot.&nbsp;&nbsp;A broker non-vote occurs when a broker, bank, or other stockholder of record, in nominee name or otherwise, exercising fiduciary powers submits a proxy for the Annual Meeting, but does not vote on a particular proposal because that holder does not have discretionary voting power with respect to that proposal and has not received voting instructions from the beneficial owner.&nbsp;&nbsp; Under the rules that govern brokers who are voting with respect to shares held in street name, brokers have the discretion to vote those shares on routine matters, but not on non-routine matters.&nbsp;&nbsp;Routine matters include the ratification of the appointment of our independent registered public accounting firm. Non-routine matters include the election of directors and the other proposals in this proxy statement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp; Who pays for the solicitation of proxies?</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;We pay the entire cost of the solicitation of proxies.&nbsp;&nbsp;This includes preparation, assembly, printing, and mailing of the Notice, this Proxy Statement and any other information we send to stockholders.&nbsp;&nbsp;We may supplement our efforts to solicit your proxy in the following ways:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We may contact you using the telephone or electronic communication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Our directors, officers or other regular employees may contact you personally; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We may hire agents for the sole purpose of contacting you regarding your proxy.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we hire soliciting agents, we will pay them a reasonable fee for their services.&nbsp;&nbsp;We will not pay directors, officers or other regular employees any additional compensation for their efforts to supplement our proxy solicitation.&nbsp;&nbsp;We anticipate banks, brokerage houses and other custodians, nominees and fiduciaries will forward soliciting material to the beneficial owners of shares of common stock entitled to vote at the Annual Meeting and that we will reimburse those persons for their out-of-pocket expenses incurred in performing such services.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp; What constitutes a quorum?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;For business to be conducted at the Annual Meeting, a quorum must be present.&nbsp;&nbsp;A quorum exists when at least 33 &#8531; % of the holders of shares of our common stock issued, outstanding and entitled to vote are represented at the meeting.&nbsp;&nbsp;Shares of common stock represented in person or by proxy (including broker non-votes and shares that abstain or do not vote with respect to one or more of the matters to be voted upon) will be counted for the purpose of determining whether a quorum exists.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;How many votes may I cast? How many shares are eligible to be voted?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;You may cast one vote for every share of our common stock that you owned on the record date. As of the record date, March 23, 2017, there were 23,672,429 shares of common stock outstanding, each of which is entitled to one vote.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp; How will voting on any &#8220;other business&#8221; be conducted?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;Although we do not know of any business to be considered at the Annual Meeting other than the proposals described in this Proxy Statement, if any additional business is presented at the Annual Meeting, your signed proxy card gives authority to the designated proxy holders to vote on such matters according to their best judgment.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Q:&nbsp;&nbsp;Where can I find the voting results of the Annual Meeting?</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A:&nbsp;&nbsp;We will publish the final voting results in a current report on Form 8-K, which we expect to file with the SEC within four business days of the Annual Meeting. If the final voting results are unavailable in time to file a current report on Form 8-K with the SEC within four business days after the Annual Meeting, we intend to file a Form 8-K to disclose the preliminary results and, within four business days after the final results are known, we will file an additional current report on Form 8-K with the SEC to disclose the final voting results.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">PROPOSAL #1</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />ELECTION OF DIRECTORS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board currently consists of eight (8) persons.&nbsp;&nbsp;On March 31, 2017, Paul W. Hawran notified the Board that he did not intend to stand for re-election at the Annual Meeting.&nbsp;&nbsp;Effective upon Mr. Hawran&#8217;s departure, the size of the Board will be reduced to seven (7) directors.&nbsp;&nbsp;The Board, upon recommendation of our Governance and Nominating Committee, has nominated the following persons listed below for election as directors. The names of the seven (7) nominees for election as directors are set forth below (the ages shown are as of February 28, 2017). All of the nominees are currently serving as a member of our Board.&nbsp;&nbsp;All directors are elected annually and serve one-year terms until the next Annual Meeting, or until their respective successors are duly elected. All of the nominees listed below are expected to serve as directors if they are elected.&nbsp;&nbsp;If any nominee should decline or be unable to accept such nomination or to serve as a director, an event which our Board does not now expect, our Board reserves the right to nominate another person or to vote to reduce the size of our Board.&nbsp;&nbsp;If another person is nominated, the proxy holders intend to vote the shares to which the proxy relates for the election of the persons nominated by our Board.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information on nomination of directors, see &#8220;Director Nominations&#8221; below in the section entitled &#8220;Corporate Governance.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Board recommends a vote &#8220;FOR&#8221; the nominees named below<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Nominees</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David M. Rickey</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, MD</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Hawkins</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gregg A. Lapointe</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Lyons</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ronald A. Martell</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gail K. Naughton, Ph.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:28.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">David M. Rickey <font style="font-style:normal;">has served on our Board since November 1999 and has served as the Chairman of our Board since June 2013.&nbsp;&nbsp;Mr. Rickey was previously President and Chief Executive Officer of Applied Micro Circuits Corporation, or AMCC, a publicly-held company that provides high-performance, high-bandwidth silicon solutions for optical networks, from February 1996 to March 2005.&nbsp;&nbsp;Mr. Rickey served on the Board of AMCC from February 1996 to March 2005, and as its Chairman from August 2000 to March 2005. Mr. Rickey also served as a director of AMI Semiconductor, Inc. from 2000 to 2006 and was a director of Netlist, Inc. from 2005 to 2008, as well as several private technology companies.&nbsp;&nbsp;He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.&nbsp;&nbsp;Mr. Rickey&#8217;s qualifications to sit on our Board include his extensive executive experience and his service on other public company boards and committees.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D. <font style="font-style:normal;">was appointed as Chief Executive Officer of the Company in April 2014. He was appointed as President of the Company in May 2004, and joined us as Chief Scientific Officer and Medical Director in October 2002.&nbsp;&nbsp;Dr. Hedrick has also served as a member of our Board since October 2002.&nbsp;&nbsp;In December 2000, Dr. Hedrick co-founded and served as President and Chief Executive Officer and Director of StemSource, Inc., a privately-held company specializing in stem cell research and development, which was acquired by us in 2002.&nbsp;&nbsp;He is a plastic surgeon and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles, or UCLA.&nbsp;&nbsp;From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA.&nbsp;&nbsp;Dr. Hedrick earned his M.D. degree from University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.&nbsp;&nbsp;Dr. Hedrick&#8217;s qualifications to sit on our Board include his experience as a general, vascular and plastic surgeon; his academic appointments and achievements in the life sciences; his executive and managerial experience in stem cell research and scientific product development; and his foundational knowledge and experience of and contributions to our technology and operations.&nbsp;&nbsp; In addition, Dr. Hedrick has extensive global experience and familiarity with the cell therapy and regenerative medical industry.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Richard J. Hawkins </font><font style="font-style:normal;">has served on our Board since December 2007.</font><font style="font-style:normal;">&nbsp;&nbsp;In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization, or CRO, that merged with the predecessor of PPD-Pharmaco in 1991 and is one of the largest CROs in the world today.&nbsp;&nbsp;In 1992, Mr. Hawkins co-founded Sensus Drug Development Corporat</font><font style="font-style:normal;">ion, or SDDC, a privately-held company focused on the treatment of drugs to treat endocrine disorders, which developed and received regulatory approval for SOMAVERT&#174;, a growth hormone antagonist approved for the treatment of acromegaly, which is now market</font><font style="font-style:normal;">ed by Pfizer, Inc., and he served as Chairman of SDDC until 2000.&nbsp;&nbsp;In 1994, Mr. Hawkins co-founded Corning Biopro, a contract protein manufacturing firm, where he served on the Board until Corning BioPro&#8217;s sale to Akzo-Nobel, N.V., a publicly-held producer</font><font style="font-style:normal;"> of paints, coatings and specialty chemicals, in 2000.&nbsp;&nbsp;In September 2003 Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and CEO until October 2009.&nbsp;&nbsp;Mr. Hawkins has</font><font style="font-style:normal;"> served on the Board of SciClone Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company, since October 2004.&nbsp;&nbsp;In February 2011, Mr. Hawkins became CEO, and is currently CEO, of Lumos Pharma, Inc., a privately-held pharmaceutical company. H</font><font style="font-style:normal;">e served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas.&nbsp;&nbsp;Mr. </font><font style="font-style:normal;">Hawkins graduated cum laude with a B.S. in Biology from Ohio University.&nbsp;&nbsp;Mr. Hawkins&#8217;s qualifications to sit on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical research and develo</font><font style="font-style:normal;">pment, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Gregg A. Lapointe<font style="font-style:normal;"> has served on our Board since March 2017.&nbsp;&nbsp;Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company. From April 2008 to March 2012, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.pA. He served as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from November 2003 to March 2008. Mr. Lapointe also serves on the boards of SciClone Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company (since March 2009), Soligenix, Inc., a publicly-held biopharmaceutical company (since March 2009), Immunocellular Therapeutics, Ltd., a publicly held pharmaceutical company (since September 2015) and S1Biopharma, Inc. a privately held biopharmaceutical company.&nbsp;&nbsp; Mr. Lapointe previously served as a director of Raptor Pharmaceuticals Corp. from December 2014 until its acquisition by Horizon Pharma plc in October 2016.&nbsp;&nbsp;Mr. Lapointe is a Certified Public Accountant in the United States.  He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and an M.B.A. from Duke University.&nbsp;&nbsp;Mr. Lapointe&#8217;s qualifications to sit on our Board include his substantial experience in finance, management and specialty drug commercialization, including operational experience as the CEO of a pharmaceutical development and sales organization.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Gary A. Lyons <font style="font-style:normal;">has served on our Board since October 2013. Mr. Lyons has served on the Board of Neurocrine Biosciences, Inc., or Neurocrine, since 1993 and served as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons has served on the Boards of Rigel Pharmaceuticals, Inc., a publicly-held biotechnology company, since October 2005 (and as Chairman since November 2014); Vical Incorporated, a publicly-held biopharmaceutical company, since 1997; and Retrophin, Inc., a publicly-held biopharmaceutical company, since 2014 (and as Chairman since May 2016).&nbsp;&nbsp;Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx, KaloBios Pharmaceuticals, Inc. and Facet Biotech Corporation. Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University&#8217;s J.L. Kellogg Graduate School of Management.&nbsp;&nbsp;Mr. Lyons&#8217; qualifications to sit on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical business development, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>Ronald A. Martell <font style="font-style:normal;">has served on our Board since December 2016.&nbsp;&nbsp; Mr. Martell has more than 25 years&#8217; experience building and managing unique businesses in the biotech industry.&nbsp;&nbsp;Mr. Martell is currently a founder of Achieve Life Sciences, ORCA BioSystems, Inc. and Cetya Therapeutics, Inc.&nbsp;&nbsp;Most recently he served as Chief Executive Officer of Sevion Therapeutics and Executive Chairman of KaloBios Pharmaceuticals, Inc.&nbsp;&nbsp;Prior to Sevion, Mr. Martell was President and CEO of NeurogesX, Inc. and sold the company&#8217;s assets to Acorda </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">Therapeutics. Prior to NeurogesX he was Chief Executive Officer of Poniard Pharmaceuticals.&nbsp;&nbsp;Befo</font><font style="font-style:normal;">re joining Poniard he served as Senior Vice President of Commercial Operations at ImClone Systems. Mr. Martell built ImClone Systems&#8217; Commercial Operations and field sales force to market and commercialize Erbitux&#174; with partners Bristol-Myers Squibb and Me</font><font style="font-style:normal;">rck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for ten years at Genentech, Inc., or Genentech, in a variety of positions, the last of which was Group Manager, Oncology Products. At Genentech, he was responsible for the launch of Herceptin&#174; </font><font style="font-style:normal;">for metastatic HER-2 positive breast cancer and Rituxan&#174; for non-Hodgkin&#8217;s lymphoma.&nbsp;&nbsp;Mr. Martell began his career at Roche Pharmaceuticals. Mr. Martell&#8217;s qualifications to sit on our Board include his executive experience working for life sciences compani</font><font style="font-style:normal;">es, his extensive experience in pharmaceutical business development, his knowledge, understanding of and experience in developing and commercializing pharmaceutical products, and his service on other public company boards and committees.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Gail K. Naughton, Ph.D., <font style="font-style:normal;">has served on our Board since July 2014.&nbsp;&nbsp;Dr. Naughton is the founder of Histogen, Inc., or Histogen, a private regenerative medicine company developing innovative therapies based upon the products of cells grown under simulated embryonic conditions. She has served as Histogen&#8217;s Chief Executive Officer and Chairman of the Board since the company&#8217;s inception in 2007.&nbsp;&nbsp;Prior to that, Dr. Naughton held key management positions, including President, Chief Operating Officer and Director, at Advanced Tissue Sciences, a company which she co-founded and was co-inventor of the core technology. Dr. Naughton has also served on the Board of C.R. Bard, Inc. since July 2004.&nbsp;&nbsp;Dr. Naughton holds a B.S. in Biology from St. Francis College as well as a Master&#8217;s in Histology and a Ph.D. from New York University Medical Center. She also holds an EMBA from the Anderson School of Business at the University of California, Los Angeles.&nbsp;&nbsp;Dr. Naughton&#8217;s qualifications to sit on our Board include her extensive executive experience, her in-depth knowledge of the healthcare industry and regenerative medicine technology, and her service on other public company boards and committees.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Required Vote</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nominees will be elected by an affirmative vote of a majority of the shares present in person or by proxy at the Annual Meeting and entitled to vote on such proposal, assuming a quorum is present. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal. Broker non-votes will not be considered as present and entitled to vote on this proposal, which will therefore reduce the number of affirmative votes needed to approve this proposal. Stockholders do not have cumulative voting rights in the election of directors.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; THE NOMINEES TO THE BOARD NAMED ABOVE.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">PROPOSAL #2</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Audit Committee has selected BDO USA, LLP, or BDO, as our independent registered public accounting firm for the fiscal year ending December 31, 2017, and has further directed that we submit the selection of the independent registered public accounting firm for ratification by our stockholders at the Annual Meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BDO has served as our independent registered public accounting firm since July 2016. Prior to commencement of BDO&#8217;s services, KPMG, LLP, or KPMG, served as our independent registered public accounting firm. The selection of the independent registered public accounting firm is not required to be submitted for stockholder approval. However, if the stockholders do not ratify this selection, the Audit Committee will reconsider its selection of BDO. Even if the selection is ratified, our Audit Committee may direct the appointment of a different independent accounting firm at any time during the year if the Audit Committee determines that the change would be in the Company&#8217;s best interests.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representatives of BDO will be present at the Annual Meeting and will have an opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions from stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information concerning the Audit Committee and BDO can be found in the &#8220;Audit Matters&#8221; section of this Proxy Statement.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Required Vote</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proposal to ratify the appointment of BDO requires the affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such proposal. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal. Because brokers have discretionary authority to vote on this proposal, we do not expect any broker non-votes in connection with this proposal.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; THE RATIFICATION OF THE SELECTION OF BDO USA, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2017<font style="font-weight:normal;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">PROPOSAL #3</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />APPROVAL OF AMENDMENT AND RESTATEMENT OF THE </font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />CYTORI T</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">HERAPEUTICS, INC.</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />2014 EQUITY INCENTIVE PLAN</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stockholders are being asked to approve the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan.&nbsp;&nbsp;The Cytori Therapeutics, Inc. 2014 Equity Incentive Plan, as amended, as in effect prior to March 31, 2017 is referred to herein as the &#8220;2014 Plan.&#8221;&nbsp;&nbsp;On March 31, 2017, our Board approved the amendment and restatement of the 2014 Plan, subject to stockholder approval.&nbsp;&nbsp;The amended and restated 2014 Plan is referred to herein as the &#8220;Restated Plan.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All share numbers in this proposal have been adjusted to reflect the 1-for-15 reverse stock split that was effected in May 2016.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview of Proposed Amendments and Key Features</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Increase in Share Reserve; ISO Limit.&nbsp;&nbsp;<font style="font-weight:normal;font-style:normal;">Our Board believes that approval of Restated Plan is in the best interests of our Company and stockholders because the availability of an adequate number of shares reserved for issuance under our equity compensation plan is an important factor in attracting, motivating and retaining qualified individuals essential to our success.&nbsp;&nbsp;As of March 31, 2017, a total of 900,133 shares of our common stock were reserved under the 2014 Plan, the aggregate number of shares of common stock subject to awards under the 2014 Plan was 869,838 and 20,891 shares of common stock remained available under the 2014 Plan for future issuance.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Restated Plan, an additional 2,000,000 shares will be reserved for issuance under the Restated Plan over the existing share reserve under the 2014 Plan.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2017, our Board granted to Gregg A. Lapointe, one of our non-employee directors, stock options to purchase an aggregate of 50,000 shares of our common stock under the Restated Plan, which awards were granted out of the proposed share reserve increase and are subject to stockholder approval of the Restated Plan (the &#8220;Contingent Options&#8221;).&nbsp;&nbsp;After giving effect to the Contingent Options, and assuming approval of this proposal, as of March 31, 2017, a total of 1,970,891 shares remained available for issuance under the Restated Plan.&nbsp;&nbsp; The Company may grant further awards to employees, including executive officers, and consultants under the Restated Plan prior to the Annual Meeting in the ordinary course of business, which awards will also be Contingent Options that are subject to stockholder approval of the Restated Plan.&nbsp;&nbsp;In the event stockholder approval of the Restated Plan is not obtained, all of the Contingent Options will automatically be forfeited, the Restated Plan will cease to be effective and the original 2014 Plan in effect prior to the adoption of the Restated Plan will continue in full force and effect.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Restated Plan, the maximum number of shares of common stock that may be issued or transferred pursuant to incentive stock options (&#8220;<font style="color:#000000;">ISOs</font>&#8221;), as defined under Section 422(b) of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="color:#000000;">Code</font>&#8221;), under the Restated Plan shall be increased from 900,133 to 2,900,133 shares.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the foregoing numbers shall be subject to adjustment pursuant to the terms of the Restated Plan in the event of certain corporate events as described below under &#8220;<font style="color:#000000;">Adjustments for Capital Structure Changes</font>.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Extension of Term.&nbsp;&nbsp;<font style="font-weight:normal;font-style:normal;">The term of the Restated Plan will also be extended for a new ten-year term so that the Restated Plan will terminate on March 30, 2027.&nbsp;&nbsp;The 2014 Plan is currently set to terminate in February 2024.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>Stockholder Approval Under Section 162(m) of the Code. <font style="font-weight:normal;font-style:normal;"> Our stockholders are being asked to approve the Restated Plan to satisfy the stockholder approval requirements of Section 162(m) (&#8220;</font><font style="color:#000000;font-weight:normal;font-style:normal;">Section 162(m)</font><font style="font-weight:normal;font-style:normal;">&#8221;) of the Code and to approve the material terms of the performance goals for awards that may be granted under the Restated Plan as required under Section 162(m). In general, Section 162(m) places a limit on the deductibility for federal income tax purposes of the compensation paid to our Chief Executive Officer or any of our three other most highly compensated executive officers (other than our Chief Financial Officer). Under Section 162(m), compensation paid to such persons in excess of $1 million in a taxable year generally is not deductible. However, compensation that qualifies as &#8220;performance-based&#8221; under Section 162(m) does not count against the $1 million deduction limitation. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">One of the requirements of &#8220;performance-based&#8221; compensation for purposes of Section 162(m) is that the material terms of the plan under which compensation may be paid be disclosed to an</font><font style="font-weight:normal;font-style:normal;">d approved by our public stockholders. For purposes of Section 162(m), the material terms include (1) the employees eligible to receive compensation, (2) a description of the business criteria on which the performance goals may be based and (3) the maximum</font><font style="font-weight:normal;font-style:normal;"> amount of compensation that can be paid to an employee under the performance goals. Each of these aspects of the Restated Plan is discussed below, and stockholder approval of this Proposal 3 is intended to constitute approval of the material terms of the </font><font style="font-weight:normal;font-style:normal;">Restated Plan for purposes of the stockholder approval requirements of Section 162(m).</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholder approval of the Restated Plan is only one of several requirements under Section 162(m) that must be satisfied for amounts realized under the Restated Plan to qualify for the &#8220;performance-based&#8221; compensation exemption under Section 162(m), and submission of the material terms of the Restated Plan performance goals for stockholder approval should not be viewed as a guarantee that we will be able to deduct all compensation under the Restated Plan. Nothing in this Proposal 3 precludes us or the plan administrator from making any payment or granting awards that do not qualify for tax deductibility under Section 162(m).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Individual Award Limits.&nbsp;&nbsp;<font style="font-weight:normal;font-style:normal;">T</font><font style="color:#000000;font-weight:normal;font-style:normal;">he Restated Plan imposes limits on the awards that may be granted to any person under the Restated Plan as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The maximum number of shares of our common stock that may be subject to one or more options or SARs granted to any one person pursuant to the Restated Plan during any fiscal year is 2,000,000 shares.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The maximum number of shares of our common stock that may be subject to one or more awards (other than options or SARs) granted to any one person pursuant to the Restated Plan during any fiscal year is 2,000,000 shares.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The maximum amount that may be paid under cash awards pursuant to the Restated Plan to any one participant during any fiscal year is $5,000,000. </font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing limits represent changes from the individual award limits under the 2014 Plan, which, after giving effect to our 1-for-15 reverse stock split effected in May 2016, were as follows:<font style="color:#000000;">&nbsp;&nbsp;(1) under the 2014 Plan, no employee could be granted within any fiscal year one or more options or SARs intended to qualify as performance-based compensation to purchase more than 133,333 shares under options or to receive compensation calculated with reference to more than that number of SARs (this number was 200,000 for a newly hired employee); (2) under the 2014 Plan, no employee could be granted within any fiscal year one or more &#8220;full value&#8221; awards intended to qualify as performance-based compensation which, in the aggregate, could result in the employee receiving more than 100,000 shares for each fiscal year in a performance period for such award participant (this number was 133,333 for a newly hired employee); and (3) with respect to a performance-based award under the 2014 Plan payable in cash, the maximum amount was $5,000,000 for each fiscal year in the performance period for such award.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Limits<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Restated Plan continues the limits on non-employee director compensation as were in effect under the 2014 Plan.&nbsp;&nbsp;Under the Restated Plan, the total aggregate value of cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of awards granted to a non-employee director as compensation for services as a non-employee director during any calendar year under the Restated Plan may not exceed $500,000 (increased to $700,000 in the calendar year of a non-employee director&#8217;s initial service as a non-employee director). The Board may make exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the Board may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Restated Plan does not amend the 2014 Plan in any material respect other than to reflect the changes described above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key Features Designed to Protect Stockholders&#8217; Interests</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The design of the Restated Plan reflects our commitment to strong corporate governance and the desire to preserve stockholder value as demonstrated by the following features of the plan:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Independent administrator</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Compensation Committee of the Board of Directors, which is comprised solely of non-employee directors, administers the Restated Plan.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">No evergreen feature</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The maximum number of shares available for issuance under the Restated Plan is fixed and cannot be increased without stockholder approval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;color:#000000;">No Single-Trigger Vesting of Awards.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;The Restated Plan does not have single-trigger accelerated vesting provisions for changes in control.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Repricing and reloading prohibited</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Stockholder approval is required for any repricing, replacement, or buyout of underwater awards.&nbsp;&nbsp;In addition, no new awards are granted automatically upon the exercise or settlement of any outstanding award.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;color:#000000;">Limitations on Dividend Payments on Awards.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;Dividends and dividend equivalents may not be paid on awards subject to vesting conditions unless and until such conditions are met.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">No discount awards; maximum term specified</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Stock options and stock appreciation rights must have an exercise price or base price no less than the fair market value on the date the award is granted and a term no longer than ten years&#8217; duration.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Award design flexibility</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Different kinds of awards may be granted under the Restated Plan, giving us the flexibility to design our equity incentives to compliment the other elements of compensation and to support the attainment of our strategic goals.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Share counting</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The number of shares remaining for grant under the Restated Plan is reduced by the gross number of shares subject to options and stock appreciation rights settled on a net basis, and shares withheld for taxes in connection with options or stock appreciation rights or tendered in payment of an option&#8217;s exercise price are not recycled.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Non-employee director limits</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Restated Plan contains a limit on the compensation that may be paid to any non-employee member of our Board in any calendar year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Limitations on Grants</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;As described below, the Restated Plan establishes limits on the number of shares for which awards may be granted to any person in any fiscal year and the maximum amount that may be paid in cash during any fiscal year with respect to cash-based awards.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">No tax gross-ups</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Restated Plan does not provide for tax gross-ups.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Fixed term</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Restated Plan has a fixed term of ten years.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares Available Under the Plan and Historical Use of Equity</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have operated, and continue to operate in a challenging marketplace in which our success depends to a great extent on our ability to attract and retain employees, directors, and other service providers of the highest caliber.&nbsp;&nbsp;One of the tools our Board regards as essential in addressing these challenges is a competitive equity incentive program.&nbsp;&nbsp;Our equity incentive program is designed to provide a vehicle under which a variety of stock-based and other awards can be granted to service providers (including, employees, consultants, and directors) of our company (and its subsidiaries) which align the interests of award recipients with those of our stockholders, reinforce key goals and objectives that help drive stockholder value, and attract, motivate and retain experienced and highly qualified individuals who will contribute to our success.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the Restated Plan is authorized and approved by our stockholders, the number of shares available for issuance under the 2014 Plan will be too limited to effec</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tively achieve its purpose as an incentive and retention tool for employees, directors and consultants that benefits all of our stockholders.&nbsp;&nbsp;The proposed increase in the share reserve under the Restated Plan over the existing share reserve under the 2014</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Plan will enable us to continue our policy of equity ownership by employees, directors and consultants as an incentive to contribute to our success.&nbsp;&nbsp;Without sufficient equity awards to effectively attract, motivate and retain employees, we may be forced </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to consider cash replacement alternatives to provide a market-competitive total compensation package necessary to attract, retain and motivate the individual talent critical to the future success of our company. These cash replacement alternatives would th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">en reduce the cash available for other purposes. Our equity incentive program is broad-based. As of March 31, 2017, 38 of our approximately 65 employees had received grants of equity awards, all seven of our non-employee directors had received grants of eq</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uity awards and none of our consultants had received grants of equity awards. We have historically granted equity awards to consultants only under specific, limited circumstances.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the number of awards outstanding under the 1997 Stock Option and Stock Purchase Plan (the &#8220;1997 Plan&#8221;), the 2004 Stock Option and Stock Purchase Plan (the &#8220;2004 Plan&#8221;), the 2014 Plan and the 2015 New Employee Incentive Plan (the &#8220;Inducement Plan&#8221;), as well as the number of shares which remain available for grant under the 2014 Plan and Inducement Plan, the number of shares we are asking stockholders to authorize for future issuance under the Restated Plan, and the Contingent Options granted under the Restated Plan subject to stockholder approval, along with the potential equity dilution represented by the outstanding shares and shares available for future awards as a percentage of the common shares outstanding (determined on a fully diluted basis), in each case as of March 31, 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:55.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom"  style="width:0.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:12.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As a % of Shares Outstanding<sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar Value<sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1997 Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,450</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.02</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,031</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average exercise price of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.19</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining term of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31 years</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004 Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,491</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,956</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average exercise price of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56.53</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining term of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.88 years</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869,838</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.45</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,372,344</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average exercise price of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.60</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining term of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.35</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares Remaining Available for Issuance</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,891</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,008</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inducement Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,333</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.13</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,666</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average exercise price of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.18</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining term of outstanding options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.35 years</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares Remaining Available for Issuance</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,333</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,666</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restated Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposed aggregate increase to share reserve</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.94</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160,000</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Options outstanding</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,000</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average exercise price of Contingent Options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining term of Contingent Options</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0 years</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares remaining available for grant under Restated Plan assuming approval of the Restated Plan</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,970,891</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,114,008</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Less than 0.01%</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on 24,940,979 shares of our common stock outstanding as of March 31, 2017, </font><font style="color:#000000;">determined on a fully diluted basis, meaning the total shares outstanding includes shares issuable under authorized and outstanding awards </font><font style="color:#000000;">under our equity compensation plans and remaining shares available for issuance under our equity compensation plans (but excluding the 11,577 shares reserved for future issuance under our 2011 Employee Stock Purchase Plan as of such date).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Based on the closing price of our common stock on March 31, 2017 of $1.58 per share.</p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the 2016 Annual Meeting, our stockholders approved a 333,333 share increase (the &#8220;2016 Increase&#8221;) to the share reserve under the 2014 Plan.&nbsp;&nbsp;The amount of this increase was carefully reviewed and analyzed with reference to a number of factors and within the context of our historical grant history and projected grants to existing and new employees. Though at the time of the 2016 Annual Meeting we believed that the 2016 Increase would be sufficient to last through mid-2017, the reverse stock split we completed in May 2016 had a materially greater negative impact on our stock price than anticipated.&nbsp;&nbsp;Thus, subsequent award grants to directors, executive officers and employees in the first quarter of 2017 consumed a larger portion of our available share reserve under the 2014 Plan than anticipated at the time of the 2016 Increase.&nbsp;&nbsp;However, the Compensation Committee deemed these grants necessary and appropriate based on relevant benchmarks for director and officer equity compensation, and as necessary and advisable to compensate our directors for their services and retain and incentivize executive management. Upon completion in March 2017 of our annual equity award grant-making process to directors, officers and employees, our remaining share reserve under the 2014 Plan was largely depleted.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among the factors the Board considered in determining the appropriate size of the increase to the share reserve for the Restated Plan was the Company&#8217;s recent stock price performance, its prior grant history and the range of potential uses of equity compensation for the next few years.&nbsp;&nbsp;Other factors considered by the Board include, but are not limited to, the ratio of the number of shares issued to employees relative to the total number of outstanding shares, the use of both time and performance-based vesting requirements, and a comparison of the Company&#8217;s rate of burn of employee equity to industry/market cap peer companies. The Board also considered the availability of shares available for issuance to new employees under our Inducement Plan.&nbsp;&nbsp;The Inducement Plan currently has 316,666 shares reserved for issuance over the term of the plan, 283,333 of which were available for issuance as of March 31, 2017.&nbsp;&nbsp;With the Inducement Plan available for use with respect to new employee grants, the Board decreased the proposed requested increase to the existing share reserve under the 2014 Plan to reflect the number of equity awards that we anticipate will be eligible to be granted under the Inducement Plan.&nbsp;&nbsp;However, as the Inducement Plan can be used only for new employees&#8217; grants in connection with commencement of their employment with us, its impact on our aggregate anticipated director, officer and employee grants is relatively modest. Based on our analysis of the foregoing considerations and other relevant considerations, we believe that, after taking into account the proposed share increase, the Restated Plan&#8217;s share reserve will be sufficient for us to make grants of equity incentive awards under the Restated Plan for approximately two years.&nbsp;&nbsp;Of course, however, changes in business practices, industry standards, our compensation strategy, or equity market performance could alter this projection.&nbsp;&nbsp;In addition, we are growing rapidly and as a result, our employee population is also growing.&nbsp;&nbsp;Accordingly, although the requested authorized share reserve is designed to accommodate equity compensation needs under a variety of scenarios for approximately two years, under some scenarios the reserve could prove to be insufficient for this period, in which case the stockholders would have the opportunity to either approve or disapprove any addition to the requested share reserve.&nbsp;&nbsp;We cannot predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Restated Plan could last for a shorter or longer time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the number of shares we have granted (under our 2004 Plan, our 2014 Plan and our Inducement Plan) during our last three fiscal years and our annual and three-year average burn rate (calculated as (1) the gross number of shares subject to equity awards granted during the year divided by (2) the weighted average common shares outstanding for such year).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:48.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal 2016</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal 2015</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal 2014</p></td>
<td valign="bottom"  style="width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three-Year Average</p></td>
<td valign="bottom"  style="width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options Granted</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347,407</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,514</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,833</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,918</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock and Restricted Stock Units</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,101</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,716</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,606</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,290,933</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,386,488</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,388,713</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,688,711</p></td>
<td valign="top"  style="width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burn Rate</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.92</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.68%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.31</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In fiscal year 2016, the end of year overhang rate was approximately 6.61%. If the Restated Plan is approved, we expect our overhang at the end of 2017 will be approximately 14.87%. Overhang is calcul</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ated by dividing (1) the sum of the number of shares subject to equity awards outstanding at the end of the fiscal year plus shares remaining available for issuance for future awards under our equity compensation plans at the end of the fiscal year, by (2)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the number of shares outstanding at the end of the fiscal year (which shares outstanding for purposes of this clause (2) will be deemed to include the total number of shares determined pursuant to clause (1) above).</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the factors described above, and the fact that the ability to continue to grant equity compensation is vital to our ability to continue to attract and retain employees in the extremely competitive labor markets in which we compete, our Board has determined that the size of the share reserve under the Restated Plan is reasonable and appropriate at this time. Our Board will not create a subcommittee to evaluate the risk and benefits for issuing shares under the Restated Plan.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholder Approval Requirement for the Proposal</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholder approval of the Restated Plan is necessary in order for us to (1) meet the stockholder approval requirements of the NASDAQ Stock Market, (2) take tax deductions for certain compensation resulting from awards granted thereunder intended to qualify as performance-based compensation under Section 162(m) of the Code, as discussed above, and (3) grant ISOs thereunder.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Restated Plan is not approved by our stockholders, the Restated Plan will cease to be effective, the&nbsp;&nbsp;original 2014 Plan in effect prior to the approval of the Restated Plan by our Board will continue in full force and effect, and we may continue to grant awards under the 2014 Plan, subject to its terms, conditions and limitations, using the limited remaining shares available for issuance thereunder.&nbsp;&nbsp;In addition, if the Restated Plan is not approved by our stockholders, all of the Contingent Options subject to stockholder approval will terminate.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of the Restated Plan</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">What follows is a summary of the material terms of the Restated Plan.&nbsp;&nbsp;This summary is qualified in its entirety by the specific language of the Restated Plan, which is attached as Appendix A to this Proxy Statement.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The purpose of the Restated Plan is to advance the interests of the Company and its stockholders by providing an incentive program that will enable the Company to attract and retain employees, consultants and directors and to provide them with an equity interest in the growth and profitability of the Company.&nbsp;&nbsp;These incentives are provided through the grant of stock options, SARs, restricted stock, restricted stock units, performance shares, performance units, other stock-based awards, cash-based awards and deferred compensation awards.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Authorized Shares<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Subject to certain equitable adjustments for capital structure changes, as described in more detail below, the maximum aggregate number of shares authorized for issuance under the Restated Plan is 2,900,133.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share Counting<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Each share subject to an award under the Restated Plan will reduce the number of shares remaining available for grant under the Restated Plan by one share.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>If any award granted under the Restated Plan expires or otherwise terminates for any reason without having been exercised or settled in full, or if shares subject to forfeiture or repurchase are forfeited or repurchased by the Company for not more than the participant&#8217;s purchase price, any such shares reacquired or subject to a terminated award will again become available for issuance under the Restated Plan.&nbsp;&nbsp;Shares will not be treated as having been issued under the Restated Plan and will, therefore, not reduce the number of shares available for issuance to the extent an award is settled in cash.&nbsp;&nbsp;Shares that are withheld or reacquired by the Company in satisfaction of a tax withholding obligation for an option or stock appreciation right, or that are tendered in payment of the exercise price of an option will not be made available for new awards under the Restated Plan.&nbsp;&nbsp;Upon the exercise of a SAR or net-exercise of an option, the number of shares available under the Restated Plan will be reduced by the gross number of shares for which the award is exercised. Shares reacquired by the Company on the open market or otherwise using </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash proceeds from the exercise of options s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hall not be added to the shares of Stock authorized for grant under the Restated Plan.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adjustments for Capital Structure Changes<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Appropriate and proportionate adjustments will be made to the number of shares authorized under the Restated Plan, to the numerical limits on certain types of awards described below, and to outstanding awards in the event of any change in our common stock effected without receipt of consideration by us, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in our capital structure, or if we make a distribution to our stockholders in a form other than common stock (excluding normal cash dividends) that has a material effect on the fair market value of our common stock.&nbsp;&nbsp;In such circumstances, the Compensation Committee also has the discretion under the Restated Plan to adjust other terms of outstanding awards as it deems appropriate.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Award Limits<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp; The maximum number of shares of our common stock that may be subject to one or more options or SARs granted to any one person pursuant to the Restated Plan during any fiscal year is 2,000,000 shares.&nbsp;&nbsp;The maximum number of shares of our common stock that may be subject to one or more awards (other than options or SARs) granted to any one person pursuant to the Restated Plan during any fiscal year is 2,000,000 shares.&nbsp;&nbsp;The maximum amount that may be paid under cash awards pursuant to the Restated Plan to any one participant during any fiscal year is $5,000,000.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to comply with applicable tax rules, the Restated Plan also limits to 2,900,133 the number of shares that may be issued upon the exercise of ISOs granted under the Restated Plan.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Restated Plan, the total aggregate value of cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of awards granted to a non-employee director as compensation for services as a non-employee director during any calendar year under the Restated Plan may not exceed $500,000 (increased to $700,000 in the fiscal year of a non-employee director&#8217;s initial service as a non-employee director). The Board may make exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the Board may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the foregoing numbers shall be subject to adjustment pursuant to the terms of the Restated Plan in the event of certain corporate events as described below under &#8220;Adjustments for Capital Structure Changes.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Administration<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Restated Plan generally will be administered by the Compensation Committee of the Board, although the Board retains the right to appoint another of its committees to administer the Restated Plan or to administer the Restated Plan directly.&nbsp;&nbsp;In the case of awards intended to qualify for the performance-based compensation exemption under Section 162(m) of the Code, administration of the Restated Plan must be by a committee comprised solely of two or more &#8220;outside directors&#8221; within the meaning of Section 162(m) of the Code.&nbsp;&nbsp;(For purposes of this summary, the term &#8220;Committee&#8221; will refer to any such duly appointed committee or the Board.)&nbsp;&nbsp;Subject to the provisions of the Restated Plan, the Committee determines in its discretion the persons to whom and the times at which awards are granted, the types and sizes of awards, and all of their terms and conditions.&nbsp;&nbsp;The Committee may, subject to certain limitations on the exercise of its discretion required by Section 162(m) of the Code or otherwise provided by the Restated Plan, amend, cancel or renew any award, waive any restrictions or conditions applicable to any award, and accelerate, continue, extend or defer the vesting of any award.&nbsp;&nbsp;The Restated Plan provides, subject to certain limitations, for indemnification by the Company of any director, officer or employee against all reasonable expenses, including attorneys&#8217; fees, incurred in connection with any legal action arising from such person&#8217;s action or failure to act in administering the Restated Plan.&nbsp;&nbsp;All awards granted under the Restated Plan will be evidenced by a written or digitally signed agreement between the Company and the participant specifying the terms and conditions of the award, consistent with the requirements of the Restated Plan.&nbsp;&nbsp;The Committee will interpret the Restated Plan and awards granted thereunder, and all determinations of the Committee generally will be final and binding on all persons having an interest in the Restated Plan or any award.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>Prohibition of Option and SAR Repricing<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Restated Plan expressly provides that, without the approval of a majority of the votes cast in person or by proxy at a meeting of our stockholders, the Committee may </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">not provide for any of the following with respect to underwater options or stock appreciation rights: (1) either the cancellation of</font><font style="font-weight:normal;font-style:normal;"> such outstanding options or stock appreciation rights in exchange for the grant of new options or stock appreciation rights at a lower exercise price or the amendment of outstanding options or stock appreciation rights to reduce the exercise price, (2) th</font><font style="font-weight:normal;font-style:normal;">e issuance of new full value awards in exchange for the cancellation of such outstanding options or stock appreciation rights, or (3) the cancellation of such outstanding options or stock appreciation rights in exchange for payments in cash.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Eligibility<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Awards may be granted to employees, directors and consultants of the Company or any present or future parent or subsidiary corporation or other affiliated entity of the Company.&nbsp;&nbsp;Incentive stock options may be granted only to employees who, as of the time of grant, are employees of the Company or any parent or subsidiary corporation of the Company.&nbsp;&nbsp;As of March 31, 2017, we had approximately 65 employees, including five&nbsp;&nbsp;executive officers, seven non-employee directors, and approximately 25 consultants who were eligible to participate in the Restated Plan.&nbsp;&nbsp;We historically have granted equity awards to consultants only under specific, limited circumstances.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant nonstatutory stock options, incentive stock options within the meaning of Section 422 of the Code, or any combination of these.&nbsp;&nbsp;The exercise price of each option may not be less than the fair market value of a share of our common stock on the date of grant.&nbsp;&nbsp;However, any incentive stock option granted to a person who at the time of grant owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary corporation of the Company (a &#8220;10% Stockholder&#8221;) must have an exercise price equal to at least 110% of the fair market value of a share of common stock on the date of grant.&nbsp;&nbsp;The closing price of our common stock on the NASDAQ Stock Market on March 31, 2017 was $1.58 per share.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Restated Plan provides that the option exercise price may be paid in cash, by check, or cash equivalent; by means of a broker-assisted cashless exercise; by means of a net-exercise procedure; by such other lawful consideration as approved by the Committee; or by any combination of these.&nbsp;&nbsp;Nevertheless, the Committee may restrict the forms of payment permitted in connection with any option grant.&nbsp;&nbsp;No option may be exercised unless the participant has made adequate provision for federal, state, local and foreign taxes, if any, relating to the exercise of the option, including, if permitted or required by the Company, through the participant&#8217;s surrender of a portion of the option shares to the Company.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options will become vested and exercisable at such times or upon such events and subject to such terms, conditions, performance criteria or restrictions as specified by the Committee.&nbsp;&nbsp;The maximum term of any option granted under the Restated Plan is ten years, provided that an incentive stock option granted to a 10% Stockholder must have a term not exceeding five years.&nbsp;&nbsp;Unless otherwise permitted by the Committee, an option generally will remain exercisable for three months following the participant&#8217;s termination of service, provided that if service terminates as a result of the participant&#8217;s death or disability, the option generally will remain exercisable for two years, but in any event the option must be exercised no later than its expiration date, and provided further that an option will terminate immediately upon a participant&#8217;s termination for cause (as defined by the Restated Plan).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options are nontransferable by the participant other than by will or by the laws of descent and distribution, and are exercisable during the participant&#8217;s lifetime only by the participant.&nbsp;&nbsp;However, a nonstatutory stock option may be assigned or transferred to certain family members or trusts for their benefit to the extent permitted by the Committee.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Appreciation Rights<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant stock appreciation rights (a &#8220;SAR&#8221;).&nbsp;&nbsp;A SAR is exercisable at such times or upon such events and subject to such terms, conditions, performance criteria or restrictions as specified by the Committee.&nbsp;&nbsp;The exercise price of each SAR may not be less than the fair market value of a share of our common stock on the date of grant.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the exercise of any SAR, the participant is entitled to receive an amount equal to the excess of the fair market value of the underlying shares of common stock as to which the right is exercised over the aggregate exercise price for such shares.&nbsp;&nbsp;At the Committee&#8217;s discretion, payment of this amount upon the exercise of a SAR may be made in cash or shares of common stock.&nbsp;&nbsp;The maximum term of any SAR granted under the Restated Plan is ten years.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARs are generally nontransferable by the participant other than by will or by th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e laws of descent and distribution, and are generally exercisable during the participant&#8217;s lifetime only by the participant.&nbsp;&nbsp;If permitted by the Committee, a SAR may be assigned or transferred to certain family members or trusts for their benefit to the e</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xtent permitted by the Committee.&nbsp;&nbsp;Other terms of SARs are generally similar to the terms of comparable stock options.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Awards<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant restricted stock awards under the Restated Plan either in the form of a restricted stock purchase right, giving a participant an immediate right to purchase common stock, or in the form of a restricted stock bonus, in which stock is issued in consideration for services to the Company rendered by the participant.&nbsp;&nbsp;The Committee determines the purchase price payable under restricted stock purchase awards, which may be less than the then current fair market value of our common stock.&nbsp;&nbsp;Restricted stock awards may be subject to vesting conditions based on such service or performance criteria as the Committee specifies, including the attainment of one or more performance goals similar to those described below in connection with performance awards.&nbsp;&nbsp;Shares acquired pursuant to a restricted stock award may not be transferred by the participant until vested.&nbsp;&nbsp;Unless otherwise provided by the Committee, a participant will forfeit any shares of restricted stock as to which the vesting restrictions have not lapsed prior to the participant&#8217;s termination of service.&nbsp;&nbsp;Unless otherwise determined by the Committee, participants holding restricted stock will have the right to vote the shares and to receive any dividends paid, except that dividends or other distributions will be subject to the same restrictions, including vesting conditions, as the original award.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant restricted stock units under the Restated Plan, which represent rights to receive shares of our common stock at a future date determined in accordance with the participant&#8217;s award agreement.&nbsp;&nbsp;No monetary payment is required for receipt of restricted stock units or the shares issued in settlement of the award, the consideration for which is furnished in the form of the participant&#8217;s services to the Company.&nbsp;&nbsp;The Committee may grant restricted stock unit awards subject to the attainment of one or more performance goals similar to those described below in connection with performance awards, or may make the awards subject to vesting conditions similar to those applicable to restricted stock awards.&nbsp;&nbsp;Unless otherwise provided by the Committee, a participant will forfeit any restricted stock units which have not vested prior to the participant&#8217;s termination of service.&nbsp;&nbsp;Participants have no voting rights or rights to receive cash dividends with respect to restricted stock unit awards until shares of common stock are issued in settlement of such awards.&nbsp;&nbsp;However, the Committee may grant restricted stock units that entitle their holders to dividend equivalent rights, which are rights to receive additional restricted stock units for a number of shares whose value is equal to any cash dividends the Company pays.&nbsp;&nbsp;Any such dividend equivalent rights will be subject to the same vesting conditions as the underlying award.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash-Based Awards and Other Stock-Based Awards<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant cash-based awards or other stock-based awards in such amounts and subject to such terms and conditions as the Committee determines.&nbsp;&nbsp;Cash-based awards will specify a monetary payment or range of payments, while other stock-based awards will specify a number of shares or units based on shares or other equity-related awards.&nbsp;&nbsp;Such awards may be subject to vesting conditions based on continued performance of service or subject to the attainment of one or more performance goals similar to those described above in connection with performance awards.&nbsp;&nbsp;Settlement of awards may be in cash or shares of common stock, as determined by the Committee.&nbsp;&nbsp;A participant will have no voting rights with respect to any such award unless and until shares are issued pursuant to the award.&nbsp;&nbsp;The committee may grant dividend equivalent rights with respect to other stock-based awards.&nbsp;&nbsp;Any such dividend equivalent rights will be subject to the same vesting conditions as the underlying award.&nbsp;&nbsp;The effect on such awards of the participant&#8217;s termination of service will be determined by the Committee and set forth in the participant&#8217;s award agreement.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>Performance Awards<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Committee may grant performance awards subject to such conditions and the attainment of such performance goals over such periods as the Committee determines in writing and sets forth in a written agreement between the Company and the participant.&nbsp;&nbsp;These awards may be designated as performance shares or performance units, which consist of unfunded bookkeeping entries generally having initial values equal to the fair market value determined on the grant date of a share of common stock in the case of performance shares and a monetary value established by the Committee at the time of grant in the case of performance units.&nbsp;&nbsp;Performance awards will specify a predetermined amount of performance shares or performance units that may be earned by the participant to the extent that one or more performance goals are attained within a predetermined performance period.&nbsp;&nbsp;To the extent earned, performance awards may be settled in cash, shares of common stock (including shares of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">restricted stock that are subject to additional vesting) or any combination thereof. In its discretion, the Committee may provide for a part</font><font style="font-weight:normal;font-style:normal;">icipant awarded performance shares of to receive dividend equivalent rights with respect to cash dividends paid on the Company&#8217;s common stock.&nbsp;&nbsp;Any such dividend equivalent rights will be subject to the same vesting conditions as the underlying award. The </font><font style="font-weight:normal;font-style:normal;">Committee may provide for performance award payments in lump sums or installments.&nbsp;&nbsp;&nbsp;&nbsp;The Committee will determine whether performance awards are intended to constitute &#8220;performance-based compensation&#8221; within the meaning of Section 162(m) of the Code, in w</font><font style="font-weight:normal;font-style:normal;">hich case the applicable performance criteria will be selected from the list below in accordance with the requirements of Section 162(m) of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Performance-based compensation under Section 162(m)<font style="font-style:normal;">. The Committee may issue performance-based awards that are intended to constitute &#8220;performance-based compensation&#8221; under Section 162(m).&nbsp;&nbsp;The Committee may also grant performance-based awards that are not intended to constitute &#8220;performance-based compensation&#8221; under Section 162(m).</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to constitute &#8220;performance-based compensation&#8221; under Section 162(m) of the Code, in addition to certain other requirements, the relevant amounts must be payable only upon the attainment of pre-established, objective performance goals set by our compensation committee and linked to stockholder-approved performance criteria.&nbsp;&nbsp;Prior to the beginning of the applicable performance period or such later date as permitted under Section 162(m) of the Code, the Committee will establish one or more performance goals applicable to the award.&nbsp;&nbsp;Performance goals will be based on the attainment of specified target levels with respect to one or more measures of business or financial performance of the Company and each subsidiary corporation consolidated with the Company for financial reporting purposes, or such division or business unit of the Company as may be selected by the Committee.&nbsp;&nbsp;The Committee, in its discretion, may base performance goals applicable to awards intended to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) on one or more of the following such measures: revenue; sales; expenses; operating income; gross margin; operating margin; earnings before any one or more of: stock-based compensation expense, interest, taxes, depreciation and amortization; pre-tax profit; net operating income; net income; economic value added; free cash flow; operating cash flow; balance of cash, cash equivalents and marketable securities; stock price; earnings per share; return on stockholder equity; return on capital; return on assets; return on investment; total stockholder return, employee satisfaction; employee retention; market share; customer satisfaction; product development; research and development expense; completion of an identified special project; and completion of a joint venture or other corporate transaction.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The target levels with respect to these performance measures may be expressed on an absolute basis or relative to an index, budget or other standard specified by the Committee.&nbsp;&nbsp;The degree of attainment of performance measures will be calculated in accordance with generally accepted accounting principles, if applicable, but prior to the accrual or payment of any performance award for the same performance period, and, according to criteria established by the Committee, excluding the effect (whether positive or negative) of changes in accounting standards or any extraordinary, unusual or nonrecurring item occurring after the establishment of the performance goals applicable to a performance award.&nbsp;&nbsp;For all awards intended to qualify as &#8220;performance-based compensation&#8221; for purposes of Section 162(m), such determinations shall be made within the time prescribed by, and otherwise in compliance with, Section 162(m).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following completion of the applicable performance period, the Committee will certify in writing the extent to which the applicable performance goals have been attained and the resulting value to be paid to the participant.&nbsp;&nbsp;The Committee retains the discretion to eliminate or reduce, but not increase, the amount that would otherwise be payable on the basis of the performance goals attained with respect to awards intended to qualify as performance-based awards under Section 162(m) of the Code.&nbsp;&nbsp;However, no such reduction may increase the amount paid to any other participant.&nbsp;&nbsp;The Committee may make positive or negative adjustments to award payments under awards that are not intended to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) to participants other than covered employees to reflect the participant&#8217;s individual job performance or other factors determined by the Committee.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>Change in Control<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Unless otherwise defined in a participant&#8217;s award or other agreement with the Company, the Restated Plan provides that a &#8220;Change in Control&#8221; occurs upon (a) a person or entity (with certain exceptions described in the Restated Plan) becoming the direct or indirect beneficial owner of more than 50% of the Company&#8217;s voting stock; (b) stockholder approval of a liquidation or dissolution of the Company; or (c) the occurrence of any of the following events upon which the stockholders of the Company immediately before the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">event do not retain immediately after the event direct or indirect beneficial ownership of more than 50% of the voting securities of the Company, i</font><font style="font-weight:normal;font-style:normal;">ts successor or the entity to which the assets of the company were transferred: (i) a sale or exchange by the stockholders in a single transaction or series of related transactions of more than 50% of the Company&#8217;s voting stock; (ii) a merger or consolidat</font><font style="font-weight:normal;font-style:normal;">ion in which the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company (other than a sale, exchange or transfer to one or more subsidiaries of the Company).</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a Change in Control occurs, the surviving, continuing, successor or purchasing entity or its parent may, without the consent of any participant, either assume or continue outstanding awards or substitute substantially equivalent awards for its stock.&nbsp;&nbsp;If so determined by the Committee, stock-based awards will be deemed assumed if, for each share subject to the award prior to the Change in Control, its holder is given the right to receive the same amount of consideration that a stockholder would receive as a result of the Change in Control.&nbsp;&nbsp;In general, any awards which are not assumed, substituted for or otherwise continued in connection with a Change in Control or exercised or settled prior to the Change in Control will terminate effective as of the time of the Change in Control.&nbsp;&nbsp;Subject to the restrictions of Section 409A of the Code, the Committee may provide for the acceleration of vesting or settlement of any or all outstanding awards upon such terms and to such extent as it determines.&nbsp;&nbsp;The Restated Plan also authorizes the Committee, in its discretion and without the consent of any participant, to cancel each or any award denominated in shares of stock upon a Change in Control in exchange for a payment to the participant with respect each vested share (and each unvested share if so determined by the Committee) subject to the cancelled award of an amount equal to the excess of the consideration to be paid per share of common stock in the Change in Control transaction over the exercise price per share, if any, under the award.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment, Suspension or Termination<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The Restated Plan will continue in effect until its termination by the Committee, provided that no awards may be granted under the Restated Plan following the tenth anniversary of the date the Restated Plan was adopted by the Board.&nbsp;&nbsp;The Committee may amend, suspend or terminate the Restated Plan at any time, provided that no amendment may be made without stockholder approval that would increase the maximum aggregate number of shares of stock authorized for issuance under the Restated Plan, change the class of persons eligible to receive incentive stock options or require stockholder approval under any applicable law.&nbsp;&nbsp;No amendment, suspension or termination of the Restated Plan may affect any outstanding award unless expressly provided by the Committee, and, in any event, may not have a materially adverse effect on an outstanding award without the consent of the participant unless necessary to comply with any applicable law, regulation or rule, including, but not limited to, Section 409A of the Code, or unless expressly provided in the terms and conditions governing the award.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of U.S. Federal Income Tax Consequences</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary is intended only as a general guide to the U.S. federal income tax consequences of participation in the Restated Plan and does not attempt to describe all possible federal or other tax consequences of such participation or tax consequences based on particular circumstances.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Incentive Stock Options<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;A participant recognizes no taxable income for regular income tax purposes as a result of the grant or exercise of an ISO qualifying under Section 422 of the Code.&nbsp;&nbsp;Participants who neither dispose of their shares within two years following the date the option was granted nor within one year following the exercise of the option will normally recognize a capital gain or loss upon the sale of the shares equal to the difference, if any, between the sale price and the purchase price of the shares.&nbsp;&nbsp;If a participant satisfies such holding periods upon a sale of the shares, we will not be entitled to any deduction for federal income tax purposes.&nbsp;&nbsp;If a participant disposes of shares within two years after the date of grant or within one year after the date of exercise (a &#8220;disqualifying disposition&#8221;), the difference between the fair market value of the shares on the option exercise date and the exercise price (not to exceed the gain realized on the sale if the disposition is a transaction with respect to which a loss, if sustained, would be recognized) will be taxed as ordinary income at the time of disposition.&nbsp;&nbsp;Any gain in excess of that amount will be a capital gain.&nbsp;&nbsp;If a loss is recognized, there will be no ordinary income, and such loss will be a capital loss.&nbsp;&nbsp;Any ordinary income recognized by the participant upon the disqualifying disposition of the shares generally should be deductible by us for federal income tax purposes, except to the extent such deduction is limited by applicable provisions of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>In general, the difference between the option exercise price and the fair market value of the shares on the date of exercise of an ISO is treated as an adjustment in computing the participant&#8217;s alternative minimum taxable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income and may be subject to an al</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ternative minimum tax which is paid if such tax exceeds the regular tax for the year.&nbsp;&nbsp;Special rules may apply with respect to certain subsequent sales of the shares in a disqualifying disposition, certain basis adjustments for purposes of computing the al</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ternative minimum taxable income on a subsequent sale of the shares and certain tax credits which may arise with respect to participants subject to the alternative minimum tax.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nonstatutory Stock Options<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Options not designated or qualifying as ISOs are nonstatutory stock options having no special tax status.&nbsp;&nbsp;A participant generally recognizes no taxable income upon receipt of such an option.&nbsp;&nbsp;Upon exercising a nonstatutory stock option, the participant normally recognizes ordinary income equal to the difference between the exercise price paid and the fair market value of the shares on the date when the option is exercised.&nbsp;&nbsp;If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes.&nbsp;&nbsp;Upon the sale of stock acquired by the exercise of a nonstatutory stock option, any gain or loss, based on the difference between the sale price and the fair market value of the shares on the exercise date, will be taxed as capital gain or loss.&nbsp;&nbsp;We generally should be entitled to a tax deduction equal to the amount of ordinary income recognized by the participant as a result of the exercise of a nonstatutory stock option, except to the extent such deduction is limited by applicable provisions of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Appreciation Rights<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;A Participant recognizes no taxable income upon the receipt of a stock appreciation right.&nbsp;&nbsp;Upon the exercise of a stock appreciation right, the participant generally will recognize ordinary income in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the exercise price.&nbsp;&nbsp;If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes.&nbsp;&nbsp;We generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the stock appreciation right, except to the extent such deduction is limited by applicable provisions of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;A participant acquiring restricted stock generally will recognize ordinary income equal to the excess of the fair market value of the shares on the &#8220;determination date&#8221; over the price paid, if any, for such shares.&nbsp;&nbsp;The &#8220;determination date&#8221; is the date on which the participant acquires the shares unless the shares are subject to a substantial risk of forfeiture and are not transferable, in which case the determination date is the earlier of (i) the date on which the shares become transferable or (ii) the date on which the shares are no longer subject to a substantial risk of forfeiture (e.g., when they become vested).&nbsp;&nbsp;If the determination date follows the date on which the participant acquires the shares, the participant may elect, pursuant to Section 83(b) of the Code, to designate the date of acquisition as the determination date by filing an election with the Internal Revenue Service no later than 30 days after the date on which the shares are acquired.&nbsp;&nbsp;If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes.&nbsp;&nbsp;Upon the sale of shares acquired pursuant to a restricted stock award, any gain or loss, based on the difference between the sale price and the fair market value of the shares on the determination date, will be taxed as capital gain or loss.&nbsp;&nbsp;We generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant on the determination date, except to the extent such deduction is limited by applicable provisions of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Unit, Performance, Cash-Based and Other Stock-Based Awards<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;A participant generally will recognize no income upon the receipt of a restricted stock unit, performance share, performance unit, cash-based or other stock-based award.&nbsp;&nbsp;Upon the settlement of such awards, participants normally will recognize ordinary income in the year of settlement in an amount equal to the cash received and the fair market value of any substantially vested shares of stock received.&nbsp;&nbsp;If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes.&nbsp;&nbsp;If the participant receives shares of restricted stock, the participant generally will be taxed in the same manner as described above under &#8220;Restricted Stock.&#8221; Upon the sale of any shares received, any gain or loss, based on the difference between the sale price and the fair market value of the shares on the determination date (as defined above under &#8220;</font>Restricted Stock<font style="font-weight:normal;font-style:normal;">&#8221;), will be taxed as capital gain or loss.&nbsp;&nbsp;We generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant on the determination date, except to the extent such deduction is limited by applicable provisions of the Code.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Section 162(m) Limitation<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;Section 162(m) denies a deduction to any publicly held corporation for compensation paid to certain &#8220;covered employees&#8221; in a taxable year to the extent that compensation to such covered employee exceeds $1,000,000. It is possible that compensation attributable to awards under the Restated Plan, when combined with all other types of compensation received by a covered employee from us, may cause this limitation to be exceeded in any particular year.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qualified &#8220;performanc</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e-based compensation&#8221;&nbsp;&nbsp;is disregarded for purposes of the deduction limitation. In accordance with Treasury Regulations issued under Section 162(m), compensation attributable to stock awards will generally qualify as performance-based compensation if (1) t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he award is granted by a compensation committee composed solely of two or more &#8220;outside directors,&#8221; (2) the plan contains a per-employee limitation on the number of awards which may be granted during a specified period, (3) the material terms of the plan a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re disclosed to and approved by the stockholders, (4) for stock options and SARs, the amount of compensation an employee could receive is based solely on an increase in the value of the stock after the date of the grant (which requires that the exercise pr</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ice of the option is not less than the fair market value of the stock on the date of grant), and for awards other than options and SARs, established performance criteria that must be met before the award actually will vest or be paid, and (5) in the case o</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f awards other than stock options and SARs, the compensation committee has certified that the performance goals have been met prior to payment.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Restated Plan is designed to permit our compensation committee to grant awards which may qualify as &#8220;performance-based compensation&#8221; under Section 162(m); however, awards granted under the Restated Plan will only be treated as &#8220;performance-based compensation&#8221; under Section 162(m) if the awards and the procedures associated with them comply with all other requirements of Section 162(m). As one of the factors in its decisions regarding grants under and administration of the Restated Plan, the compensation committee will consider the anticipated effect of Section 162(m). These effects will depend upon a number of factors, including not only whether the grants qualify for the performance exception, but also the timing of executives&#8217; vesting in or exercise of previously granted equity awards and receipt of other compensation. Furthermore, interpretations of and changes in the tax laws and other factors beyond the compensation committee&#8217;s control may also affect the deductibility of compensation. For these and other reasons, the compensation committee may make grants that do not qualify for the performance exception and our tax deductions for those grants may be limited or eliminated as a result of the application of Section 162(m).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Plan Benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Plan Benefits<font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;The following table shows the number of shares issued pursuant to awards or subject to awards issued as of February 28, 2017 under the 2014 Plan since its inception to the following individuals and groups:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:64.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Position</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying Options Granted (#)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying RSUs Granted (#)(2)</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:64.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D. <br />President and Chief Executive Officer</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,613</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:64.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago Gir&#227;o <br />VP of Finance and Chief Financial Officer</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,322</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:64.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris <br />Vice President and General Manager of Cell Therapy</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,655</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All executive officers as a group (5 persons) </p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,966</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All directors who are not employees, as a group (6 persons) <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,270</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,404</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All employees as a group (excluding executive officers) (60 persons)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,414</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,841</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Our non-employee directors are eligible to receive automatic equity awards under our director compensation policy, as described under the heading &#8220;Executive Compensation &#8211; Director Compensation&#8221; below.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Reflects the target number of RSUs granted. The maximum number of RSUs was equal to 200% of target.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Plan Benefits</font><font style="font-weight:normal;font-style:normal;">.&nbsp;&nbsp;On March 31, 2017, our Board granted the Contingent Options to Gregg A. Lapointe under the Restated Plan, subject to stockholder approval.&nbsp;&nbsp; The Contingent Options vest in two equal installments on each of the first two anniversaries of</font><font style="font-weight:normal;font-style:normal;"> the date of Mr. Lapointe&#8217;s appointment to the Board.&nbsp;&nbsp;The following table sets forth information pertaining to the Contingent Options granted under the Restated Plan. In the event stockholder approval of the Restated Plan is not obtained, all of the Conti</font><font style="font-weight:normal;font-style:normal;">ngent Options will be automatically forfeited.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:77.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Position</p></td>
<td valign="top"  style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying Contingent Options Granted (#)</p></td>
<td valign="bottom"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:77.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:77.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago Gir&#227;o</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP of Finance and Chief Financial Officer</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="bottom"  style="width:77.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President and General Manager of Cell Therapy</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:77.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All executive officers as a group (5 persons)</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:77.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All directors who are not employees, as a group (7 persons) <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:77.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All employees as a group (excluding executive officers) (58 persons)</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Our non-employee directors are eligible to receive automatic equity awards under the Restated Plan under our director compensation policy, as described under the heading &#8220;Executive Compensation &#8211; Director Compensation&#8221; below.</p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The granting of all other future awards under the Restated Plan is subject to the discretion of the Board or the Committee, therefore, the benefits or amounts that any participant or group of participants may receive in the future under the Restated Plan are not currently determinable. The Committee may grant further awards to eligible individuals under the Restated Plan prior to the annual meeting in the ordinary course of business, which awards will also be Contingent Options that are subject to stockholder approval of the Restated Plan.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vote Required</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of this proposal would require the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting.&nbsp;&nbsp;Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal.&nbsp;&nbsp;Broker non-votes will have no effect on the outcome of this proposal.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Recommendation</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board believes that the amendment and restatement of the 2014 Plan is in the best interests of Cytori and its stockholders for the reasons stated above.&nbsp;&nbsp;<font style="font-weight:bold;">Therefore, the Board unanimously recommends a vote &#8220;FOR&#8221; approval of the amendment and restatement of the 2014 Plan.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">PROPOSAL #4</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />NON-BINDI</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">NG ADVISORY VOTE REGARDING FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, enacted in July 2010, and related SEC regulations, we are required to provide our stockholders not less than once every six years with the opportunity to cast an advisory vote on the frequency at which future advisory &#8220;say on pay&#8221; votes on executive compensation will be proposed to our stockholders.&nbsp;&nbsp;We last provided our stockholders with the opportunity to vote on the frequency of future advisory &#8220;say on pay&#8221; votes on executive compensation at our 2011 annual meeting, at which time our stockholders voted that advisory &#8220;say on pay&#8221; votes on executive compensation would take place every three years.&nbsp;&nbsp;The most recent &#8220;say on pay&#8221; vote on executive compensation occurred at our 2015 annual meeting.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are again asking stockholders to vote on whether future non-binding advisory &#8220;say on pay&#8221; votes on executive compensation should occur every year, every two years or every three years. After careful consideration of this proposal, our Board has determined that an advisory vote on executive officer compensation that occurs every year is the most appropriate alternative for us, and therefore our Board recommends that you vote for an advisory vote on executive compensation to occur every year. Even though our executive compensation programs stress long-term value creation and look at long-term performance, we still believe a one-year interval for the advisory vote on executive compensation is most appropriate.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Proposal gives you the opportunity to express your views on the frequency of stockholder advisory votes regarding our executive officer compensation.&nbsp;&nbsp;The advisory vote by the stockholders on frequency is distinct from the advisory vote on the compensation of our executive officers; this Proposal deals with the issue of how frequently such a vote on such compensation should be presented to our stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this regard, we are soliciting your vote on whether the compensation of our executive officers be submitted to stockholders for an advisory vote every year, every two years, or every three years. You may vote for one of these three alternatives or you may abstain from making a choice.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vote on this Proposal is advisory and therefore not binding on us or our Board.&nbsp;&nbsp;However, we value your opinions and to the extent there is any significant vote in favor of one frequency over the other options, the Board will take this into account when considering how frequently we should conduct future advisory votes on the compensation of our executive officers.&nbsp;&nbsp; The Board may, however, decide that it is in the best interest of the Company and the stockholders to hold future advisory votes on executive compensation more or less frequently than the option that has been selected by the stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Required Vote and Board Recommendation</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option of every year, every two years or every three years that receives the affirmative vote of holders of a majority of shares present in person or by proxy and entitled to vote on the proposal will be the frequency recommended by stockholders for the advisory vote on the compensation of our executive officers, unless none of the frequency options receives a majority vote, in which case the option that receives the highest number of votes will be considered to be the frequency recommended by stockholders. Abstentions have the same effect as a vote against each of the frequency options. Broker non-votes are not counted for any purpose in determining which frequency option has been recommended by stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR A FREQUENCY OF &#8220;EVERY YEAR&#8221; FOR FUTURE NON-BINDING ADVISORY VOTES ON EXECUTIVE COMPENSATION.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">CORPORATE GOVERNANCE</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2016:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Board held eleven meetings and took action via unanimous written consent six times;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Audit Committee met eight times and took action via unanimous written consent one time;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Compensation Committee met two times and took action via unanimous written consent one time;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Governance and Nominating Committee met three times and did not take any actions via unanimous written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Executive Committee met one time did not take action via unanimous written consent; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sub-committee of the Executive Committee, comprised of our Chairman and our CEO, took action via unanimous written consent two times.&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each member of the Board attended seventy-five percent (75%) or more of the aggregate of (i) the total number of Board meetings held during the period of such member&#8217;s service and (ii) the total number of meetings of committees of the Board on which such member served, during the period of such member&#8217;s service, other than Richard Hawkins, whose attendance rate was slightly under 75% due to the fact that we were required to reschedule certain calendared Board and Committee meetings to dates and times that precluded Mr. Hawkins&#8217; attendance.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Board members are encouraged to attend our annual meetings of stockholders in person. However, in 2016, our stockholder meeting date did not coincide with our regularly scheduled quarterly Board meeting.&nbsp;&nbsp;Mr. Rickey, our Chairman, and Dr. Hedrick attended our 2016 Annual Meeting of Stockholders.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Independence</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board has determined that Dr. Naughton and Messrs. Hawkins, Hawran, Lapointe, Lyons, Martell and Rickey are &#8220;independent&#8221; under the rules of the NASDAQ Stock Market. Under applicable SEC and the NASDAQ rules, the existence of certain &#8220;related person&#8221; transactions above certain thresholds between a director and the Company are required to be disclosed and preclude a finding by the Board that the director is independent. The Board is not able to consider Dr. Hedrick, our President and Chief Executive Officer, independent, as a result of his employment with us during his tenure as one of our directors.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Leadership Structure</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws and governance principles provide the Board with the flexibility to combine or separate the positions of Chairman and Chief Executive Officer. Historically, these positions have been separate. Our Board believes that the separation of these positions strengthens the independence of our Board and allows us to have a Chairman focused on the leadership of the Board while allowing our Chief Executive Officer to focus more of his time and energy on managing our operations. The Board currently believes this structure works well to meet the leadership needs of the Board and of the Company. Dr. Hedrick, our President and Chief Executive Officer, has comprehensive industry expertise and is able to devote substantial time to the Company, and Mr. Rickey, our Chairman, is able to devote focus on longer term and strategic matters, and to provide related leadership to the Board. As a result, we do not currently intend to combine these positions; however a change in this leadership structure could be made if the Board determined it was in the best long-term interests of stockholder based upon a departure of either our Chief Executive Officer or Chairman. For example, if the two roles were to be combined, we believe that the independence of the majority of our directors, and the three fully independent Board committees, would provide effective oversight of our management and the Company.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Board&#8217;s Role in Risk Oversight</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>The Board&#8217;s role in risk oversight includes assessing and monitoring risks and risk management. The Board reviews and oversees strategic, financial and operating plans and holds management responsible for identifying and moderating risk in accordance with those plans. The Board fulfills its risk oversight function by reviewing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessing reports from members of management on a regular basis regarding material risks faced by us Company and applicable mitigation strategy and activity. The reports cover the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> critical areas of operations, sales and marketing, development, regulatory and quality affairs, intellectual property, clinical development, legal and financial affairs. The Board and its Committees (described below) consider these reports; discuss matter</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s with management and identify and evaluate any potential strategic or operational risks, and appropriate activity to address those risks.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Committees</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board has standing Audit, Compensation, Executive, and Governance and Nominating Committees.&nbsp;&nbsp;All members of the Compensation Committee, Audit Committee, and Governance and Nominating Committee are independent directors.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Compensation Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Compensation Committee currently consists of Mr. Lyons (Chairman), Dr. Naughton and Mr. Rickey.&nbsp;&nbsp; In May 2016, Tommy Thompson, a former director, stepped down as the Chairman (and a member) of our Compensation Committee. Mr. Lyons replaced Mr. Thompson as Chairman of the Compensation Committee, and Mr. Rickey joined the Compensation Committee to fill the vacancy created by Mr. Thompson&#8217;s departure.&nbsp;&nbsp;Each of the members of our Compensation Committee is independent as defined by NASDAQ, a &#8220;Non-Employee Director&#8221; as defined by rule 16b-3(b)(3)(i) of the Securities Exchange Act of 1934, as amended, and an &#8220;outside director&#8221; as defined by Section 162(m) of the Internal Revenue Code of 1986, as amended.&nbsp;&nbsp;The Committee Chairman is responsible for setting the Committee&#8217;s calendar and meeting agenda.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Compensation Committee is responsible for developing and implementing compensation programs for our executive officers and other employees, subject only to the discretion of the full Board. More specifically, our Compensation Committee establishes base salary rates for each of the Company&#8217;s officers, and administers our 2004 Equity Incentive Plan, our 2014 Equity Incentive Plan, our Executive Management Incentive Compensation Plan, our 2011 Employee Stock Purchase Plan and our 2015 New Employee Incentive Plan. The Compensation Committee establishes the compensation and benefits for our Chief Executive Officer and other executive officers, and also reviews the relationship between our performance and our compensation policies as well as assessing any risks associated with our compensation policies. In addition, the Compensation Committee reviews, and advises the Board on director compensation matters and on, regional and industry-wide compensation practices and trends in order to assess the adequacy of our executive compensation programs. The charter of the Compensation Committee has been established and approved by the Board, and a copy of the charter has been posted on our website at www.cytori.com under Investor Relations &#8211; Corporate Governance.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CEO attends some of the meetings of the Compensation Committee upon invitation, but does not participate in the executive sessions of the Compensation Committee.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Audit Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Audit Committee currently consists of Mr. Hawran (Chairman), Mr. Hawkins and Mr. Lyons.&nbsp;&nbsp;At the outset of 2016, Mr. Hawran (Chairman), Mr. Thompson and Mr. Hawkins were the members of our Audit Committee.&nbsp;&nbsp;Upon Mr. Thompson&#8217;s departure in May 2016, Mr. Lyons joined the Audit Committee.&nbsp;&nbsp;The Audit Committee is comprised solely of independent directors, as defined by NASDAQ.&nbsp;&nbsp;The Board has determined that Mr. Hawran is an &#8220;audit committee financial expert&#8221; within the meaning of Item 407(d)(5) of SEC Regulation S-K.&nbsp;&nbsp;Effective automatically upon Mr. Hawran&#8217;s departure from the Board as of date of our Annual Meeting, Mr. Lapointe shall be appointed as a member and Chairperson of our Audit Committee.&nbsp;&nbsp;Mr. Lapointe has been deemed to be an independent director, as defined by NASDAQ, and the Board has further made the determined that Mr. Lapointe is an &#8220;audit committee financial expert&#8221; within the meaning of Item 407(d)(5) of SEC Regulation S-K.&nbsp;&nbsp;The charter of the Audit Committee has been established and approved by the Board, and a copy of the charter has been posted on our website at www.cytori.com under Investor Relations &#8211; Corporate Governance.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>The Audit Committee selects our auditors, reviews the scope of the annual audit, approves the audit fees and non-audit fees to be paid to our auditors, and reviews our financial accounting controls with the staff and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">auditors.&nbsp;&nbsp;The Audit Committee is also charge</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d with review and oversight of management&#8217;s enterprise risk management assessment.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Governance and Nominating Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Governance and Nominating Committee currently consists of Mr. Hawkins (Chairman), Mr. Martell and Dr. Naughton.&nbsp;&nbsp;Mr. Martell replaced Mr. Lyons as a member of Governance and Nominating Committee in December 2016.&nbsp;&nbsp;The Governance and Nominating Committee is comprised solely of independent directors, as defined by NASDAQ.&nbsp;&nbsp;The Governance and Nominating Committee interviews, evaluates, nominates and recommends individuals for membership on the Board, evaluates the effectiveness of the Board and its serving members, and recommends the structure, responsibility and composition of the committees of the Board.&nbsp;&nbsp;The Committee is also responsible for recommending guidelines and policies for corporate governance for adoption by the Board.&nbsp;&nbsp;The charter of the Governance and Nominating Committee has been established and approved by the Board, and a copy of the charter has been posted on our website at www.cytori.com under &#8220;Investor Relations &#8211; Corporate Governance.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Executive Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Executive Committee is comprised of our Chief Executive Officer, Chairman of the Board, and Chairpersons of each committee of the Board.&nbsp;&nbsp;The Executive Committee currently consists of Dr. Hedrick, Mr. Rickey, Mr. Hawkins, Mr. Hawran, and Mr. Lyons.&nbsp;&nbsp;Effective automatically as of the Mr. Hawran&#8217;s departure from the Board as of the date of Annual Meeting, Mr. Lapointe shall replace Mr. Hawran on the Executive Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Executive Committee&#8217;s responsibilities, when such responsibilities are not discharged by our full Board, include to evaluate and approve the material terms of any financing transactions or business transactions as well as to authorize and approve accompanying the issuance of stock and/or other equity securities. The Executive Committee also would be able to act on behalf of the full Board in urgent or exigent circumstances wherein it would be very difficult or impossible to assemble the full Board between regularly scheduled meetings.&nbsp;&nbsp;In 2016, our Executive Committee acted as a special pricing committee of the Board with respect to our rights offering financing, consummated in June 2016.&nbsp;&nbsp;The sub-committee of the Executive Committee, consists of our Chairman of the Board and our Chief Executive Officer, has the authority to approve corporate expenditures presented by our management in excess of $250,000 up to a maximum of $1,000,000 for a single corporate transaction.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">DIRECTOR NOMINATIONS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Criteria for Board Membership</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Governance and Nominating Committee is responsible for annually reviewing the applicable skills and characteristics required of Board nominees with the Board in the context of current Board composition and our circumstances. In making its recommendations to the Board, the Governance and Nominating Committee considers, among other things, the qualifications of individual director candidates in light of the Board&#8217;s membership criteria as set forth in our Corporate Governance Guidelines. The Governance and Nominating Committee may utilize a variety of sources, including stockholder recommendations, Board member recommendations, executive search firms, management recommendations or other reasonable means to identify director candidates.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Governance and Nominating Committee considers candidates recommended by our Board and management, as well as candidates submitted by our stockholders (as discussed below).&nbsp;&nbsp;Board members or management that wish to recommend that a person be considered for Board membership are required to provide relevant qualifications and other information regarding the prospective candidate to the Governance and Nominating Committee along with their recommendations and reasons why such person should be considered. The Governance and Nominating Committee then, at its next regularly scheduled meeting, reviews each of the proposed candidates and determine whether or not to add such person to the proposed candidates list.&nbsp;&nbsp;In the event the Board determines to add an additional Board member, the Committee shall select candidates from this list in addition to candidates drawn from any search firm that the Committee deems necessary to retain for this purpose.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria we use in selecting Board candidates include the candidate&#8217;s integrity, business acumen, commitment, reputation among our various constituencies and communities, ability to make independent analytical inquiries, understanding of our business environment, and willingness to devote adequate time to Board duties. The Board has also determined that gender and ethnic diversity of the Board will be an important factor in evaluation of candidates. There are no other pre-established qualifications, qualities or skills at this time that any particular Director nominee must possess and nominees are not discriminated against on the basis of race, religion, national origin, sexual orientation, disability or any other basis proscribed by law. The Governance and Nominating Committee does not assign specific weights to particular criteria, nor has it adopted a particular policy. Rather, the Board believes that the backgrounds and qualifications of the directors, considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities. The goal of the Governance and Nominating Committee is to assemble a Board that brings a variety of skills derived from high quality businesses and professional experience. The Governance and Nominating Committee seeks to ensure that at least a majority of the directors are independent under NASDAQ rules, and that members of the Company&#8217;s Audit Committee meet the financial literacy and sophistication requirements under the NASDAQ rules, and at least one of them qualifies as an &#8220;audit committee financial expert&#8221; under the rules of the SEC.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Nominees</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Governance and Nominating Committee is responsible for the consideration of any director candidates recommended by security holders, provided such nominations are made in accordance with our bylaws and applicable law. Any recommendations received from the security holders will be evaluated in the same manner that potential nominees suggested by Board members, management or other parties are evaluated. Any such nominations should be submitted to the Governance and Nominating Committee c/o the Secretary of the Company and should include the following information: (a) all information relating to such nominee that is required by the Company&#8217;s Amended and Restated Bylaws (&#8220;Bylaws&#8221;), and that is required to be disclosed pursuant to Regulation 14A under the Securities Exchange Act of 1934 (including such person&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); (b) the names and addresses of the stockholders making the nomination and the number of shares of the Company&#8217;s common stock which are owned beneficially and of record by such stockholders; and (c) other appropriate biographical information and a statement as to the qualification of the nominee, and should be submitted no later than the deadlines described in our Bylaws and under the caption, &#8220;Stockholder Proposals for the 2018 Annual Meeting&#8221; below.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">STOCKHOLDER COMMUNICATION WITH THE BOARD</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders may contact an individual director, the Board as a group, or a specified Board committee or group, including the independent directors as a group, by the following means:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Mail:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board<br />Cytori Therapeutics, Inc.<br />3020 Callan Road<br />San Diego, CA 92121<br />CC:<font style="margin-left:36pt;"></font>General Counsel</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">E-mail:chairman@cytori.com</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each communication should specify the applicable addressee or addressees to be contacted as well as the general topic of the communication. The Chairman of the Board will initially receive and process communications before forwarding them to the addressee. Communications also may be referred to other departments within the Company. The Chairman of the Board generally will not forward to the directors a communication that he/she determines to be primarily commercial in nature or related to an improper or irrelevant topic, or that requests general information about us. Concerns about questionable accounting or auditing matters or possible violations of the Cytori Code of Business Conduct and Ethics should be reported pursuant to the procedures outlined in the Code of Business Conduct and Ethics, which are available on the Company&#8217;s website in the Investor Relations section under &#8220;Corporate Governance Materials.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">CODE OF BUSINESS CONDUCT AND ETHICS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. This Code of Business Conduct and Ethics has been posted on our website at www.cytori.com. We intend to post amendments to this code, or any waivers of its requirements, on our website at www.cytori.com in the Investor Relations section under &#8220;Corporate Governance,&#8221; as permitted under SEC rules and regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:7.69%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding ownership of our Common Stock as of February 28, 2017 (or earlier date for information based on filings with the SEC) by (a) each person known to us to own more than 5% of the outstanding shares of our Common Stock, (b) each director and nominee for director, (c) our President and Chief Executive Officer, VP of Finance and Chief Financial Officer and each other named executive officer, or NEO, named in the compensation tables appearing later in this Proxy Statement, and (d) all directors and executive officers as a group.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this table is based solely on statements in filings with the SEC or other reliable information.&nbsp;&nbsp;We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 23,568,403 shares of our common stock were issued and outstanding as of February 28, 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:48.86%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Address of Beneficial Owner <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Owned<sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards/Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Within 60 Days <sup style="font-size:85%; vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total&#160;Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficially</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Owned <sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td>
<td valign="bottom"  style="width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sabby Management, LLC. <sup style="font-size:85%; vertical-align:top">(5)</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,651,835</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,651,835</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 Mountainview Road, Suite 205</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upper Saddle River, NJ 07458</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, MD</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,133</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,739</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,872</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,084</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,067</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,151</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,000</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,501</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,501</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David M. Rickey</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,231</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,935</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,166</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Hawkins</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,433</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16, 405</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,838</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paul W. Hawran</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,236</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,727</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,963</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gregg A. Lapointe</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Lyons</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,357</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,604</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,961</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ronald A. Martell</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gail K. Naughton, Ph.D.</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,654</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,054</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All executive officers and directors as a group (11) <sup style="font-size:85%; vertical-align:top">(6)</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,517</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,833</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">446,350</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9 </p></td>
<td valign="bottom"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Represents beneficial ownership of less than one percent (1%) of the outstanding shares as of February 28, 2017.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Unless otherwise indicated, the address of each of the named individuals is c/o Cytori Therapeutics, Inc., 3020 Callan Road, San Diego, CA 92121.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Unless otherwise indicated, represents shares of outstanding common stock owned by the named parties as of February 28, 2017.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Shares of common stock subject to stock options or warrants currently exercisable or exercisable within 60 days of February 28, 2017 are deemed to be outstanding for computing the percentage ownership of the person holding such options and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The amounts and percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of such security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities for which that person has a right to acquire beneficial ownership within 60 days.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Based upon a Schedule 13G/A filed January 6, 2017, reporting beneficial ownership as of December 31, 2016. Sabby Healthcare Master Fund, Ltd. (&#8220;Sabby Healthcare&#8221;) has shared voting and dispositive power with respect to 1,132,643 shares. Sabby Volatility Warrant Master Fund, Ltd. (&#8220;Sabby Volatility&#8221;) has shared voting and dispositive power with respect to 519,192 shares.&nbsp;&nbsp;Sabby Management , LLC (&#8220;Sabby Management&#8221;) serves as the investment manager of Sabby Healthcare and Sabby Volatility and has shared voting and dispositive power with respect to 1,651,835 of these shares. Hal Mintz, in his capacity as manager of Sabby Management, has shared voting and dispositive power with respect to 1,651,835 of these shares. Each of Sabby Management, LLC and Hal Mintz disclaim beneficial ownership over the securities owned except to the extent of their pecuniary interest therein. The address for Sabby Management is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458. The address for Mr. Mintz is c/o Sabby Management, LLC, 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">This aggregate amount includes 14,844 shares owned (or subject to options that are exercisable within sixty days of February 28, 2017) by Jeremy Hayden, General Counsel and Vice President of Business Development.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIO</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">NS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Related Party Transactions</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following includes a summary of transactions since January 1, 2016 to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.&nbsp;&nbsp;We also describe below certain other transactions with our directors, executive officers and 5% stockholders. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rights Offering</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, we consummated a rights offering, or Rights Offering, to our stockholders of record (as of May 20, 2016) to subscribe for units at a subscription price of $2.55 per unit.&nbsp;&nbsp;Pursuant to the Rights Offering, we sold an aggregate of 6,704,852 units consisting of a total of 6,704,852 shares of common stock and 3,352,306 warrants to our stockholders, or Warrants, with each Warrant exercisable for one share of common stock at an exercise price of $3.06 per share.&nbsp;&nbsp;Certain of our directors participated in the Rights Offering and along with other participants in the Rights Offering, purchased common stock and Warrants to purchase our common stock.&nbsp;&nbsp;The Warrants trade on the Nasdaq Stock Market under the symbol &#8220;CYTXW.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director and Officer Indemnification</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws, as amended, provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Equity Award Grants to Executive Officers and Directors</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted equity awards to our executive officers and non-employee directors as more fully described elsewhere in this Proxy Statement.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information under the heading &#8220;Board Independence&#8221; in this Proxy Statement is incorporated herein by reference.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 16(a) of the Securities Exchange Act of 1934 requires our directors, executive officers, and persons or entities who own more than ten percent of our common stock, to file with the SEC reports of beneficial ownership and changes in beneficial ownership of our common stock.&nbsp;&nbsp;Those directors, officers, and stockholders are required by regulations to furnish us with copies of all forms they file under Section 16(a).&nbsp;&nbsp;Based solely upon a review of the copies of such reports furnished to us and written representations from such directors, officers, and stockholders, we believe that all such reports required to be filed during 2016 were filed on a timely basis.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">EXECUTIVE OFFICERS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth biographical information regarding our executive officers as of February 28, 2017.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position(s)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:25%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D.<sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance and Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Marino, M.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President and Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President and General Manager of Cell Therapy</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeremy Hayden.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel, Chief Compliance Officer, Secretary and Vice President of Business Development</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Proposal No. 1 Election of Directors&#8221; for biographical information regarding Dr. Hedrick.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o <font style="font-style:normal;">joined us as Vice President of Finance and Chief Financial Officer in September 2014. Mr. Gir&#227;o joined us from NuVasive, Inc., or NuVasive, a publicly-held medical device company, where he last served as International Controller from February 2014 to August 2014. Prior to his position as International Controller, he served as NuVasive&#8217;s Director of Financial Reporting from March 2012 to February 2014. In his position as Director of Financial Reporting, Mr. Gir&#227;o managed a team responsible for all corporate technical accounting and SEC-related matters for Nuvasive. Prior to joining NuVasive, Mr. Gir&#227;o served as Senior Manager, Assurance at KPMG, LLP from October 2004 to March 2012. Prior to joining KPMG, Mr. Gir&#227;o was a senior accountant for Ernst &amp;Young in Brazil from October 2000 to August 2004. Mr. Gir&#227;o is a certified public accountant with over 15 years&#8217; experience in the accounting, finance and reporting for U.S. and public companies and substantial experience in global finance and operations.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">John D. Harris <font style="font-style:normal;">has served as our Vice President and General Manager of Cell Therapy since he joined us in October 2015. Mr. Harris has over 20 years&#8217; experience in medical device and biotechnology, most recently serving as the Vice President and General Manager of Becton Dickinson&#8217;s operations in Japan. Prior to Becton Dickinson, Mr. Harris held business development, product development, and marketing and sales leadership roles with Tyco Electronics (now TE Connectivity Corp.), Delphi Automotive, Sorenson Medical, Kimberly-Clark Healthcare and Ballard Medical Products. Mr. Harris is a member of the Board of Governors of the American Chamber of Commerce in Japan (ACCJ) and a member of the Executive Committee of the American Medical Device &amp; Diagnostics Association, where he chairs the Regenerative Medicine Working Group. Mr. Harris holds Master of Business Administration and Bachelor of Arts degrees from the University of Utah.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Mark Marino, M.D. <font style="font-style:normal;">joined us as Senior Vice President of Medical Affairs in May 2016, and was also appointed as Chief Medical Officer of the Company in August 2016. Before joining us, Dr. Marino served as Senior Vice President of Early Clinical Development for Turing Pharmaceuticals from November 2015 to May 2016. Prior to Turing, Dr. Marino served as Executive Director of Clinical Development at Daiichi-Sankyo from September 2012 to February 2013, and then as Vice President of Clinical Development at Daiichi-Sankyo from February 2013 to November 2015. Prior to Daiichi-Sankyo, Dr. Marino held various senior clinical positions at Archimedes Pharma, Inc., MannKind Corporation and Hoffman-LaRoche from August 2006 to September 2012.&nbsp;&nbsp;Dr. Marino also previously served as Chief of the Department of Pharmacology at the Walter Reed Army Institute of Research as well as Associate Professor of Medicine at the Uniformed Services University of the Health Sciences and a staff physician at the Walter Reed Army Medical Center. Dr. Marino received his medical degree from the Albert Einstein School of Medicine and his specialty training in internal medicine at the Eisenhower Army Medical Center and sub-specialty training in Clinical Pharmacology at the Uniformed Services University of the Health Sciences.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Jeremy B. Hayden <font style="font-style:normal;">joined us as General Counsel and Vice President of Business Development in July 2015.&nbsp;&nbsp;Prior to joining us, Mr. Hayden served as Assistant General Counsel at Volcano Corporation, a publicly-held medical device company that was acquired by Koninklijke Philips N.V in early 2015.&nbsp;&nbsp;Prior to Volcano Corporation, Mr. Hayden practiced corporate and securities law at several national and international law firms, including Mintz Levin Cohn Ferris Glovsky &amp; Popeo, P.C. and McKenna Long &amp; Aldridge, LLP (now Dentons).&nbsp;&nbsp;Mr. Hayden received his A.B. in Politics from Princeton University and his J. D. from the University of Michigan Law School.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">Executive Compensation</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers, or NEOs, for fiscal year 2016 are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Marc H. Hedrick, M.D., our President and Chief Executive Officer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Tiago M. Gir&#227;o, our Vice President of Finance and Chief Financial Officer; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">John D. Harris, our Vice President and General Manager of Cell Therapy.</font></p></td></tr></table></div>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors are encouraged to read the compensation discussion below in conjunction with the compensation tables and related notes, which include more detailed information about the compensation of our NEOs for 2016 and 2015.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2016 Summary Compensation Table</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning compensation earned during 2015 and 2016 for services rendered to us by our NEOs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:23.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(h)</p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Awards <font style="font-family:Times New Roman Bold;"><sup style="font-size:85%; vertical-align:top">(1)</sup></font></p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards <font style="font-family:Times New Roman Bold;"><sup style="font-size:85%; vertical-align:top">(2)</sup></font></p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Equity Incentive&#160;Plan Comp.<font style="font-family:Times New Roman Bold;"><sup style="font-size:85%; vertical-align:top"> (3)</sup></font></p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other Compensation<font style="font-family:Times New Roman Bold;"><sup style="font-size:85%; vertical-align:top">(4)</sup></font></p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D.,</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,000</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,273</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,250</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">752,523</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,000</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,200</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,475</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">845,847</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o,</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,000</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,535</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,560</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410,095</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP of Finance, Chief Financial Officer and Chief Accounting Officer</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,000</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,086</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,600</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,563</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,249</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris,</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,830</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(5)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,535</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,365</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,249</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(6)</sup></p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616,979</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP and General Manager of Cell Therapy</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,167</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(5)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,982</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,988</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,647</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(6)</sup></p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,784</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">This column represents the dollar amount of the aggregate grant date fair value of stock awards granted in 2015, computed in accordance with FASB ASC Topic 718. For information relating to the assumptions made by us in valuing the stock awards made to our NEOs in 2016, refer to Note 12 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 24, 2017.&nbsp;&nbsp;These amounts do not reflect the actual economic value that will be realized by our NEOs upon vesting of the stock awards or sale of the common stock underlying the stock.&nbsp;&nbsp;On May 26, 2015, the Compensation Committee granted performance-based RSUs and the grant date fair value in the table was calculated based on the probable achievement of the performance objectives applicable to such awards, which was estimated at &#8220;target&#8221; performance for this purpose. Had maximum achievement of the performance criteria been achieved, the full grant date fair value of the awards, assuming maximum achievement of the performance criteria, would have been 200% of the amount set forth in the table.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">This column represents the dollar amount of the aggregate grant date fair value of option awards, computed in accordance with FASB ASC Topic 718. For information relating to the assumptions made by us in valuing the option awards made to our NEOs in 2016 and 2015, refer to Note 12 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 24, 2017.&nbsp;&nbsp;These amounts do not reflect the actual economic value that will be realized by our NEOs upon vesting of the stock options, exercise of the stock options, or sale of the common stock underlying the stock options.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The amounts in column (f) reflect the cash awards under our EMIC Plan, which is discussed in further detail below under the heading in the subsection entitled &#8220;<font style="font-style:italic;">Annual Bonuses (Executive Management Incentive Compensation Plan)</font>&#8221; of the &#8220;Narrative Disclosure to Compensation Tables&#8221; below.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Dollar value of the perquisites and other personal benefits for Dr. Hedrick and Mr. Gir&#227;o were less than $10,000 for the year reported.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">We paid Mr. Harris in Japanese Yen.&nbsp;&nbsp;During 2015, and 2016 his salary was reported at the average exchange rate over the year, or 0.0083 and 0.0086 Japanese Yen to US dollar in 2015 and 2016, respectively.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Per the terms of his employment offer letter with us, Mr. Harris was eligible to receive a housing allowance while on assignment in Japan up to a maximum of 13,900,000 Japanese Yen per year, including direct payment by us of Mr. Harris&#8217; local rent (not to exceed 1,100,000 Japanese Yen per month) and additional healthcare coverage.&nbsp;&nbsp;We paid these benefits in Japanese Yen, and we recorded them in 2015 and 2016 at the average exchange rate over the applicable year, or 0.0083 and 0.0086 Japanese Yen to U.S. dollar in 2015 and 2016, respectively.&nbsp;&nbsp;During 2015 and 2016, Mr. Harris&#8217; rent expense was $18,260 and $111,994, respectively, and cost of his additional health care coverage was $1,387 and $13,255, respectively.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Narrative Disclosures to Summary Compensation Table</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the process of determining compensation for our NEOs, the Compensation Committee considers our current financial position, our strategic goals and the performance of each of our NEOs. The Compensation Committee also benchmarks the various components (described below) of our compensation program for executives to compensation paid by other public companies in our defined peer group, compensation data from Radford Global Life Sciences Survey and BIOCOM Total Rewards Survey, historical review of all executive officer compensation, and recommendations from our Chief Executive Officer (other than for his own salary). From time to time the Compensation Committee engages the services of outside compensation consultants to provide compensation research, analysis and recommendations. The Compensation Committee has the sole authority to select, compensate and terminate its external advisors.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Compensation Committee utilizes the following components of compensation (described further below) to strike an appropriate balance between promoting sustainable and excellent performance and discouraging any inappropriate short-sighted risk-taking behavior:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Base salary;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Annual long-term equity compensation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Personal benefits and perquisites; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Acceleration and severance agreements tied to changes on control of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Base Salaries</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of our NEOs received base salary increases for 2016.&nbsp;&nbsp;While the Compensation Committee had previously approved an increase in Mr. Gir&#227;o&#8217;s annual base salary from $265,000 to $300,000 for fiscal year 2016, at Mr. Gir&#227;o&#8217;s request, this salary increase was deferred. Commencing effective as of January 1, 2017, Mr. Gir&#227;o&#8217;s annual base salary was increased from $265,000 to $300,000.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with determination of executive compensation for fiscal year 2017, the Compensation Committee directed Barney &amp; Barney, LLC, its independent compensation consultant, to prepare an updated senior management compensation assessment.&nbsp;&nbsp;The Compensation Committee reviewed this assessment at its normally scheduled meeting in January 2017.&nbsp;&nbsp;Based on this assessment and including other data points and information considered by the Compensation Committee in its discretion, the Compensation Committee approved the following NEO base salaries for fiscal year 2017, which base salaries went into effect in March 2017:&nbsp;&nbsp;Dr. Hedrick: $510,000; Mr. Harris:&nbsp;&nbsp;$360,500; Mr. Gir&#227;o: $309,000.&nbsp;&nbsp;The increases to Dr. Hedrick&#8217;s and Mr. Gir&#227;o&#8217;s base salaries were made to move such salaries closer to or within the 50th and 60th percentile range of base salary compensation for similarly situated executive at our peer companies, per our corporate compensation philosophy. Our compensation analysis indicates that Dr. Hedrick&#8217;s base salary is substantially closer to, but still below, this stated range, while Mr. Gir&#227;o&#8217;s base salary is now within this stated range. Mr. Harris&#8217; base salary remains above our stated range, but we believe that the Mr. Harris&#8217; actual duties and responsibilities, combined with his experience and skills (including Japanese linguistic and business/cultural fluency) are appropriately reflected in his base salary and other compensation.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barney &amp; Barney did not provide any services to us in 2016 beyond its engagement as an advisor to the Compensation Committee on compensation matters. After review and consultation with Barney &amp; Barney, the Compensation Committee has determined that Barney &amp; Barney is independent and there is no conflict of interest resulting from retaining Barney &amp; Barney currently or during the year ended December 31, 2016. In reaching these conclusions, the Compensation Committee considered the factors set forth in Exchange Act Rule 10C-1 and NASDAQ listing standards.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Bonuses (Executive Management Incentive Compensation Plan)</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>Our Compensation Committee adopted the Cytori Therapeutics Executive Management Incentive Compensation, or EMIC, plan to increase the performance-based component of our executives&#8217; compensation by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">linking their </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual cash bonus payments to achievement of shorter-term performance goals. Target bonuses are reviewed annually and established as a percentage of the executives&#8217; base salaries, generally based upon seniority of the officer and targeted at or near the me</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dian of the peer group (with reference to our corporate compensation philosophy) and relevant survey data (including the Radford Global Life Sciences Survey and BIOcom Total Rewards Survey). Each year the Compensation Committee establishes corporate and in</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dividual objectives and respective target percentages, taking into account recommendations from our Chief Executive Officer as it relates to executive positions other than the Chief Executive Officer&#8217;s compensation. Our Chief Executive Officer&#8217;s EMIC plan </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is set by the Compensation Committee to align entirely with our overall corporate objectives, while the other NEOs are also provided individual goals that constitute a portion of their overall EMIC plans. After each fiscal year-end, our Chief Executive Off</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">icer provides the Compensation Committee with a written evaluation showing actual performance as compared to corporate and/or individual objectives, and the Compensation Committee uses that information, along with the overall corporate performance, to dete</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rmine what percentage of each executive&#8217;s bonus target will be paid out as a bonus for that year.&nbsp;&nbsp;Overall, we attempt to set the corporate and individual functional goals to be highly challenging yet attainable.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For 2016, the general corporate goals approved by the Board (upon recommendation of the Compensation Committee for purposes of executive compensation) were determined by the Compensation Committee to account for 100% of the target cash bonus amount payable under the EMIC plan for our Chief Executive Officer, Dr. Hedrick, and to account for 75% of the overall target bonus amount payable under the EMIC plans for our other NEOs. The Company&#8217;s general corporate objectives included clinical, financial and operational objectives, including the achievement of certain enrollment goals for our STAR clinical trial; the achievement of certain year-end cash objectives, revenue goals and business development objectives; and various operational objectives.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following individual objectives for the NEOs other than Dr. Hedrick expanded upon their particular functions in the overall corporate objectives and were to weighted as 25% of their respective overall target bonus amounts.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Gir&#227;o&#8217;s individual objectives included the achievement of certain investor-related, liquidity, and partner-related goals.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Harris&#8217;s individual objectives included&nbsp;&nbsp;achievement of certain revenue, product utilization and business development/partnering goals.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our NEOs&#8217; target bonuses for 2016 as a percentage of base salary were as follows:&nbsp;&nbsp;Dr. Hedrick, 50% (increased from 45% in 2015); Mr. Gir&#227;o, 40% (increased from 30% in 2015); and Mr. Harris, 30% (unchanged from 2015, as Mr. Harris commenced employment with us in October 2015).&nbsp;&nbsp;The Compensation Committee, in its January 2017 meeting, evaluated our achievement in 2016 as compared to overall the corporate and individual objectives for the NEOs in the 2016 EMIC Plan described above. The Committee evaluated the overall results and then evaluated the NEOs&#8217; achievement relative to their own functional objectives and the results are tabulated in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:48.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Officer and Position</p></td>
<td valign="bottom"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Target Bonus as a % of Salary</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Target Bonus Awarded</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus Awarded as a % of Salary</p></td>
<td valign="bottom"  style="width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount of 2016 Bonus Payable in 2017<font style="font-weight:normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup></font></p></td>
<td valign="bottom"  style="width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D., President and CEO</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.0</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.5</p></td>
<td valign="bottom"  style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,688</p></td>
<td valign="top"  style="width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o, Vice President of Finance and Chief Financial Officer</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.3</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.5</p></td>
<td valign="bottom"  style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,670</p></td>
<td valign="top"  style="width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John D. Harris, VP &amp; General Manager of Cell Therapy</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.3</p></td>
<td valign="bottom"  style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.4</p></td>
<td valign="bottom"  style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,274</p></td>
<td valign="top"  style="width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The 2016 bonus amounts are payable in 2017 in installments as follows:&nbsp;&nbsp;50% of such amounts are payable on July 2, 2017, 25% of such amounts are payable on October 1, 2017 and the remaining 25% of such amounts are payable on January 1, 2018.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Mr. Gir&#227;o&#8217;s 2016 bonus amount is based off of the increased base salary previously approved by the Compensation Committee for fiscal year 2016, but at Mr. Gir&#227;o&#8217;s request, this salary increase was deferred. Commencing effective as of January 1, 2017, Mr. Gir&#227;o&#8217;s annual base salary was increased from $265,000 to $300,000.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 37</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its determination of target executive compensation for fiscal year 2017, the Compensation Committee determined bonus targets for our NEOs in consultation </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with Barney &amp; Barney and with reference to Barney &amp; Barney&#8217;s senior management compensation assessment and other materials and information, as deemed necessary or appropriate by the Compensation Committee in its discretion.&nbsp;&nbsp;Upon completion of this review,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Compensation Committee approved target bonuses (as a percentage of base salary) for our NEOs for fiscal year 2017 as follows: Dr. Hedrick: 55%; Mr. Gir&#227;o: 40%; Mr. Harris: 40%.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Long-Term Equity Compensation</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We designed our long-term equity grant program to further align the interests of our executives with those of our stockholders and to reward the executives&#8217; longer-term performance. Historically, the Compensation Committee has granted individual option grant awards, although from time-to-time, to further increase the emphasis on compensation tied to performance, the Compensation Committee may grant other equity awards as allowed by the 2014 Equity Incentive Plan. The Compensation Committee grants stock options, restricted stock, restricted stock units and similar equity awards permitted under our plans based on its judgment as to whether the complete compensation packages to our executives, including prior equity awards, are appropriate and sufficient to retain and incentivize the executives and whether the grants balance long-term versus short-term compensation. The Compensation Committee also considers our overall performance as well as the individual performance of each NEO, and the potential dilutive effect of restricted stock awards, and the dilutive and overhang effect of the equity grant awards, and recommendations from the Chief Executive Officer (other than with respect to his own equity awards).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are granted with an exercise price equal to the fair market value of our common stock on the date of grant.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, our NEOs were granted stock options to acquire shares of our common stock at an exercise price equal to the fair market value of our common stock on the Nasdaq Stock Market as of the date of grant, vesting in accordance with our standard four-year vesting schedules. Specifically, Dr. Hedrick, Mr. Gir&#227;o and Mr. Harris were granted (on a post-split basis reflecting the 1-for-15 reverse stock split that we consummated in May 2016) options to purchase 55,613, 23,322 and 23,322 shares of our common stock, respectively.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, as part of its determination of target executive compensation for fiscal year 2017, the Compensation Committee assessed long-term incentive compensation for our NEOs in consultation with Barney &amp; Barney and with reference to Barney &amp; Barney&#8217; s senior management compensation assessment and other materials and information, as deemed necessary or appropriate by the Compensation Committee in its discretion. Upon completion of its review, the Compensation Committee granted stock options to our NEOs to acquire shares of our common stock at an exercise price equal to the fair market value of our common stock on the Nasdaq Stock Market as of the date of grant, such options to vest in accordance with our standard four-year vesting schedules (subject to the NEOs&#8217; continued service as of the applicable vesting dates). Specifically, Dr. Hedrick, Mr. Gir&#227;o and Mr. Harris were granted options to purchase 96,350, 31,100 and 31,100 shares of our common stock, respectively.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Personal Benefits and Perquisites</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our executives are eligible to participate in our employee benefit plans, including medical, dental, vision, life insurance, short-term and long-term disability insurance, flexible spending accounts, 401(k), and an Employee Stock Purchase Program (ESPP). These plans are available to all full-time employees. In keeping with our philosophy to provide total compensation that is competitive within our industry, we offer limited personal benefits and perquisites to executive officers that include supplemental long-term disability insurance. You can find more information on the amounts paid for these perquisites to or on behalf of our NEOs in our 2016 Summary Compensation Table.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Company Acquisition / Post-Termination Compensation</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>We have entered into individual change of control and severance agreements, or CIC Agreements, with each of our NEOs. The CIC Agreements provide for certain severance benefits to be paid to each of our NEOs in the event of his involuntary termination without cause, or due to the executive&#8217;s resignation for good reason (including the Company&#8217;s material breach of its obligations, material reduction in duties, responsibilities, compensation or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefits, or relocation by more than 30 miles wit</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hout prior consent), provided such termination or resignation occurs in connection with an acquisition of the Company. Upon such termination or resignation in the event of an acquisition, Dr. Hedrick would receive a lump sum payment of 18 times his monthly</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> base salary, and 18 times his monthly COBRA payments, and Mr. Gir&#227;o and Mr. Harris would each receive a lump sum payment of 12 times his monthly base salary, and 12 times his monthly COBRA payments. Notwithstanding the foregoing, these NEOs&#8217; employment ma</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y be terminated for cause (including extended disability, repudiation of their CIC Agreements, conviction of a plea of no contest to certain crimes or misdemeanors, negligence that materially harms us, failure to perform material duties without cure, drug </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or alcohol use that materially interferes with performance, and chronic unpermitted absence) without triggering an obligation for us to pay severance benefits under the CIC Agreements.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the CIC Agreements, any unvested stock options granted to each of the above named executive officers would vest in full upon (1) the date of the executive&#8217;s termination under the circumstances described above following entry into an acquisition agreement (subject to the actual consummation of the acquisition) or (2) consummation of an acquisition.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In all events, each NEO&#8217;s entitlement to the benefits described above is expressly conditioned upon his execution and delivery to us of a CIC Agreement and a general release of claims, in the form attached to each CIC Agreement.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Outstanding Equity Awards at December 31, 2016</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding outstanding equity awards held by our NEOs as of December 31, 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:23.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  style="width:52.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style="width:19.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Awards</p></td>
<td valign="bottom"  style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option&#160;Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date (1)</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#)Exercisable (5)</p></td>
<td valign="bottom"  style="width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Un- Exercisable (2)(5)</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price ($) (5)</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock That</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Have Not</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested (#)</p></td>
<td valign="bottom"  style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units&#160;of&#160;Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">That Have</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Vested ($)</p></td>
<td valign="bottom"  style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick, M.D.,</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/26/2007</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,332</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.60</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/26/2017</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2008</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.10</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2018</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2009</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.00</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/05/2010</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,333</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.65</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/05/2020</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/27/2011</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,666</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83.55</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/27/2021</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/26/2012</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,666</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.60</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/26/2022</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2013</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,968</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.10</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2023</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2013</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,984</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.00</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2023</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2014</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,068</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,932</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.70</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2024</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/21/2014</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,666</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/21/2024</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/30/2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,675</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,325</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/30/2025</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,904</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,709</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2026</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tiago M. Gir&#227;o,</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/2/2014</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,160</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.40</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/2/2024</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP of Finance Chief Financial Officer</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/30/2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,841</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/30/2025</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,831</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,491</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2026</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Harris, VP and General Manager Cell Therapy</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/11/2015</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,516</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,817</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.55</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/11/2025</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:23.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2016</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,831</p></td>
<td valign="top"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,491</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/04/2026</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">For a better understanding of this table, we have included an additional column showing the grant date of the stock options.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Unless otherwise provided, stock options are subject to four-year vesting, and have a contractual term of 10 years from the date of grant. Awards presented in this table contain one of the following two vesting provisions:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">With respect to an initial stock option grant to an employee, 25% of the shares subject to the award vest on the one-year anniversary of the vesting start date, while an additional 1/48th of the remaining option shares vest at the end of each month thereafter for 36 consecutive months, or</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 39</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to stock option grants made to an employee after one full year of employment, 1/48th of the shares subject </font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the award vest </font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the end of</font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> each month over a four-year period, as measured from the vesting start date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The August 2014 stock option awards vested as to 50% of the shares subject to such awards after one year of service and the additional 50% vested on the second anniversary of the grant.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">These options were granted during the first year of the NEO&#8217;s employment and thus were subject to the following vesting schedule: 25% of the shares subject to the award vest on the one-year anniversary of the vesting start date, while an additional 1/48th of the remaining option shares vest at the end of each month thereafter for 36 consecutive months.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">We consummated a 1-for-15 reverse stock split in May 2016.&nbsp;&nbsp;The amounts set forth in this column reflect this 1-for-15 reverse stock split.</p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Compensation</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, our Board believes that the level of director compensation should be based on time spent carrying out Board and committee responsibilities and be competitive with comparable companies. In addition, the Board believes that a significant portion of director compensation should align director interests with the long-term interests of stockholders. The Board makes changes in its director compensation practices upon the recommendation of the Compensation Committee, and discussion and approval by the Board.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes director compensation awarded to, earned by or paid to our non-employee directors who served on our Board during fiscal year 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:48.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees&#160;Earned&#160;or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid in Cash <sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock&#160;Awards</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option&#160;Awards&#160;<sup style="font-size:85%; vertical-align:top">(3)(4)(5)</sup></p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Name <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:10.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  style="width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:11.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David M. Rickey, Chairman</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,667</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,749</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Hawkins</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,082</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paul W. Hawran</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,082</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Lyons</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,082</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gail K. Naughton, Ph.D.</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,082</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tommy G. Thompson <sup style="font-size:85%; vertical-align:top">(6)</sup></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,750</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,082</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,832</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ronald A. Martell <sup style="font-size:85%; vertical-align:top">(7)</sup></p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Dr. Hedrick is not included in this table as he is an employee of ours and receives no extra compensation for his service as a director. The compensation received by Dr. Hedrick in his capacity as an employee is set forth in the 2016 Summary Compensation Table and further described in the &#8220;Narrative Disclosures to Summary Compensation Table&#8221; above</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">In fiscal year 2016, (i) each non-employee director received a $30,000 retainer for service on our Board; (ii)&nbsp;&nbsp;each Compensation Committee, Governance and Nominating Committee and Audit Committee member received a $10,000 retainer for Committee service; (iii) the Chairman of the Board received an additional annual stipend of $30,000; (iv) the Chairman of the Audit Committee received an additional annual stipend of $15,000; and (v) the Chairmen of the Compensation Committee and the Governance and Nominating Committee each received an additional annual stipend of $15,000, respectively.&nbsp;&nbsp;Executive Committee members were exempt from receiving committee fees.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Column (d) represents the grant date fair value of the option awards, computed in accordance with FASB ASC Topic 718, granted to our non-employee directors during 2016. For additional information on the valuation assumptions with respect to the 2016 grants, refer to Note 12 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 24, 2017, regarding assumptions underlying valuation of equity awards. These amounts do not reflect the actual economic value that will be realized by our non-employee directors upon vesting of the stock options, exercise of the stock options or sale of the common stock underlying the stock.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">On January 4, 2016, our non-employee directors were awarded options to purchase 3,588 shares of our common stock. These options vested on the first anniversary of the date of grant. These option amounts reflect a 1-for 15 reverse stock split consummated by us on May 10, 2016.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">As of December 31, 2016, our non-employee directors held the following aggregate options: Mr. Rickey: 12,727 option shares; Richard Hawkins: 14,728 option shares; Paul Hawran: 12,728 option shares; Mr. Lyons:&nbsp;&nbsp;6,654 option shares; Ronald Martell: None;&nbsp;&nbsp;Dr. Naughton: 6,654 option shares.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Mr. Thompson stepped down from our Board in May 2016.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Mr. Martell joined our Board in mid-December 2016, and did not receive any compensation for his brief service in 2016.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Director Compensation Program</font></p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the Compensation Committee approved a Director Compensation Program for fiscal year 2017, as subsequently amended.&nbsp;&nbsp;The materials elements of the 2017 Director Compensation Program are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$40,000 annual cash retainer for Board members (an increase from $30,000 in 2016);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$30,000 annual cash retainer for the Chairman of the Board (no change from 2016);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$20,000 annual cash retainer for the Chairman of the Audit Committee (no change from 2016);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$15,000 annual cash retainer for the Chairman of our Compensation Committee and Governance and Nominating Committee (no change from 2016);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$10,000 annual cash retainer for each non-Chairman committee member (no change from 2016);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Initial grants for new directors</font><font style="font-family:Times New Roman;"> :&nbsp;&nbsp;Initial option grant, upon commencement of services, to purchase 50,000 shares of our common stock, vesting over two years in equal, annual installments as measured from the grant date;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';color:#231F20;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Annual grants for existing directors</font><font style="font-family:Times New Roman;"> : Recurring option grants to purchase 25,000 shares of our common stock, vesting in one installment on the first anniversary of the grant date.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the Board granted options to our non-employee directors for fiscal year 2017 in accordance with the terms of the Director Compensation Program described immediately above, including approval of an initial option grant to Ron Martell in connection with his commencement of service as a Board member.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Compensation Committee believes that these enhancements to the Director Compensation Program allow us to remain aligned with director compensation practices at our peer companies.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table gives information as of December 31, 2016 about shares of our common stock that may be issued upon the exercise of outstanding options, warrants and rights and shares remaining available for issuance under all of our equity compensation plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:55.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:12.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to be Issued<font style="font-weight:normal;"> </font>upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">warrants and rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding&#160;options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">warrants and rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:12.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for future issuance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">compensation plans</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(excluding&#160;securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">reflected in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">column(a)) (c)</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by security holders<sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,782</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.23</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by security holders<sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,748</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56.75</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by security holders<sup style="font-size:85%; vertical-align:top">(3)</sup></p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,764</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.64</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,522</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by security holders<sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,333</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.18</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,333</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636,627</p></td>
<td valign="top"  style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.37</p></td>
<td valign="top"  style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570,855</p></td>
<td valign="top"  style="width:0.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The 1997 Stock Option and Stock Purchase Plan expired in October 2007.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The 2004 Stock Option and Stock Purchase Plan expired in August 2014.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">See Proposal #3 above for a description of our 2014 Equity Incentive Plan.&nbsp;&nbsp;Also includes 11,557 shares available for issuance under our 2011 Employee Stock Purchase Plan.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">See Note 12 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 24, 2017 for a description of our 2015 New Employee Incentive Plan.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">AUDIT MATTERS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Report of the Audit Committee</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duties and responsibilities of the Audit Committee are set forth in its written charter, a copy which is available on the Company&#8217;s website. Under the guidance of a written charter adopted by the Board, the purpose of the Audit Committee is to oversee the accounting and financial reporting processes of the Company and audits of its financial statements. The responsibilities of the Audit Committee include appointing and providing for the compensation of the Company&#8217;s registered public accounting firm. Each of the members of the Audit Committee meets the independence requirements of NASDAQ.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has primary responsibility for the system of internal controls over financial reporting, disclosure controls and procedures, and for preparing the Company&#8217;s consolidated financial statements. The independent registered public accounting firm has the responsibility to express an opinion on the financial statements based on an audit conducted in accordance with generally accepted auditing standards.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this context and in connection with the audited financial statements contained in the Company&#8217;s Annual Report on Form 10-K, the Audit Committee provided the following report:</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee has reviewed and discussed the Company&#8217;s audited financial statements for the year ended December 31, 2016 with the Company&#8217;s management and the Company&#8217;s independent registered public accounting firm, BDO USA, LLP (&#8220;BDO&#8221;).&nbsp;&nbsp;The Audit Committee has discussed with BDO the matters required to be discussed by Auditing Standard No. 16, &#8221;Communication with Audit Committees,&#8221; as adopted by the Public Company Accounting Oversight Board in Rule 3200T. The Audit Committee has received the written disclosures and the letter from BDO required by the applicable requirements of the Public Company Accounting Oversight Board Rule 3526, Communication with Audit Committees Concerning Independence regarding BDO&#8217;s communications with the Audit Committee concerning independence, discussed with BDO their independence, and concluded that the non-audit services performed by BDO are compatible with maintaining their independence.&nbsp;&nbsp;BDO advised the audit committee that BDO was and continues to be independent accountants with respect to the Company.&nbsp;&nbsp;Based upon the Audit Committee&#8217;s review and discussions as noted above, the Audit Committee recommended to the Board that the Company&#8217;s audited financial statements be included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016 for filing with the Securities and Exchange Commission.</p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Respectfully submitted,<br />Paul W. Hawran (Chairman)<br />Richard J. Hawkins<br />Gary A. Lyons</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principal Accountant Fees and Services</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 12, 2016, we notified KPMG, LLP, or KPMG, of its dismissal as our independent registered public accounting firm, effective as of that date. The decision to change independent registered public accounting firms was recommended by our Audit Committee and was approved by the Board.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The audit reports of KPMG on our financial statements as of and for the years ended December 31, 2015 and 2014 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except that the reports contained a separate paragraph stating that our recurring losses from operations and liquidity position raise substantial doubt about our ability to continue as a going concern.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the two fiscal years ended December 31, 2015 and 2014, and the subsequent interim period through July 12, 2016, the date of KPMG&#8217;s dismissal, there were no: (1) disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference in connection with its opinion to the subject matter of the disagreement, or (2) reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 42</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KPMG&#8217;s letter to the SEC stating its agreement with the statements in the foregoing paragraphs was filed as Exhibit 16.1 to our Current Report on Form 8-K filed with the SEC on July 14, 2016.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 12, 2016, the Audit Committee appointed BDO USA, LLP, or BDO, as our independent registered public accounting firm for the fiscal year ending December 31, 2016, subject to completion of its standard client acceptance procedures (which were subsequently completed). The decision to engage BDO as our independent registered public accounting firm was recommended by the Audit Committee and approved by the Board.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee reviews and must pre-approve all audit and non-audit services performed by our independent registered public accounting firm, as well as the fees charged by it for such services.&nbsp;&nbsp;No fees charged by KPMG or BDO during 2016 were approved under the Regulation S-X Rule 2.01(c)(7)(i)(C) exception to the pre-approval requirement.&nbsp;&nbsp;In its review of non-audit service fees, the Audit Committee considers, among other things, the possible impact of the performance of such services on the accounting firm&#8217;s independence.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the aggregate fees paid or accrued by us for the audit and other services provided by KPMG for fiscal years ended December 31, 2016 and 2015, and provided by BDO for the fiscal year ended December 31, 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:55.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  style="width:42.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year Ended December 31,</p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BDO</p></td>
<td valign="bottom"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style="width:28.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">KPMG</p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees(1)</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281,204</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,400</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Related Fees(2)</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees(3)</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,823</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,000</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  style="width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,204</p></td>
<td valign="top"  style="width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,223</p></td>
<td valign="top"  style="width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">568,000</p></td>
<td valign="top"  style="width:0.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:76.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Audit fees consist of fees for professional services performed by BDO and KPMG for the audit of our annual financial statements included in this Form 10-K filing and review of financial statements included in our quarterly Form 10-Q filings, reviews of registration statements and issuances of consents, and services that are normally provided in connection with statutory and regulatory filings or engagements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Audit related fees consist of fees for assurance and related services, performed by BDO and KPMG that are reasonably related to the performance of the audit or review of our financial statements.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Tax fees consist of fees for professional services performed by BDO and KPMG with respect to tax compliance, tax advice, tax consulting and tax planning.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 43</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">OTHER MATTERS</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the time of preparation of this Proxy Statement, neither the Board nor management intends to bring before the meeting any business other than the matters referred to in the Notice of Annual Meeting and this Proxy Statement. If any other business should be properly brought before the meeting, or any adjournment or postponement thereof, the persons named in the proxy will vote on such matters according to their best judgment.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders Sharing the Same Address</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with notices previously sent to many stockholders who hold their shares through a bank, broker or other holder of record (a &#8220;street-name stockholder&#8221;) and share a single address, only one Notice of Availability of Proxy Materials is being delivered to that address unless contrary instructions from any stockholder at that address were received.&nbsp;&nbsp;This practice, known as &#8220;householding,&#8221; is intended to reduce our printing and postage costs.&nbsp;&nbsp;However, any such street-name stockholder residing at the same address who wishes to receive a separate copy of this Proxy Statement or accompanying Annual Report to Stockholders may request a copy by contacting the bank, broker or other holder of record, or the Company by telephone at: (858) 458-0900.&nbsp;&nbsp;The voting instruction sent to a street-name stockholder should provide information on how to request (1) householding of future Company materials or (2) separate materials if only one set of documents is being sent to a household.&nbsp;&nbsp;If it does not, a stockholder who would like to make one of these requests should contact us as indicated above.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholder Proposals for the 2018 Meeting</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders interested in submitting a proposal for consideration at our 2018 Annual Meeting must do so by sending such proposal to our Corporate Secretary at Cytori Therapeutics, Inc., 3020 Callan Road, San Diego, CA 92121, Attention:&nbsp;&nbsp;Corporate Secretary. Under the SEC&#8217;s proxy rules, the deadline for submission of proposals to be included in our proxy materials for the 2018 Annual Meeting is December 11, 2017. Accordingly, for a stockholder proposal to be considered for inclusion in our proxy materials for the 2018 Annual Meeting, any such stockholder proposal must be received by our Corporate Secretary on or before December 11, 2017 and comply with the procedures and requirements set forth in Rule 14a&#8209;8 under the Securities Exchange Act of 1934, as well as the applicable requirements of our bylaws. . Our bylaws require advance notice of business to be brought before a stockholders&#8217; meeting, including nominations of persons for election as directors. To be timely, notice to our Corporate Secretary must be received at our principal executive offices not less than 120 days prior to the anniversary date of the preceding year&#8217;s proxy statement and must contain specified information concerning the matters to be brought before such meeting and concerning the stockholder proposing such matters. Any stockholder proposal received after December 11, 2017 will be considered untimely, and will not be included in our proxy materials; <font style="color:#000000;">provided, however, that in the event we hold the 2018 Annual Meeting of stockholders more than 30 days before or after the one-year anniversary date of the 2017 Annual Meeting, </font>a proposal must be received by us a reasonable time before the proxy solicitation is made.</p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Order of the Board of Directors,</p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g20170410210550394558.jpg" title="" alt="" style="width:254px;height:68px;"><br />MARC H. HEDRICK<br /><font style="font-style:italic;">President and Chief Executive Officer</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement | Page 44</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">APPENDIX A</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />AMENDED AND RESTATED</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />2014 EQUITY INCENTIV</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">E PLAN</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />of</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br />CYTORI THERAPEUTICS, INC.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 EQUITY INCENTIVE PLAN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CYTORI THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:24pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(As Amended and Restated March 31, 2017)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cytori Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(As Amended and Restated March 31, 2017)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636149"></a>1.<font style="font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp; Establishment</font><font style="font-weight:bold;text-decoration:underline;">, Purpose and Term of Plan</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636150"></a>1.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Establishment</font><font style="font-weight:bold;font-style:italic;">.</font>&nbsp;&nbsp;This Plan constitutes an amendment and restatement of the 2014 Equity Incentive Plan of Cytori Therapeutics, Inc. (as amended to date, the &#8220;<font style="font-weight:bold;font-style:italic;">Original Plan</font>&#8221;), which was first approved by the Board on February 27, 2014, and approved by the stockholders of the Company on July 31, 2014, as amended by the Board on June 12, 2015, which amendment was approved by the stockholders of the Company on August 13, 2015, and as further amended by the Board on March 3, 2016, which amendment was approved by the stockholders of the Company on May 10, 2016, and as further amended by the Board on January 26, 2017.&nbsp;&nbsp;This amended and restated Plan was approved by the Board on March 31, 2017 (the &#8220;<font style="font-weight:bold;font-style:italic;">Restatement Effective Date</font>&#8221;), subject to stockholder approval.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636151"></a>1.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Purpose</font><font style="font-weight:bold;font-style:italic;">.</font>&nbsp;&nbsp;The purpose of the Plan is to advance the interests of the Participating Company Group and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Participating Company Group and by motivating such persons to contribute to the growth and profitability of the Participating Company Group.&nbsp;&nbsp;The Plan seeks to achieve this purpose by providing for Awards in the form of Options, Stock Appreciation Rights, Restricted Stock Purchase Rights, Restricted Stock Bonuses, Restricted Stock Units, Performance Shares, Performance Units, Cash-Based Awards, Other Stock-Based Awards, and Deferred Compensation Awards.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636152"></a>1.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Term of Plan.</font>&nbsp;&nbsp;The Plan shall continue in effect until its termination by the Committee; provided, however, that all Awards shall be granted, if at all, on or before ten (10) years from the Restatement Effective Date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Stockholder Approval</font>.&nbsp;&nbsp;This Plan shall be submitted for the approval of the Company&#8217;s stockholders within twelve (12) months after the Restatement Effective Date.&nbsp;&nbsp;Awards may be granted or awarded prior to such stockholder approval of this Plan; provided that no shares of Stock shall be issued upon the exercise, vesting, distribution or payment of any such Awards prior to the time when the Plan is approved by the Company&#8217;s stockholders; and, provided, further, that if such approval has not been obtained at the end of said 12-month period, all Awards previously granted or awarded under the Plan on or after the Restatement Effective Date and subject to such stockholder approval shall thereupon be canceled and become null and void and the Original Plan, as in effect prior to the Restatement Effective Date, and all Awards thereunder granted prior to the Restatement Effective Date, shall continue in full force and effect on the terms and conditions as in effect immediately prior to the Restatement Effective Date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:69.23%;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636153"></a><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">2.&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;text-decoration:underline;">Definitions and Construction</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636154"></a>2.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Definitions. </font> Whenever used herein, the following terms shall have their respective meanings set forth below:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Affiliate</font><font style="font-style:italic;">&#8221;</font> means (i)&#160;a parent entity, other than a Parent Corporation, that directly, or indirectly through one or more intermediary entities, controls the Company or (ii)&#160;a subsidiary entity, other than a Subsidiary Corporation, that is controlled by the Company directly or indirectly through one or more intermediary entities.&nbsp;&nbsp;For this purpose, the terms &#8220;parent,&#8221; &#8220;subsidiary,&#8221; &#8220;control&#8221; and &#8220;controlled by&#8221; shall have the meanings assigned such terms for the purposes of registration of securities on Form S-8 under the Securities Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;">Award</font><font style="font-style:italic;">&#8221;</font> means any Option, Stock Appreciation Right, Restricted Stock Purchase Right, Restricted Stock Bonus, Restricted Stock Unit, Performance Share, Performance Unit, Cash-Based Award, Other Stock-Based Award or Deferred Compensation Award granted under the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Award Agreement</font><font style="font-style:italic;">&#8221;</font> means a written or electronic agreement between the Company and a Participant setting forth the terms, conditions and restrictions applicable to an Award.&nbsp;&nbsp;Award Agreements evidencing Awards intended to qualify as Performance-Based Compensation shall contain such terms and conditions as may be necessary to meet the applicable provisions of Section 162(m). Award Agreements evidencing Incentive Stock Options shall contain such terms and conditions as may be necessary to meet the applicable provisions of Section 422 of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;">Board</font><font style="font-style:italic;">&#8221;</font> means the Board of Directors of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Cash-Based Award</font><font style="font-style:italic;">&#8221;</font> means an Award denominated in cash and granted pursuant to Section&#160;11.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Cashless Exercise</font><font style="font-style:italic;">&#8221;</font> means a Cashless Exercise as defined in Section&#160;6.3(b)(i).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>(e)<font style="font-style:italic;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Cause</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="color:#000000;"> means, unless such term or an equivalent term is otherwise defined by the applicable Award Agreement or other written agreement between a Participant and a Participating Company applicable to an Award, any of the following: (i)&#160;the Participant&#8217;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any Participating Company documents or records; (ii)&#160;the Participant&#8217;s material failure to abide by a Participating Company&#8217;s code of conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); (iii)&#160;the Participant&#8217;s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of a Participating Company (including, without limitation, the Participant&#8217;s improper use or disclosure of a Participating Company&#8217;s confidential or proprietary information); (iv)&#160;any intentional act by the Participant which has a material detrimental effect on a Participating Company&#8217;s reputation or business; (v)&#160;the Participant&#8217;s repeated failure or inability to perform any reasonable assigned duties after written notice from a Participating Company of, and a reasonable opportunity to cure, such failure or inability; (vi)&#160;any material breach by the Participant of any employment, service, non-disclosure, non-competition, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">non-solicitation or other similar agreement between the Participant and a Participating Company, which breach is not cured pursuant to the terms</font><font style="color:#000000;"> of such agreement; or (vii)&#160;the Participant&#8217;s conviction (including any plea of guilty or </font><font style="font-style:italic;color:#000000;">nolo contendere</font><font style="color:#000000;">) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant&#8217;s ability to perform his or h</font><font style="color:#000000;">er duties with a Participating Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref108845738"></a>(h)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Change in Control</font><font style="font-style:italic;">&#8221;</font> means the occurrence of any one or a combination of the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&nbsp;&nbsp;&nbsp;&nbsp; any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as such term is defined in Rule&#160;13d&#8209;3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total Fair Market Value or total combined voting power of the Company&#8217;s then&#8209;outstanding securities entitled to vote generally in the election of Directors; provided, however, that a Change in Control shall not be deemed to have occurred if such degree of beneficial ownership results from any of the following: (A)&#160;an acquisition by any person who on the Restatement Effective Date is the beneficial owner of more than fifty percent (50%) of such voting power, (B)&#160;any acquisition directly from the Company, including, without limitation, pursuant to or in connection with a public offering of securities, (C)&#160;any acquisition by the Company, (D)&#160;any acquisition by a trustee or other fiduciary under an employee benefit plan of a Participating Company or (E)&#160;any acquisition by an entity owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the voting securities of the Company; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)&nbsp;&nbsp;&nbsp;&nbsp; an Ownership Change Event or series of related Ownership Change Events (collectively, a <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Transaction</font><font style="font-style:italic;">&#8221;</font>) in which the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities entitled to vote generally in the election of Directors or, in the case of an Ownership Change Event described in Section&#160;2.1(ff)(iii), the entity to which the assets of the Company were transferred (the <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Transferee</font><font style="font-style:italic;">&#8221;</font>), as the case may be; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&nbsp;&nbsp;&nbsp;&nbsp; approval by the stockholders of a plan of complete liquidation or dissolution of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities.&nbsp;&nbsp;The Committee shall determine whether multiple acquisitions of the voting securities of the Company and/or multiple Ownership Change Events are related and to be treated in the aggregate as a single Change in Control, and its determination shall be final, binding and conclusive.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;">Code</font><font style="font-style:italic;">&#8221;</font> means the Internal Revenue Code of 1986, as amended, and any applicable regulations or administrative guidelines promulgated thereunder.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font><font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Committee</font><font style="font-style:italic;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means the Compensation Committee and such other committee or subcommittee of the Board, if any, duly appointed to administer the Plan and having </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such powers in each instance as shall be specified by the Board.&nbsp;&nbsp;If, at any time, there is no committee of the Board then authorized or properly constituted to administer the Plan, the Board shall exercise all of the powers of the Committee granted herein</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and, in any event, the Board may in its discretion exercise any or all of such powers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k) <font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Company</font><font style="font-style:italic;">&#8221;</font> means Cytori Therapeutics, Inc., a Delaware corporation, or any successor corporation thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l) <font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Consultant</font><font style="font-style:italic;">&#8221;</font> means a person engaged to provide consulting or advisory services (other than as an Employee or a member of the Board) to a Participating Company, provided that the identity of such person, the nature of such services or the entity to which such services are provided would not preclude the Company from offering or selling securities to such person pursuant to the Plan in reliance on registration on Form&#160;S&#8209;8 under the Securities Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)&nbsp;&nbsp; <font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Covered Employee</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="color:#000000;"> means, at any time the Plan is subject to Section 162(m), any Employee who is or may reasonably be expected to become a &#8220;covered employee&#8221; as defined in Section 162(m), or any successor statute.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Deferred Compensation Award</font><font style="font-style:italic;">&#8221;</font> means an Award granted to a Participant pursuant to Section&#160;12.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Director</font><font style="font-style:italic;">&#8221;</font> means a member of the Board.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="font-style:italic;">&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-style:italic;">Disability</font><font style="font-style:italic;">&#8221;</font> means the permanent and total disability of the Participant, within the meaning of Section&#160;22(e)(3) of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="font-style:italic;">&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Dividend Equivalent Right</font><font style="font-style:italic;">&#8221;</font> means the right of a Participant, granted at the discretion of the Committee or as otherwise provided by the Plan, to receive a credit for the account of such Participant in an amount equal to the cash dividends paid on one share of Stock for each share of Stock represented by an Award (other than an Option or SAR) held by such Participant. Notwithstanding anything to the contrary contained in the Plan, no dividends or Dividend Equivalent Rights that are paid prior to the vesting of any Award subject to Vesting Conditions shall be paid to a Participant with respect to such Award unless and until such Vesting Conditions are subsequently satisfied and the Award vests.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>(r)<font style="font-style:italic;">&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Employee</font><font style="font-style:italic;">&#8221;</font> means any person treated as an employee (including an Officer or a member of the Board who is also treated as an employee) in the records of a Participating Company and, with respect to any Incentive Stock Option granted to such person, who is an employee for purposes of Section&#160;422 of the Code; provided, however, that neither service as a member of the Board nor payment of a director&#8217;s fee shall be sufficient to constitute employment for purposes of the Plan.&nbsp;&nbsp;The Company shall determine in good faith and in the exercise of its discretion, whether an individual has become or has ceased to be an Employee and the effective date of such individual&#8217;s employment or termination of employment, as the case may be.&nbsp;&nbsp;For purposes of an individual&#8217;s rights, if any, under the terms of the Plan as of the time of the Company&#8217;s determination of whether or not the individual is an Employee, all such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determinations by the Company shall be final, binding and conclusive as to such rights, if any, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination as to such individual&#8217;s status as an</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Employee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">ERISA</font><font style="font-style:italic;">&#8221;</font> means the Employee Retirement Income Security Act of 1974 and any applicable regulations or administrative guidelines promulgated thereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(t)&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Exchange Act</font><font style="font-style:italic;">&#8221;</font> means the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)<font style="font-style:italic;">&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Fair Market Value</font><font style="font-style:italic;">&#8221;</font> means, as of any date, the value of a share of Stock or other property as determined by the Committee, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&nbsp;&nbsp;&nbsp;&nbsp; Except as otherwise determined by the Committee, if, on such date, the Stock is listed or quoted on a national or regional securities exchange or quotation system, the Fair Market Value of a share of Stock shall be the closing price of a share of Stock as quoted on the national or regional securities exchange or quotation system constituting the primary market for the Stock, as reported in <font style="font-style:italic;">The Wall Street Journal</font> or such other source as the Company deems reliable.&nbsp;&nbsp;If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or quotation system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded or quoted prior to the relevant date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)&nbsp;&nbsp;&nbsp;&nbsp; <font style="color:#000000;">Notwithstanding the foregoing, the Committee may, in its discretion, determine the Fair Market Value of a share of Stock on the basis of the opening, closing, or average of the high and low sale prices of a share of Stock on such date or the preceding trading day, the actual sale price of a share of Stock received by a Participant, any other reasonable basis using actual transactions in the Stock as reported on</font> a national or regional securities exchange or quotation system, or on any other basis consistent with the requirements of Section 409A.&nbsp;&nbsp;<font style="color:#000000;">The Committee may vary its method of determination of the Fair Market Value as provided in this Section for different purposes under the Plan to the extent consistent with the requirements of Section 409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&nbsp;&nbsp;&nbsp;&nbsp; If, on such date, the Stock is not listed or quoted on a national or regional securities exchange or quotation system, the Fair Market Value of a share of Stock shall be as determined by the Committee in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse, and in a manner consistent with the requirements of Section 409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp; &#8220;</font><font style="font-weight:bold;font-style:italic;">Full Value Award</font><font style="font-style:italic;">&#8221;</font> means any Award settled in Stock, other than (i)&#160;an Option, (ii)&#160;a Stock Appreciation Right, or (iii)&#160;a Restricted Stock Purchase Right or an Other Stock-Based Award under which the Company will receive monetary consideration equal to the Fair Market Value (determined on the effective date of grant) of the shares subject to such Award.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(w)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Incentive Stock Opti</font><font style="font-weight:bold;font-style:italic;">on</font><font style="font-style:italic;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means an Option intended to be (as set forth in the Award Agreement) and which qualifies as an incentive stock option within the meaning of Section&#160;422(b) of the Code.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Insider</font><font style="font-style:italic;">&#8221;</font> means an Officer, Director or any other person whose transactions in Stock are subject to Section&#160;16 of the Exchange Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y)&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Net Exercise</font><font style="font-style:italic;">&#8221;</font> means a Net Exercise as defined in Section&#160;6.3(b)(ii).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(z)&nbsp;&nbsp;<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Nonemployee Director</font><font style="font-style:italic;">&#8221;</font> means a Director who is not an Employee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(aa)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Nonemployee Director Award</font><font style="font-style:italic;">&#8221;</font> means any Award granted to a Nonemployee Director.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(bb) <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Nonstatutory Stock Option</font><font style="font-style:italic;">&#8221;</font> means an Option not intended to be (as set forth in the Award Agreement) or which does not qualify as an incentive stock option within the meaning of Section&#160;422(b) of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(cc)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Officer</font><font style="font-style:italic;">&#8221;</font> means any person designated by the Board as an officer of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(dd)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Option</font><font style="font-style:italic;">&#8221;</font> means an Incentive Stock Option or a Nonstatutory Stock Option granted pursuant to the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ee)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Other Stock-Based Award</font><font style="font-style:italic;">&#8221;</font> means an Award denominated in shares of Stock and granted pursuant to Section&#160;11.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref63758123"></a>(ff)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Ownership Change Event</font><font style="font-style:italic;">&#8221;</font> means the occurrence of any of the following with respect to the Company:&nbsp;&nbsp;(i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of securities of the Company representing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of Directors; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (other than a sale, exchange or transfer to one or more subsidiaries of the Company).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(gg)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Parent Corporation</font><font style="font-style:italic;">&#8221;</font> means any present or future &#8220;parent corporation&#8221; of the Company, as defined in Section&#160;424(e) of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hh)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Participant</font><font style="font-style:italic;">&#8221;</font> means any eligible person who has been granted one or more Awards.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Participating Company</font><font style="font-style:italic;">&#8221;</font> means the Company or any Parent Corporation, Subsidiary Corporation or Affiliate.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(jj)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Participating Company Group</font><font style="font-style:italic;">&#8221;</font> means, at any point in time, the Company and all other entities collectively which are then Participating Companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(kk)</font><font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Award</font><font style="font-style:italic;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means an Award of Performance Shares or Performanc</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Units.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ll)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Award Formula</font><font style="font-style:italic;">&#8221;</font> means, for any Award, a formula or table established by the Committee pursuant to Section&#160;10.3 which provides the basis for computing the value of an Award at one or more levels of attainment of the applicable Performance Goal(s) measured as of the end of the applicable Performance Period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(mm)<font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Performance-Based Compensation</font><font style="color:#000000;">&#8221; means compensation under an Award that is intended to </font>qualify as &#8220;performance-based compensation&#8221; as described in Section&#160;162(m)(4)(C) of the Code<font style="color:#000000;"> paid to Covered Employees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(nn)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Goal</font><font style="font-style:italic;">&#8221;</font> means a performance goal established by the Committee pursuant to Section&#160;10.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(oo)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Period</font><font style="font-style:italic;">&#8221;</font> means a period established by the Committee pursuant to Section&#160;10.3 at the end of which one or more Performance Goals are to be measured.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(pp)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Share</font><font style="font-style:italic;">&#8221;</font> means a right granted to a Participant pursuant to Section 10 to receive a payment equal to the value of a Performance Share, as determined by the Committee, based upon attainment of applicable Performance Goal(s).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(qq)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Performance Unit</font><font style="font-style:italic;">&#8221;</font> means a right granted to a Participant pursuant to Section 10 to receive a payment equal to the value of a Performance Unit, as determined by the Committee, based upon attainment of applicable Performance Goal(s).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(rr)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Restricted Stock Award</font><font style="font-style:italic;">&#8221;</font> means an Award of a Restricted Stock Bonus or a Restricted Stock Purchase Right.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ss)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Restricted Stock Bonus</font><font style="font-style:italic;">&#8221;</font> means Stock granted to a Participant pursuant to Section&#160;8.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(tt)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Restricted Stock Purchase Right</font><font style="font-style:italic;">&#8221;</font> means a right to purchase Stock granted to a Participant pursuant to Section&#160;8.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(uu)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Restricted Stock Unit</font><font style="font-style:italic;">&#8221;</font> means a right granted to a Participant pursuant to Section 9 to receive on a future date or event a share of Stock or cash in lieu thereof, as determined by the Committee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vv)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Rule 16b&#8209;3</font><font style="font-style:italic;">&#8221;</font> means Rule&#160;16b&#8209;3 under the Exchange Act, as amended from time to time, or any successor rule or regulation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ww)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">SAR</font><font style="font-style:italic;">&#8221;</font> or <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Stock Appreciation Right</font><font style="font-style:italic;">&#8221;</font> means a right granted to a Participant pursuant to Section&#160;7 to receive payment, for each share of Stock subject to such Award, of an amount equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the Award over the exercise price thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xx)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Section&#160;162(m)</font><font style="font-style:italic;">&#8221;</font> means Section&#160;162(m) of the Code.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(yy)</font><font style="font-style:italic;color:#000000;"> &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Section&#160;409A</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="color:#000000;"> means Section&#160;409A of the Code.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(zz)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Section 409A Deferred Compensation</font><font style="font-style:italic;">&#8221;</font> means compensation provided pursuant to an Award that constitutes nonqualified deferred compensation within the meaning of Section 409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(aaa)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Securities Act</font><font style="font-style:italic;">&#8221;</font> means the Securities Act of 1933, as amended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(bbb)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Service</font><font style="font-style:italic;">&#8221;</font> means a Participant&#8217;s employment or service with the Participating Company Group, whether as an Employee, a Director or a Consultant.&nbsp;&nbsp;Unless otherwise provided by the Committee, a Participant&#8217;s Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders such Service or a change in the Participating Company for which the Participant renders such Service, provided that there is no interruption or termination of the Participant&#8217;s Service.&nbsp;&nbsp;Furthermore, a Participant&#8217;s Service shall not be deemed to have been interrupted or terminated if the Participant takes any military leave, sick leave, or other bona fide leave of absence approved by the Company.&nbsp;&nbsp;However, unless otherwise provided by the Committee, if any such leave taken by a Participant exceeds ninety (90) days, then on the ninety-first (91st) day following the commencement of such leave the Participant&#8217;s Service shall be deemed to have terminated, unless the Participant&#8217;s right to return to Service is guaranteed by statute or contract.&nbsp;&nbsp;Notwithstanding the foregoing, unless otherwise designated by the Company or required by law, an unpaid leave of absence shall not be treated as Service for purposes of determining vesting under the Participant&#8217;s Award Agreement.&nbsp;&nbsp;A Participant&#8217;s Service shall be deemed to have terminated either upon an actual termination of Service or upon the business entity for which the Participant performs Service ceasing to be a Participating Company.&nbsp;&nbsp;Subject to the foregoing, the Company, in its discretion, shall determine whether the Participant&#8217;s Service has terminated and the effective date of such termination.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ccc)&nbsp;&nbsp;Subject to the provisions of Section&#160;409A, the term &#8220;<font style="font-weight:bold;font-style:italic;">Short-Term Deferral Period</font><font style="font-style:italic;">&#8221;</font> means the 2&#189; month period ending on the later of (i)&#160;the 15th day of the third month following the end of the Participant&#8217;s taxable year in which the right to payment under the applicable portion of the Award is no longer subject to a substantial risk of forfeiture or (ii)&#160;the 15th day of the third month following the end of the Company&#8217;s taxable year in which the right to payment under the applicable portion of the Award is no longer subject to a substantial risk of forfeiture.&nbsp;&nbsp;For this purpose, the term &#8220;substantial risk of forfeiture&#8221; shall have the meaning provided by Section&#160;409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ddd)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Stock</font><font style="font-style:italic;">&#8221;</font> means the common stock of the Company, as adjusted from time to time in accordance with Section&#160;4.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(eee)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Subsidiary Corporation</font><font style="font-style:italic;">&#8221;</font> means any present or future &#8220;subsidiary corporation&#8221; of the Company, as defined in Section&#160;424(f) of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(fff)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Ten Percent Owner</font><font style="font-style:italic;">&#8221;</font> means a Participant who, at the time an Option is granted to the Participant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of a Participating Company (other than an Affiliate) within the meaning of Section&#160;422(b)(6) of the Code.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ggg)</font><font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Trading Compliance Policy</font><font style="font-style:italic;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means the written policy of the Company pertaining to the purchase, sale, transfer or other disposition of the Company&#8217;s equity securities by Directors, Officers, Employees or other se</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rvice providers who may possess material, nonpublic information regarding the Company or its securities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hhh)<font style="font-style:italic;"> &#8220;</font><font style="font-weight:bold;font-style:italic;">Vesting Conditions</font><font style="font-style:italic;">&#8221;</font> mean those conditions established in accordance with the Plan prior to the satisfaction of which an Award or shares subject to an Award remain subject to forfeiture or a repurchase option in favor of the Company exercisable for the Participant&#8217;s monetary purchase price, if any, for such shares upon the Participant&#8217;s termination of Service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636155"></a>2.2&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;">Construction.</font>&nbsp;&nbsp;Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan.&nbsp;&nbsp;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&nbsp;&nbsp;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636156"></a>3.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Administration</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636157"></a>3.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Administration by the Committee.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Plan shall be administered by the Committee.&nbsp;&nbsp;All questions of interpretation of the Plan, of any Award Agreement or of any other form of agreement or other document employed by the Company in the administration of the Plan or of any Award shall be determined by the Committee, and such determinations shall be final, binding and conclusive upon all persons having an interest in the Plan or such Award, unless fraudulent or made in bad faith.&nbsp;&nbsp;Any and all actions, decisions and determinations taken or made by the Committee in the exercise of its discretion pursuant to the Plan or Award Agreement or other agreement thereunder (other than determining questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest therein.&nbsp;&nbsp;All expenses incurred in the administration of the Plan shall be paid by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636158"></a>3.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Authority of Officers.</font><font style="font-variant: normal;">&nbsp;&nbsp;Any Officer shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided that the Officer has apparent authority with respect to such matter, right, obligation, determination or election.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636159"></a>3.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Administration with Respect to Insiders.</font><font style="font-variant: normal;">&nbsp;&nbsp;With respect to participation by Insiders in the Plan, at any time that any class of equity security of the Company is registered pursuant to Section&#160;12 of the Exchange Act, the Plan shall be administered in compliance with the requirements, if any, of Rule&#160;16b&#8209;3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636160"></a>3.4&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Committee Complying with Section&#160;162(m).</font><font style="font-variant: normal;">&nbsp;&nbsp;If the Company is a &#8220;publicly held corporation&#8221; within the meaning of Section&#160;162(m), the Board shall establish a Committee of &#8220;outside directors&#8221; within the meaning of Section&#160;162(m) to approve the grant of any Award intended to qualify as Performance-Based Compensation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636161"></a><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>3.5&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Powers of the Committee</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;In addition to any other powers set forth in the Plan and subject to the provisions of the Plan, including, but not limited to the prohibitions on </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Option or SAR repricings set forth in Section 3.6, the Committee shall have the full and final power and authority, in its discretion:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) to determine the persons to whom, and the time or times at which, Awards shall be granted and the number of shares of Stock, units or monetary value to be subject to each Award;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) to determine the type of Award granted;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) to determine the Fair Market Value of shares of Stock or other property;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) to determine the terms, conditions and restrictions applicable to each Award (which need not be identical) and any shares acquired pursuant thereto, including, without limitation, (i)&#160;the exercise or purchase price of shares pursuant to any Award, (ii)&#160;the method of payment for shares purchased pursuant to any Award, (iii)&#160;the method for satisfaction of any tax withholding obligation arising in connection with any Award, including by the withholding or delivery of shares of Stock, (iv)&#160;the timing, terms and conditions of the exercisability or vesting of any Award or any shares acquired pursuant thereto, (v)&#160;the Performance Measures, Performance Period, Performance Award Formula and Performance Goals applicable to any Award and the extent to which such Performance Goals have been attained, (vi)&#160;the time of the expiration of any Award, (vii)&#160;the effect of the Participant&#8217;s termination of Service on any of the foregoing, and (viii)&#160;all other terms, conditions and restrictions applicable to any Award or shares acquired pursuant thereto not inconsistent with the terms of the Plan;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) to determine whether an Award will be settled in shares of Stock, cash, other property or in any combination thereof;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) to approve one or more forms of Award Agreement;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) to amend, modify, or cancel any Award or to waive any restrictions or conditions applicable to any Award or any shares acquired pursuant thereto;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h) to accelerate, continue, extend or defer the exercisability or vesting of any Award or any shares acquired pursuant thereto, including with respect to the period following a Participant&#8217;s termination of Service;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) to prescribe, amend or rescind rules, guidelines and policies relating to the Plan, or to adopt sub-plans or supplements to, or alternative versions of, the Plan, including, without limitation, as the Committee deems necessary or desirable to comply with the laws or regulations of or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions whose citizens may be granted Awards; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j) to correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award Agreement and to make all other determinations and take such other actions with respect to the Plan or any Award as the Committee may deem advisable to the extent not inconsistent with the provisions of the Plan or applicable law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636162"></a><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;">Option or SAR Repricing</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Without the affirmative vote of holders of a majority of the shares of Stock cast in person or by proxy at a meeting of the stockholders of the Company at which a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> quorum representing a majority of all outstanding shares of Stock is present or represented by proxy, the Committee shall not approve a program providing for either (a)&#160;the cancellation of outstanding Options or SARs having exercise prices per share great</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er than the then Fair Market Value of a share of Stock (</font><font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Underwater Awards</font><font style="font-style:italic;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and the grant in substitution therefore of new Options or SARs having a lower exercise price, Full Value Awards, or payments in cash, or (b)&#160;the amendment of outstanding Underwate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r Awards to reduce the exercise price thereof.&nbsp;&nbsp;This Section shall not apply to adjustments pursuant to the assumption of or substitution for an Option or SAR in a manner that would comply with Section 424(a) or Section 409A of the Code or to an adjustment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pursuant to Section&#160;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636163"></a>3.7&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Indemnification.</font>&nbsp;&nbsp;In addition to such other rights of indemnification as they may have as members of the Board or the Committee or as officers or employees of the Participating Company Group, to the extent permitted by applicable law, members of the Board or the Committee and any officers or employees of the Participating Company Group to whom authority to act for the Board, the Committee or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including attorneys&#8217; fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle and defend the same.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref204339699"></a><a name="_Toc384636164"></a>4&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;text-decoration:underline;font-variant: small-caps;">Shares Subject to Plan</font><font style="font-weight:bold;font-variant: small-caps;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57606357"></a><a name="_Toc384636165"></a>4.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Maximum Number of Shares Issuable.</font>&nbsp;&nbsp;Subject to adjustment as provided in Section 4.3, as of the Restatement Effective Date, the maximum number of shares of Stock that may be issued under the Plan pursuant to Awards shall be equal to two million nine hundred thousand one hundred thirty-three (2,900,133) shares.&nbsp;&nbsp;Shares of Stock that may be issued under the Plan pursuant to Awards shall consist of authorized or reacquired shares of Stock or any combination thereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref77919556"></a><a name="_Ref224451690"></a><a name="_Ref247703761"></a><a name="_Toc384636166"></a><a name="_Ref99255977"></a><a name="_Ref254710227"></a>4.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;"><a name="_Ref254710227"></a>Share Counting.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>(a) If an outstanding Award for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of Stock acquired pursuant to an Award subject to forfeiture or repurchase are forfeited or repurchased by the Company for an amount not greater than the Participant&#8217;s purchase price, then in each case the shares of Stock allocable to the terminated portion of such Award or such forfeited or repurchased shares of Stock shall again be available for issuance under the Plan.&nbsp;&nbsp;Shares of Stock shall not be deemed to have been issued pursuant to the Plan with respect to any portion of an Award that is settled in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash.&nbsp;&nbsp;Shares withheld or reacquired by the Company in satisfaction of tax withholding obligations applicable to SARs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Options pursuant to Section 17.2, shall not again be available for issuance under the Plan.&nbsp;&nbsp;Shares withheld by the Company in satisfaction of tax withholding obligations described in Section 17.2 with respect to Full Value Awards, shall again be avai</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lable for issuance under the Plan.&nbsp;&nbsp;Upon payment in shares of Stock pursuant to the exercise of a SAR, the number of shares available for issuance under the Plan shall be reduced by the gross number of shares subject to the SAR.&nbsp;&nbsp;If the exercise price of a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n Option is paid by means of a Net-Exercise, the number of shares available for issuance under the Plan shall be reduced by the gross number of shares for which the Option is exercised.&nbsp;&nbsp;Shares reacquired by the Company on the open market or otherwise usin</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g cash proceeds from the exercise of Options shall not be added to the shares of Stock authorized for grant under this Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Any shares of Stock that again become available for grant pursuant to this Section shall be added back as one (1) share of Stock for every one share subject to an Award.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref32362547"></a><a name="_Toc384636167"></a><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>4.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Adjustments for Changes in Capital Structure</font><font style="font-weight:bold;font-style:italic;">.</font>&nbsp;&nbsp;Subject to any required action by the stockholders of the Company and the requirements of Sections 409A and 424 of the Code to the extent applicable, in the event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders of the Company in a form other than Stock (excepting regular, periodic cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number and kind of shares subject to the Plan and to any outstanding Awards, the Award limits set forth in Section&#160;5.3, and in the exercise or purchase price per share under any outstanding Award in order to prevent dilution or enlargement of Participants&#8217; rights under the Plan.&nbsp;&nbsp;For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &#8220;effected without receipt of consideration by the Company.&#8221;&nbsp;&nbsp;If a majority of the shares which are of the same class as the shares that are subject to outstanding Awards are exchanged for, converted into, or otherwise become (whether or not pursuant to an Ownership Change Event) shares of another corporation (the <font style="font-style:italic;font-family:Tms Rmn;">&#8220;</font><font style="font-weight:bold;font-style:italic;">New Shares</font><font style="font-style:italic;font-family:Tms Rmn;">&#8221;</font>), the Committee may unilaterally amend the outstanding Awards to provide that such Awards are for New Shares.&nbsp;&nbsp;In the event of any such amendment, the number of shares subject to, and the exercise or purchase price per share of, the outstanding Awards shall be adjusted in a fair and equitable manner as determined by the Committee, in its discretion.&nbsp;&nbsp;Any fractional share resulting from an adjustment pursuant to this Section shall be rounded down to the nearest whole number, and in no event may the exercise or purchase price under any Award be decreased to an amount less than the par value, if any, of the stock subject to such Award.&nbsp;&nbsp;The Committee in its discretion, may also make such adjustments in the terms of any Award to reflect, or related to, such changes in the capital structure of the Company or distributions as it deems appropriate, including modification of Performance Goals, Performance Award Formulas and Performance Periods.&nbsp;&nbsp;The adjustments determined by the Committee pursuant to this Section shall be final, binding and conclusive.&nbsp;&nbsp;Unless otherwise determined by the Committee, no adjustment or action described in this Section 4.3 or in any other provision of the Plan shall be authorized to the extent it would (i) with respect to Awards which are granted to Covered </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees and are intended to qualify as Performance-Based Compensation, cause such Awards to fail to so qualify </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as Performance-Based Compensation, (ii) cause the Plan to violate Section&#160;422(b)(1) of the Code, (iii) result in short-swing profits liability under Section 16 of the Exchange Act or violate the exemptive conditions of Rule 16b-3 of the Exchange Act, or (i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v) cause an Award to fail to be exempt from or comply with Section 409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636168"></a>4.4&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Assumption or Substitution of Awards.</font>&nbsp;&nbsp;The Committee may, without affecting the number of shares of Stock reserved or available hereunder, authorize the issuance or assumption of benefits under this Plan in connection with any merger, consolidation, acquisition of property or stock, or reorganization upon such terms and conditions as it may deem appropriate, subject to compliance with Section&#160;409A and any other applicable provisions of the Code.&nbsp;&nbsp;In addition, subject to compliance with applicable laws, and listing requirements, shares available for grant under a stockholder approved plan of an acquired company (as appropriately adjusted to reflect the transaction) may be used for awards under the Plan to individuals who were not Employees or Directors of the Participating Company Group prior to the transaction and shall not reduce the share reserve set forth above.&nbsp;&nbsp;Shares reacquired by the Company on the open market or otherwise using cash proceeds from the exercise of Options shall not be added to the shares of Stock authorized for grant under this Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57608549"></a><a name="_Toc384636169"></a>5.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;font-variant: small-caps;">Eligibility, Participation and Award Limitations</font><font style="font-weight:bold;font-variant: small-caps;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636170"></a>5.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Persons Eligible for Awards.</font>&nbsp;&nbsp;Awards may be granted only to Employees, Consultants and Directors.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636171"></a>5.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Participation in the Plan.</font>&nbsp;&nbsp;Awards are granted solely at the discretion of the Committee.&nbsp;&nbsp;Eligible persons may be granted more than one Award.&nbsp;&nbsp;However, eligibility in accordance with this Section shall not entitle any person to be granted an Award, or, having been granted an Award, to be granted an additional Award.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc384636172"></a><a name="_Ref192931021"></a><a name="_Ref99260560"></a>5.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">Award Limitations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-style:italic;">Incentive Stock Option Limitations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="font-weight:bold;">Maximum Number of Shares Issuable Pursuant to Incentive Stock Options.</font>&nbsp;&nbsp;Subject to adjustment as provided in Section&#160;4.3, the maximum aggregate number of shares of Stock that may be issued under the Plan pursuant to the exercise of Incentive Stock Options shall not exceed two million nine hundred thousand one hundred thirty-three (2,900,133) shares.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="font-weight:bold;">Persons Eligible.</font>&nbsp;&nbsp;An Incentive Stock Option may be granted only to a person who, on the effective date of grant, is an Employee of the Company, a Parent Corporation or a Subsidiary Corporation (each being an <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">ISO-Qualifying Corporation</font><font style="font-style:italic;">&#8221;</font>).&nbsp;&nbsp;Any person who is not an Employee of an ISO-Qualifying Corporation on the effective date of the grant of an Option to such person may be granted only a Nonstatutory Stock Option.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>(iii) <font style="font-weight:bold;">Fair Market Value Limitation.</font>&nbsp;&nbsp;To the extent that options designated as Incentive Stock Options (granted under all stock option plans of the Participating Company Group, including the Plan) become exercisable by a Participant for the first time </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during any calendar year for stock having a Fair Ma</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rket Value greater than One Hundred Thousand Dollars ($100,000), the portion of such options which exceeds such amount shall be treated as Nonstatutory Stock Options.&nbsp;&nbsp;For purposes of this Section, options designated as Incentive Stock Options shall be tak</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">en into account in the order in which they were granted, and the Fair Market Value of stock shall be determined as of the time the option with respect to such stock is granted.&nbsp;&nbsp;If the Code is amended to provide for a limitation different from that set for</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th in this Section, such different limitation shall be deemed incorporated herein effective as of the date and with respect to such Options as required or permitted by such amendment to the Code.&nbsp;&nbsp;If an Option is treated as an Incentive Stock Option in par</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t and as a Nonstatutory Stock Option in part by reason of the limitation set forth in this Section, the Participant may designate which portion of such Option the Participant is exercising.&nbsp;&nbsp;In the absence of such designation, the Participant shall be deem</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed to have exercised the Incentive Stock Option portion of the Option first.&nbsp;&nbsp;Upon exercise, shares issued pursuant to each such portion shall be separately identified.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref204347987"></a>(b) <font style="font-weight:bold;font-style:italic;">Section&#160;162(m) Award Limits</font><font style="font-weight:bold;">.</font>&nbsp;&nbsp;Notwithstanding any provision in the Plan to the contrary, and subject to adjustment as provided in Section&#160;4.3:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Options and SARs</font>.&nbsp;&nbsp;The maximum aggregate number of shares of Stock with respect to one or more Options or SARs that may be granted to any one person during any fiscal year of the Company shall be two million (2,000,000) shares of Stock.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Other Awards</font>.&nbsp;&nbsp;The maximum aggregate number of shares of Stock with respect to one or more Awards (other than Options or SARs) that may be granted to any one person during any fiscal year of the Company shall be two million (2,000,000) shares of Stock.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cash Awards</font>.&nbsp;&nbsp;The maximum aggregate amount of cash that may be paid to any one person during any fiscal year of the Company with respect to one or more Awards payable in cash (including Cash-Based Awards) shall be five million dollars ($5,000,000). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cancelled Awards</font>.&nbsp;&nbsp;Any cancelled Awards shall continue to count against the foregoing limits to the extent required by Section 162(m).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>(c) <font style="font-weight:bold;font-style:italic;">Limit on Awards to Nonemployee Directors</font>.&nbsp;&nbsp;Notwithstanding any other provision of the Plan to the contrary, the Board may establish compensation for Nonemployee Directors from time to time, subject to the limitations in the Plan.&nbsp;&nbsp;The Board will from time to time determine the terms, conditions and amounts of all such Nonemployee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a Nonemployee Director as compensation for services as a Nonemployee Director during any calendar year of the Company may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service as a Nonemployee Director).&nbsp;&nbsp;The Board may make exceptions to this limit for individual Nonemployee Directors in extraordinary circumstances, as the Board </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may determine in its discretion, provided that the Nonemployee Director receiving such additional compensation may not participate in the decision to award such </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation or in other contemporaneous compensation decisions involving Nonemployee Directors.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636173"></a>6.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Stock Options</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options shall be evidenced by Award Agreements specifying the number of shares of Stock covered thereby, in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Options may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref100999809"></a><a name="_Toc384636174"></a>6.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Exercise Price.</font><font style="font-variant: normal;">&nbsp;&nbsp;The exercise price for each Option shall be established in the discretion of the Committee; provided, however, that (a) the exercise price per share shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of the Option and (b) no Incentive Stock Option granted to a Ten Percent Owner shall have an exercise price per share less than one hundred ten percent (110%) of the Fair Market Value of a share of Stock on the effective date of grant of the Option.&nbsp;&nbsp;Notwithstanding the foregoing, an Option (whether an Incentive Stock Option or a Nonstatutory Stock Option) may be granted with an exercise price lower than the minimum exercise price set forth above if such Option is granted pursuant to an assumption or substitution for another option in a manner that would qualify under the provisions of Section 409A or 424(a) of the Code.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636175"></a>6.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Exercisability and Term of Options.</font><font style="font-variant: normal;">&nbsp;&nbsp;Options shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such Option; provided, however, that (a) no Option shall be exercisable after the expiration of ten (10) years after the effective date of grant of such Option, (b) no Incentive Stock Option granted to a Ten Percent Owner shall be exercisable after the expiration of five (5) years after the effective date of grant of such Option and (c) no Option granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable until at least six (6) months following the date of grant of such Option (except in the event of such Employee&#8217;s death, disability or retirement, upon a Change in Control, or as otherwise permitted by the Worker Economic Opportunity Act).&nbsp;&nbsp;Subject to the foregoing, unless otherwise specified by the Committee in the grant of an Option, each Option shall terminate ten (10) years after the effective date of grant of the Option, unless earlier terminated in accordance with its provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636176"></a>6.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Payment of Exercise Price.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>(a)&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-style:italic;">Forms of Consideration Authorized.</font>&nbsp;&nbsp;Except as otherwise provided below, payment of the exercise price for the number of shares of Stock being purchased pursuant to any Option shall be made (i)&#160;in cash, by check or in cash equivalent; (ii)&#160;if permitted by the Committee and subject to the limitations contained in Section&#160;6.3(b), by means of (1)&#160;a Cashless Exercise, or (2)&#160;a Net Exercise; (iii)&#160;by such other consideration as may be approved by the Committee from time to time to the extent permitted by applicable law, or (iv)&#160;by any combination thereof.&nbsp;&nbsp;The Committee may at any time or from time to time grant Options which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do not permit all of the foregoing forms of consideration to be used in payment of the exercise price or which otherwise restrict one or more forms of consideration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248046513"></a>(b)&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-style:italic;">Limitations on Forms of Consideration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248047253"></a>(i) <font style="font-weight:bold;">Cashless Exercise.</font>&nbsp;&nbsp;A <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Cashless Exercise</font><font style="font-style:italic;">&#8221;</font> means the delivery of a properly executed notice of exercise together with irrevocable instructions to a broker providing for the assignment to the Company of the proceeds of a sale or loan with respect to some or all of the shares being acquired upon the exercise of the Option (including, without limitation, through an exercise complying with the provisions of Regulation T as promulgated from time to time by the Board of Governors of the Federal Reserve System).&nbsp;&nbsp;The Company reserves, at any and all times, the right, in the Company&#8217;s sole and absolute discretion, to establish, decline to approve or terminate any program or procedures for the exercise of Options by means of a Cashless Exercise, including with respect to one or more Participants specified by the Company notwithstanding that such program or procedures may be available to other Participants.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248047283"></a>(ii) <font style="font-weight:bold;">Net Exercise.</font>&nbsp;&nbsp;A <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Net Exercise</font><font style="font-style:italic;">&#8221;</font> means the delivery of a properly executed exercise notice followed by a procedure pursuant to which (1)&#160;the Company will reduce the number of shares otherwise issuable to a Participant upon the exercise of an Option by the largest whole number of shares having a Fair Market Value that does not exceed the aggregate exercise price for the shares with respect to which the Option is exercised, and (2)&#160;the Participant shall pay to the Company in cash the remaining balance of such aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref99259564"></a><a name="_Toc384636177"></a>6.4&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref99259032"></a>(a) <font style="font-weight:bold;font-style:italic;">Option Exercisability.</font>&nbsp;&nbsp;Subject to earlier termination of the Option as otherwise provided by this Plan and unless otherwise provided by the Committee, an Option shall terminate immediately upon the Participant&#8217;s termination of Service to the extent that it is then unvested and shall be exercisable after the Participant&#8217;s termination of Service to the extent it is then vested only during the applicable time period determined in accordance with this Section and thereafter shall terminate.&nbsp;&nbsp;Except as otherwise provided in the Award Agreement, or other agreement governing the Option, and subject to Section 6.2 above, vested Options shall remain exercisable following a termination of Service as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="font-weight:bold;">Disability.</font>&nbsp;&nbsp;If the Participant&#8217;s Service terminates because of the Disability of the Participant, the Option, to the extent unexercised and exercisable for vested shares on the date on which the Participant&#8217;s Service terminated, may be exercised by the Participant (or the Participant&#8217;s guardian or legal representative) at any time prior to the expiration of two (2) years after the date on which the Participant&#8217;s Service terminated, but in any event no later than the date of expiration of the Option&#8217;s term as set forth in the Award Agreement evidencing such Option (the <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Option Expiration Date</font><font style="font-style:italic;">&#8221;</font>).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>(ii) <font style="font-weight:bold;">Death.</font>&nbsp;&nbsp;If the Participant&#8217;s Service terminates because of the death of the Participant, the Option, to the extent unexercised and exercisable for vested shares on the date on which the Participant&#8217;s Service terminated, may be exercised by the Participant&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal representative or other person who acquired the right to exercise the Option by reason of the Participant&#8217;s death at any time </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to the expiration of two (2) years after the date on which the Participant&#8217;s Service terminated, but in any event no later than the Option Expiration Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref77684310"></a>(iii) <font style="font-weight:bold;">Termination for Cause.</font>&nbsp;&nbsp;Notwithstanding any other provision of the Plan to the contrary, if the Participant&#8217;s Service is terminated for Cause or if, following the Participant&#8217;s termination of Service and during any period in which the Option otherwise would remain exercisable, the Participant engages in any act that would constitute Cause, the Option shall terminate in its entirety and cease to be exercisable immediately upon such termination of Service or act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) <font style="font-weight:bold;">Other Termination of Service.</font>&nbsp;&nbsp;If the Participant&#8217;s Service terminates for any reason, except Disability, death or Cause, the Option, to the extent unexercised and exercisable for vested shares on the date on which the Participant&#8217;s Service terminated, may be exercised by the Participant at any time prior to the expiration of ninety (90) days after the date on which the Participant&#8217;s Service terminated, but in any event no later than the Option Expiration Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:bold;font-style:italic;">Extension if Exercise Prevented.</font>&nbsp;&nbsp;Notwithstanding the foregoing, other than with respect to a termination of Service for Cause, and subject to the requirements of Section 409A, if the exercise of an Option within the applicable time periods set forth in Section&#160;<font style="font-variant: small-caps;">6.4</font>(a) is prevented by the provisions of Section&#160;15 below because such exercise would violate applicable securities laws, the Option shall remain exercisable until the later of (i)&#160;thirty (30) days after the date such exercise first would no longer violate applicable securities laws or (ii)&#160;the end of the applicable time period under Section&#160;<font style="font-variant: small-caps;">6.4</font>(a), but in any event no later than the Option Expiration Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636178"></a>6.5&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Transferability of Options.</font><font style="font-variant: normal;">&nbsp;&nbsp;During the lifetime of the Participant, an Option shall be exercisable only by the Participant or the Participant&#8217;s guardian or legal representative.&nbsp;&nbsp;An Option shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer by will or by the laws of descent and distribution.&nbsp;&nbsp;Notwithstanding the foregoing, to the extent permitted by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option, a Nonstatutory Stock Option may be assignable or transferable subject to the applicable limitations, described in the General Instructions to Form&#160;S&#8209;8 under the Securities Act; provided that no consideration may be received for any transfer.&nbsp;&nbsp;An Incentive Stock Option shall not be assignable or transferable in any manner.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref99259486"></a><a name="_Toc384636179"></a>7.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Stock Appreciation Rights</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights shall be evidenced by Award Agreements specifying the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing SARs may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636181"></a><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">7.1&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;font-variant: normal;">Exercise Price.</font><font style="font-variant: normal;">&nbsp;&nbsp;The exercise price for each SAR </font><font style="font-variant: normal;">shall be established in the discretion of the Committee; provided, however, that&nbsp;&nbsp;the exercise price per share subject to a SAR shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of the SAR.&nbsp;&nbsp;Notwithstanding the</font><font style="font-variant: normal;"> foregoing, a SAR may be granted with an exercise price lower than the minimum exercise price set forth above if such SAR is granted pursuant to an assumption or substitution for another stock appreciation right in a manner that would qualify under the pro</font><font style="font-variant: normal;">visions of Section 409A of the Code.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636182"></a>7.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Exercisability and Term of SARs.&nbsp;&nbsp;</font><font style="font-variant: normal;">SARs shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such SAR; provided, however, that (i) no SAR shall be exercisable after the expiration of ten (10) years after the effective date of grant of such SAR, and (ii) no SAR granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable until at least six (6) months following the date of grant of such SAR (except in the event of such Employee&#8217;s death, disability or retirement, upon a Change in Control, or as otherwise permitted by the Worker Economic Opportunity Act).&nbsp;&nbsp;Subject to the foregoing, unless otherwise specified by the Committee in the grant of a SAR, each SAR shall terminate ten (10) years after the effective date of grant of the SAR, unless earlier terminated in accordance with its provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636183"></a>7.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Exercise of SARs.</font><font style="font-variant: normal;">&nbsp;&nbsp;Upon the exercise of a SAR, the Participant (or the Participant&#8217;s legal representative or other person who acquired the right to exercise the SAR by reason of the Participant&#8217;s death) shall be entitled to receive payment of an amount for each share with respect to which the SAR is exercised equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price.&nbsp;&nbsp;Payment of such amount shall be made in cash, shares of Stock, or any combination thereof as determined by the Committee, in a lump sum upon the date of exercise of the SAR.&nbsp;&nbsp;When payment is to be made in shares of Stock, the number of shares to be issued shall be determined on the basis of the Fair Market Value of a share of Stock on the date of exercise of the SAR.&nbsp;&nbsp;For purposes of Section&#160;7, a SAR shall be deemed exercised on the date on which the Company receives notice of exercise from the Participant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636184"></a><a name="_Toc384636185"></a>7.4&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service.</font><font style="font-variant: normal;">&nbsp;&nbsp;Subject to earlier termination of the SAR as otherwise provided herein and unless otherwise provided by the Committee, a SAR shall be exercisable after a Participant&#8217;s termination of Service only to the extent and during the applicable time period determined in accordance with Section&#160;6.4<a name="_Toc384636185"></a> (treating the SAR as if it were an Option) and thereafter shall terminate. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>7.5&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Transferability of SARs.</font><font style="font-variant: normal;">&nbsp;&nbsp;During the lifetime of the Participant, a SAR shall be exercisable only by the Participant or the Participant&#8217;s guardian or legal representative.&nbsp;&nbsp;A SAR shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer by will or by the laws of descent and distribution.&nbsp;&nbsp;Notwithstanding the foregoing, to the extent permitted by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Award, a SAR may be assignable or transferable subject to the applicable limitations, described in the General Instructions to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Form&#160;S</font><font style="font-variant: normal;">&#8209;8 under the Securities Act; provided that no consideration may be received for any transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref32362569"></a><a name="_Toc384636186"></a>8.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Restricted Stock Awards</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards shall be evidenced by Award Agreements specifying whether the Award is a Restricted Stock Bonus or a Restricted Stock Purchase Right and the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Restricted Stock Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636187"></a>8.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Types of Restricted Stock Awards Authorized.</font><font style="font-variant: normal;">&nbsp;&nbsp;Restricted Stock Awards may be granted in the form of either a Restricted Stock Bonus or a Restricted Stock Purchase Right.&nbsp;&nbsp;Restricted Stock Awards may be granted upon such conditions as the Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals described in Section&#160;10.4.&nbsp;&nbsp;If a Restricted Stock Award is intended to qualify as Performance-Based Compensation, the Committee shall follow the procedures set forth in Sections&#160;10.3 through 10.5(a) applicable to Awards intended to qualify as Performance-Based Compensation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref99255667"></a><a name="_Toc384636188"></a>8.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Purchase Price.</font><font style="font-variant: normal;">&nbsp;&nbsp;The purchase price for shares of Stock issuable under each Restricted Stock Purchase Right shall be established by the Committee in its discretion.&nbsp;&nbsp;No monetary payment (other than applicable tax withholding) shall be required as a condition of receiving shares of Stock pursuant to a Restricted Stock Bonus, the consideration for which shall be services actually rendered to a Participating Company or for its benefit.&nbsp;&nbsp;Notwithstanding the foregoing, if required by applicable state corporate law, the Participant shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock subject to a Restricted Stock Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636189"></a>8.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Purchase Period.</font><font style="font-variant: normal;">&nbsp;&nbsp;A Restricted Stock Purchase Right shall be exercisable within a period established by the Committee, which shall in no event exceed thirty (30) days from the effective date of the grant of the Restricted Stock Purchase Right.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636190"></a>8.4&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Payment of Purchase Price.&nbsp;&nbsp;</font><font style="font-variant: normal;">Except as otherwise provided below, payment of the purchase price for the number of shares of Stock being purchased pursuant to any Restricted Stock Purchase Right shall be made (a)&#160;in cash, by check or in cash equivalent, (b)&#160;by such other consideration as may be approved by the Committee from time to time to the extent permitted by applicable law, or (c)&#160;by any combination thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref32362367"></a><a name="_Toc384636191"></a><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>8.5&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Vesting and Restrictions on Transfer.</font><font style="font-variant: normal;">&nbsp;&nbsp;Shares issued pursuant to any Restricted Stock Award may (but need not) be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section&#160;10.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award.&nbsp;&nbsp;During any period in which shares acquired pursuant to a Restricted Stock Award remain subject to Vesting Conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">otherwise disposed of other than pursuant to an Ownership Change Event or as provided in Section&#160;</font><font style="font-variant: normal;">8.8</font><font style="font-variant: normal;">.&nbsp;&nbsp;The Committee, in i</font><font style="font-variant: normal;">ts discretion, may provide in any Award Agreement evidencing a Restricted Stock Award that, if the satisfaction of Vesting Conditions with respect to any shares subject to such Restricted Stock Award would otherwise occur on a day on which the sale of such</font><font style="font-variant: normal;"> shares would violate the provisions of the Trading Compliance Policy, then satisfaction of the Vesting Conditions automatically shall be determined on the next trading day on which the sale of such shares would not violate the Trading Compliance Policy.&nbsp;&nbsp;</font><font style="font-variant: normal;">Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to the Company any and all certificates representing shares of Stoc</font><font style="font-variant: normal;">k acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636192"></a>8.6&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Voting Rights; Dividends and Distributions.</font><font style="font-variant: normal;">&nbsp;&nbsp;Except as provided in this Section, Section 8.5 and any Award Agreement, during any period in which shares acquired pursuant to a Restricted Stock Award remain subject to Vesting Conditions, the Participant shall have all of the rights of a stockholder of the Company holding shares of Stock, including the right to vote such shares and to receive all dividends and other distributions paid with respect to such shares; provided, however, that such dividends and distributions shall vest and become nonforfeitable only if the underlying shares of Stock subject to the Restricted Stock Award become vested (including, but not limited to, the satisfaction of any performance related Vesting Condition).&nbsp;&nbsp;In the event of a dividend or distribution paid in shares of Stock or other property or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.3, any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant is entitled by reason of the Participant&#8217;s Restricted Stock Award shall be immediately subject to the same Vesting Conditions as the shares subject to the Restricted Stock Award with respect to which such dividends or distributions were paid or adjustments were made.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636193"></a>8.7&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service.</font><font style="font-variant: normal;">&nbsp;&nbsp;Unless otherwise provided by the Committee in the Award Agreement evidencing a Restricted Stock Award, if a Participant&#8217;s Service terminates for any reason, whether voluntary or involuntary (including the Participant&#8217;s death or Disability), then (a)&#160;the Company shall have the option to repurchase for the purchase price paid by the Participant any shares acquired by the Participant pursuant to a Restricted Stock Purchase Right which remain subject to Vesting Conditions as of the date of the Participant&#8217;s termination of Service and (b)&#160;the Participant shall forfeit to the Company any shares acquired by the Participant pursuant to a Restricted Stock Bonus which remain subject to Vesting Conditions as of the date of the Participant&#8217;s termination of Service.&nbsp;&nbsp;The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57607753"></a><a name="_Ref101004489"></a><a name="_Ref101005786"></a><a name="_Toc384636194"></a>8.8&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Nontransferability of Restricted Stock Award Rights.</font><font style="font-variant: normal;">&nbsp;&nbsp;Rights to acquire shares of Stock pursuant to a Restricted Stock Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer by will or the laws of descent and distribution.&nbsp;&nbsp;All rights with respect to a Restricted Stock Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#8217;s guardian or legal representative.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57606706"></a><a name="_Toc384636195"></a><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">9.&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;text-decoration:underline;">Restricted Stock Unit Awards</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards shall be evidenced by Award Agreements specifying the number of Restricted Stock Units subject to the Award, in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Restricted Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636196"></a>9.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Grant of Restricted Stock Unit Awards.</font><font style="font-variant: normal;">&nbsp;&nbsp;Restricted Stock Unit Awards may be granted upon such conditions as the Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals described in Section&#160;10.4.&nbsp;&nbsp;If a Restricted Stock Unit Award is intended to qualify as Performance-Based Compensation, the Committee shall follow procedures set forth in Sections&#160;10.3 through&#160;10.5(a) applicable to Awards intended to qualify as Performance-Based Compensation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636197"></a>9.2&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Purchase Price.</font><font style="font-variant: normal;">&nbsp;&nbsp;</font><font style="color:#000000;font-variant: normal;">No monetary payment (other than applicable tax withholding, if any) shall be required as a condition of receiving a Restricted Stock Unit Award, the consideration for which shall be services actually rendered to a Participating Company or for its benefit</font><font style="font-variant: normal;">.&nbsp;&nbsp;Notwithstanding the foregoing, if required by applicable state corporate law, the Participant shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock issued upon settlement of the </font><font style="color:#000000;font-variant: normal;">Restricted Stock Unit Award</font><font style="font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57606887"></a><a name="_Toc384636198"></a>9.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Vesting.</font><font style="font-variant: normal;">&nbsp;&nbsp;Restricted Stock Unit Awards may (but need not) be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section&#160;10.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award.&nbsp;&nbsp;The Committee, in its discretion, may provide in any Award Agreement evidencing a Restricted Stock Unit Award that, if the satisfaction of Vesting Conditions with respect to any shares subject to the Award would otherwise occur on a day on which the sale of such shares would violate the provisions of the Trading Compliance Policy, then the satisfaction of the Vesting Conditions automatically shall be determined on the first to occur of (a) the next trading day on which the sale of such shares would not violate the Trading Compliance Policy or (b) the later of (i)&#160;last day of the calendar year in which the original vesting date occurred or (ii) the last day of the Company&#8217;s taxable year in which the original vesting date occurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57608346"></a><a name="_Toc384636199"></a><a name="_AEIOULastRenderedPageBreakAEIOU70"></a>9.4&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Voting Rights, Dividend Equivalent Rights and Distributions.</font><font style="font-variant: normal;">&nbsp;&nbsp;Participants shall have no voting rights with respect to shares of Stock represented by Restricted Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).&nbsp;&nbsp;However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Restricted Stock Unit Award that the Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Stock during the period beginning on the date such Award is granted and ending, with respect to each share subject to the Award, on the earlier of the date the Award is settled or the date on which it is terminated.&nbsp;&nbsp;Such Dividend Equivalent Rights, if any, shall be paid by crediting the Participant with additional whole Restricted Stock </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Units as of the date of payment of such cash dividends on Stock.&nbsp;&nbsp;The number of additional Restricted Stock Units (rounded to the nearest whole number) to be so credited shall b</font><font style="font-variant: normal;">e determined by dividing (a)&#160;the amount of cash dividends paid on such date with respect to the number of shares of Stock represented by the Restricted Stock Units previously credited to the Participant by (b)&#160;the Fair Market Value per share of Stock on su</font><font style="font-variant: normal;">ch date.&nbsp;&nbsp;Such additional Restricted Stock Units shall be subject to the same terms and conditions, including any Vesting Conditions, and shall be settled in the same manner and at the same time as the Restricted Stock Units originally subject to the Restr</font><font style="font-variant: normal;">icted Stock Unit Award.&nbsp;&nbsp;In the event of a dividend or distribution paid in shares of Stock or other property or any other adjustment made upon a change in the capital structure of the Company as described in Section&#160;4.3, appropriate adjustments shall be m</font><font style="font-variant: normal;">ade in the Participant&#8217;s Restricted Stock Unit Award so that it represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant w</font><font style="font-variant: normal;">ould be entitled by reason of the shares of Stock issuable upon settlement of the Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same Vesting Conditions as are applicable to the Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636200"></a>9.5&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service.</font><font style="font-variant: normal;">&nbsp;&nbsp;Unless otherwise provided by the Committee and set forth in the Award Agreement evidencing a Restricted Stock Unit Award, if a Participant&#8217;s Service terminates for any reason, whether voluntary or involuntary (including the Participant&#8217;s death or Disability), then the Participant shall forfeit to the Company any Restricted Stock Units pursuant to the Award which remain subject to Vesting Conditions as of the date of the Participant&#8217;s termination of Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref77917211"></a><a name="_Toc384636201"></a>9.6&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Settlement of Restricted Stock Unit Awards.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Company shall issue to a Participant on the date on which Restricted Stock Units subject to the Participant&#8217;s Restricted Stock Unit Award vest or on such other date determined by the Committee, in its discretion (but in any event within the Short-Term Deferral Period, except as otherwise provided by the Committee or consistent with the requirements of Section&#160;409A), and set forth in the Award Agreement, one (1) share of Stock (and/or any other new, substituted or additional securities or other property pursuant to an adjustment described in Section&#160;9.4) for each Restricted Stock Unit then becoming vested or otherwise to be settled on such date, subject to the withholding of applicable taxes, if any.&nbsp;&nbsp;If permitted by the Committee, the Participant may elect, consistent with the requirements of Section&#160;409A, to defer receipt of all or any portion of the shares of Stock or other property otherwise issuable to the Participant pursuant to this Section, and such deferred issuance date(s) and amount(s) elected by the Participant shall be set forth in the Award Agreement.&nbsp;&nbsp;Notwithstanding the foregoing, the Committee, in its discretion, may provide for settlement of any Restricted Stock Unit Award by payment to the Participant in cash of an amount equal to the Fair Market Value on the payment date of the shares of Stock or other property otherwise issuable to the Participant pursuant to this Section.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636202"></a><a name="_AEIOULastRenderedPageBreakAEIOU71"></a>9.7&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Nontransferability of Restricted Stock Unit Awards.</font><font style="font-variant: normal;">&nbsp;&nbsp;The right to receive shares pursuant to a Restricted Stock Unit Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer by will or by the laws of descent and distribution.&nbsp;&nbsp;All rights with respect to a Restricted Stock Unit </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participan</font><font style="font-variant: normal;">t&#8217;s guardian or legal representative.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref32362274"></a><a name="_Toc384636203"></a>10.&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;text-decoration:underline;">Performance Awards</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance Awards shall be evidenced by Award Agreements in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Performance Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636204"></a>10.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Types of Performance Awards Authorized.</font><font style="font-variant: normal;">&nbsp;&nbsp;Performance Awards may be granted in the form of either Performance Shares or Performance Units.&nbsp;&nbsp;Each Award Agreement evidencing a Performance Award shall specify the number of Performance Shares or Performance Units subject thereto, the Performance Award Formula, the Performance Goal(s) and Performance Period applicable to the Award, and the other terms, conditions and restrictions of the Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636205"></a>10.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Initial Value of Performance Shares and Performance Units.</font><font style="font-variant: normal;">&nbsp;&nbsp;Unless otherwise provided by the Committee in granting a Performance Award, each Performance Share shall have an initial monetary value equal to the Fair Market Value of one (1) share of Stock, subject to adjustment as provided in Section&#160;4.3, on the effective date of grant of the Performance Share, and each Performance Unit shall have an initial monetary value established by the Committee at the time of grant.&nbsp;&nbsp;The final value payable to the Participant in settlement of a Performance Award determined on the basis of the applicable Performance Award Formula will depend on the extent to which Performance Goals established by the Committee are attained within the applicable Performance Period established by the Committee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref32362220"></a><a name="_Toc384636206"></a>10.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Establishment of Performance Period, Performance Goals and Performance Award Formula.</font><font style="font-variant: normal;">&nbsp;&nbsp;In granting each Performance Award or any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right), the Committee shall establish in writing the applicable Performance Period, Performance Award Formula and one or more Performance Goals which, when measured at the end of the Performance Period, shall determine on the basis of the Performance Award Formula the final value of the Award to be paid to the Participant.&nbsp;&nbsp;Unless otherwise permitted in compliance with the requirements under Section&#160;162(m) with respect to each Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right), the Committee shall establish the Performance Goal(s) and Performance Award Formula applicable to each such Award no later than the earlier of (a)&#160;the date ninety (90) days after the commencement of the applicable Performance Period or (b)&#160;the date on which 25% of the Performance Period has elapsed, and, in any event, at a time when the outcome of the Performance Goals remains substantially uncertain.&nbsp;&nbsp;Once established, the Performance Goals and Performance Award Formula applicable to an Award intended to result in the payment of Performance-Based Compensation shall not be changed during the Performance Period.&nbsp;&nbsp;The Company shall notify each Participant granted a Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation) of the terms of such Award, including, if applicable, the Performance Period, Performance Goal(s) and Performance Award Formula.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57607569"></a><a name="_Toc384636207"></a><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">10.4&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-weight:bold;font-variant: normal;">Measurement of Performance Goals.</font><font style="font-variant: normal;">&nbsp;&nbsp;Performance Goals shall be established by the Committee on the basis of targets to be attained (</font><font style="font-style:italic;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">Performance Targets</font><font style="font-style:italic;font-variant: normal;">&#8221;</font><font style="font-variant: normal;">) with respect to one or more measures of business or financial performance (each, a </font><font style="font-style:italic;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">Performance Measure</font><font style="font-style:italic;font-variant: normal;">&#8221;</font><font style="font-variant: normal;">), subject to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:29.49%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:bold;font-style:italic;">Performance Measures.</font>&nbsp;&nbsp;Performance Measures shall be calculated in accordance with the Company&#8217;s financial statements, or, if such terms are not used in the Company&#8217;s financial statements, they shall be calculated in accordance with generally accepted accounting principles, a method used generally in the Company&#8217;s industry, or in accordance with a methodology established by the Committee prior to the grant of the Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right)).&nbsp;&nbsp;Performance Measures shall be calculated with respect to the Company and each Subsidiary Corporation consolidated therewith for financial reporting purposes or such division or other business unit as may be selected by the Committee.&nbsp;&nbsp;Unless otherwise determined by the Committee prior to the grant of the Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right)), the Performance Measures applicable to the Award shall be calculated prior to the accrual of expense for the Award for the same Performance Period and excluding the effect (whether positive or negative) on the Performance Measures of any change in accounting standards or any extraordinary, unusual or nonrecurring item, as determined by the Committee, occurring after the establishment of the Performance Goals applicable to the Award.&nbsp;&nbsp;Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period to period for the calculation of Performance Measures in order to prevent the dilution or enlargement of the Participant&#8217;s rights with respect to a Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right)).&nbsp;&nbsp;Performance Measures may be one or more of the following, as determined by the Committee:&nbsp;&nbsp;(i) revenue; (ii) sales; (iii) expenses; (iv) operating income; (v) )gross margin; (vi) operating margin; (vii) earnings before any one or more of: stock-based compensation expense, interest, taxes, depreciation and amortization; (vii) pre-tax profit; (ix) net operating income; (x) net income; (xi) economic value added; (xii) free cash flow; (xiii) operating cash flow; (xiv) balance of cash, cash equivalents and marketable securities; (xv) stock price; (xvi) earnings per share; (xvii) return on stockholder equity; (xviii) return on capital; (xix) return on assets; (xx) return on investment; (xxi) total stockholder return; (xxii) employee satisfaction; (xxiii) employee retention; (xxiv) market share; (xxv) customer satisfaction; (xxvi) product development; (xxvii) research and development expenses; (xxviii) completion of an identified special project; and (xxix) completion of a joint venture or other corporate transaction. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:bold;font-style:italic;">Performance Targets.</font>&nbsp;&nbsp;Performance Targets may include a minimum, maximum, target level and intermediate levels of performance, with the final value of a Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right)) determined under the applicable Performance Award Formula by the level attained during the applicable Performance Period.&nbsp;&nbsp;A Performance Target may be stated as an absolute value, an increase or decrease in a value, or as a value determined relative to an index, budget or other standard selected by the Committee.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57607610"></a><a name="_Toc384636208"></a><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">10.5&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-weight:bold;font-variant: normal;">Settlement of Performance Awards.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57607612"></a>(a) <font style="font-weight:bold;font-style:italic;">Determination of Final Value.</font>&nbsp;&nbsp;As soon as practicable following the completion of the Performance Period applicable to a Performance Award (and any other Award intended to result in the payment of Performance-Based Compensation (other than an Option or Stock Appreciation Right)), the Committee shall certify in writing the extent to which the applicable Performance Goals have been attained and the resulting final value of the Award earned by the Participant and to be paid upon its settlement in accordance with the applicable Performance Award Formula.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57607922"></a>(b) <font style="font-weight:bold;font-style:italic;">Discretionary Adjustment of Award Formula.</font>&nbsp;&nbsp;In its discretion, and other than with respect to Awards intended to qualify as Performance-Based Compensation, the Committee may, either at the time it grants a Performance Award or at any time thereafter, provide for the positive or negative adjustment of the Performance Award Formula applicable to a Performance Award granted to any Participant who is not a Covered Employee to reflect such Participant&#8217;s individual performance in his or her position with the Company or such other factors as the Committee may determine.&nbsp;&nbsp;In determining amounts payable under Awards&nbsp;&nbsp;intended to qualify as Performance-Based Compensation (other than an Option or Stock Appreciation Right), unless otherwise provided under an Award Agreement, the Committee shall have the discretion, on the basis of such criteria as may be established by the Committee, to reduce (but not increase) some or all of the value of the Award that would otherwise be paid to the Covered Employee upon its settlement notwithstanding the attainment of any Performance Goal and the resulting value of the Award determined in accordance with the Performance Award Formula.&nbsp;&nbsp;No such reduction may result in an increase in the amount payable upon settlement of another Participant&#8217;s Award that is intended to qualify as Performance-Based Compensation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:bold;font-style:italic;">Effect of Leaves of Absence.</font>&nbsp;&nbsp;Unless otherwise required by law or a Participant&#8217;s Award Agreement, payment of the final value, if any, of a Performance Award held by a Participant who has taken in excess of thirty (30) days in unpaid leaves of absence during a Performance Period shall be prorated on the basis of the number of days of the Participant&#8217;s Service during the Performance Period during which the Participant was not on an unpaid leave of absence.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="font-weight:bold;font-style:italic;">Notice to Participants.</font>&nbsp;&nbsp;As soon as practicable following the Committee&#8217;s determination and certification in accordance with Sections&#160;10.5(a) and (b), the Company shall notify each Participant of the determination of the Committee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>(e) <font style="font-weight:bold;">General Provisions Applicable to Performance-Based Compensation</font>.&nbsp;&nbsp;The Committee may, in its sole discretion, (i) determine whether an Award (including a Performance Award) is intended to qualify as Performance-Based Compensation and (ii) at any time after any such determination, alter such intent for any or no reason. If the Committee, in its sole discretion, decides to grant an Award that is intended to qualify as Performance-Based Compensation (other than an Option or Stock Appreciation Right), then the provisions of Sections 10.3 through 10.5 shall control over any contrary provision contained in the Plan that are inconsistent with such intention; provided that, if after such decision the Committee alters such intention for any reason, the provisions of Sections 10.3 through 10.5 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall no longer control over any other provision contained in the Plan.&nbsp;&nbsp;The Committee, in its sole discretion, may (i) grant Awards to eligible individuals that are ba</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sed on Performance Measures or any such other criteria and goals as the Committee shall establish, but that do not satisfy the requirements of Sections 10.3 through 10.5 and that are not intended to qualify as Performance-Based Compensation and (ii) subjec</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t any Awards intended to qualify as Performance-Based Compensation to additional conditions and restrictions unrelated to any Performance Measures or Performance Goals (including, without limitation, continued employment or Service requirements) to the ext</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent such Awards otherwise satisfy the requirements of Sections 10.3 through 10.5 with respect to the Performance Goals applicable thereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) <font style="font-weight:bold;">Additional Limitations</font>.&nbsp;&nbsp;Notwithstanding any other provision of the Plan and except as otherwise determined by the Committee, any Award which is intended to qualify as Performance-Based Compensation shall be subject to any additional limitations set forth in Section 162(m) of the Code or any regulations or rulings issued thereunder that are requirements for qualification as Performance-Based Compensation, and the Plan and the applicable Award Agreement shall be deemed amended to the extent necessary to conform to such requirements. Unless otherwise provided in the applicable Award Agreement and only to the extent otherwise permitted by Section 162(m) of the Code, as to an Award that is intended to qualify as Performance-Based Compensation (other than an Option or Stock Appreciation Right), the Participant must be employed by the Company or a Participating Company throughout the Performance Period. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636209"></a>10.6&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Payment in Settlement of Performance Awards</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;As soon as practicable following the Committee&#8217;s determination and certification in accordance with Sections&#160;10.5(a) and (b), but in any event within the Short-Term Deferral Period (except as otherwise provided by the Committee or consistent with the requirements of Section&#160;409A), payment shall be made to each eligible Participant (or such Participant&#8217;s legal representative or other person who acquired the right to receive such payment by reason of the Participant&#8217;s death) of the final value of the Participant&#8217;s Performance Award.&nbsp;&nbsp;Payment of such amount shall be made in cash, shares of Stock, or a combination thereof as determined by the Committee.&nbsp;&nbsp;Unless otherwise provided in the Award Agreement evidencing a Performance Award, payment shall be made in a lump sum.&nbsp;&nbsp;If permitted by the Committee, the Participant may elect, consistent with the requirements of Section&#160;409A, to defer receipt of all or any portion of the payment to be made to the Participant pursuant to this Section, and such deferred payment date(s) elected by the Participant shall be set forth in the Award Agreement.&nbsp;&nbsp;If any payment is to be made on a deferred basis, the Committee may, but shall not be obligated to, provide for the payment during the deferral period of Dividend Equivalent Rights or interest.&nbsp;&nbsp;If payment is to be made in shares of Stock, the number of such shares shall be determined by dividing the final value of the Performance Award by the Fair Market Value of a share of Stock determined by the method specified in the Award Agreement.&nbsp;&nbsp;Shares of Stock issued in payment of any Performance Award may be fully vested and freely transferable shares or may be shares of Stock subject to Vesting Conditions as provided in Section&#160;8.5.&nbsp;&nbsp;Any shares subject to Vesting Conditions shall be evidenced by an appropriate Award Agreement and shall be subject to the provisions of Sections&#160;8.5 through 8.8 above.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">10.7&nbsp;&nbsp;</font><font style="font-weight:bold;font-variant: normal;">Voting Rights; Dividend Equivalent Rights and </font><font style="font-weight:bold;font-variant: normal;">Distributions.</font><font style="font-variant: normal;">&nbsp;&nbsp;Participants shall have no voting rights with respect to shares of Stock represented by Performance Share Awards until the date of the issuance of such shares, if any (as evidenced by the appropriate entry on the books of the Company or of </font><font style="font-variant: normal;">a duly authorized transfer agent of the Company).&nbsp;&nbsp;However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Performance Share Award that the Participant shall be entitled to Dividend Equivalent Rights with respect to the</font><font style="font-variant: normal;"> payment of cash dividends on Stock during the period beginning on the date the Award is granted and ending, with respect to each share subject to the Award, on the earlier of the date on which the Performance Shares are settled or the date on which they a</font><font style="font-variant: normal;">re forfeited.&nbsp;&nbsp;Such Dividend Equivalent Rights, if any, shall be credited to the Participant in the form of additional whole Performance Shares as of the date of payment of such cash dividends on Stock.&nbsp;&nbsp;The number of additional Performance Shares (rounded</font><font style="font-variant: normal;"> down to the nearest whole number) to be so credited shall be determined by dividing (a)&#160;the amount of cash dividends paid on the dividend payment date with respect to the number of shares of Stock represented by the Performance Shares previously credited </font><font style="font-variant: normal;">to the Participant by (b)&#160;the Fair Market Value per share of Stock on such date.&nbsp;&nbsp;Dividend Equivalent Rights shall be accumulated and paid to the extent that Performance Shares become nonforfeitable, as determined by the Committee.&nbsp;&nbsp;Settlement of Dividend </font><font style="font-variant: normal;">Equivalent Rights may be made in cash, shares of Stock, or a combination thereof as determined by the Committee, and may be paid on the same basis as settlement of the related Performance Share as provided in Section&#160;</font><font style="font-variant: normal;">10.5</font><font style="font-variant: normal;">.&nbsp;&nbsp;In the event of a dividend or di</font><font style="font-variant: normal;">stribution paid in shares of Stock or other property or any other adjustment made upon a change in the capital structure of the Company as described in Section&#160;4.3, appropriate adjustments shall be made in the Participant&#8217;s Performance Share Award so that </font><font style="font-variant: normal;">it represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant would be entitled by reason of the shares of Stock issuable up</font><font style="font-variant: normal;">on settlement of the Performance Share Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same Performance Goals and Vesting Conditions as are applicable to the Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636210"></a>10.8&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service.</font><font style="font-variant: normal;">&nbsp;&nbsp;Unless otherwise provided by the Committee and set forth in the Award Agreement evidencing a Performance Award or in the Participant&#8217;s employment agreement, if any, referencing such Awards, the effect of a Participant&#8217;s termination of Service on the Performance Award shall be as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref199734218"></a>(a) <font style="font-weight:bold;font-style:italic;">Death or Disability.</font>&nbsp;&nbsp;If the Participant&#8217;s Service terminates because of the death or Disability of the Participant before the completion of the Performance Period applicable to the Performance Award, the final value of the Participant&#8217;s Performance Award shall be determined by the extent to which the applicable Performance Goals have been attained with respect to the entire Performance Period and shall be prorated based on the number of months of the Participant&#8217;s Service during the Performance Period.&nbsp;&nbsp;Payment shall be made following the end of the Performance Period in any manner permitted by Section&#160;10.5.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:bold;font-style:italic;">Other Termination of Service.</font>&nbsp;&nbsp;If the Participant&#8217;s Service terminates for any reason except death or Disability before the completion of the Performance Period applicable to the Performance Award, such Award shall be forfeited in its entirety.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636211"></a><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">10.9&nbsp;&nbsp;</font><font style="font-weight:bold;font-variant: normal;">Nontransferability of Performance Awards.</font><font style="font-variant: normal;">&nbsp;&nbsp;Prior to settlement in accordance with the prov</font><font style="font-variant: normal;">isions of the Plan, no Performance Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer</font><font style="font-variant: normal;"> by will or by the laws of descent and distribution.&nbsp;&nbsp;All rights with respect to a Performance Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#8217;s guardian or legal represen</font><font style="font-variant: normal;">tative.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref99350459"></a><a name="_Toc384636212"></a>11.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Cash-Based Awards and Other Stock-Based Awards</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash-Based Awards and Other Stock-Based Awards shall be evidenced by Award Agreements in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Cash-Based Awards and Other Stock-Based Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636213"></a>11.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Grant of Cash-Based Awards</font><font style="font-variant: normal;">.&nbsp;&nbsp;Subject to the provisions of the Plan, the Committee, at any time and from time to time, may grant Cash-Based Awards to Participants in such amounts and upon such terms and conditions, including the achievement of performance criteria, as the Committee may determine.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636214"></a>11.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Grant of Other Stock-Based Awards</font><font style="font-variant: normal;">.&nbsp;&nbsp;The Committee may grant other types of equity-based or equity-related Awards not otherwise described by the terms of this Plan (including the grant or offer for sale of unrestricted securities, stock-equivalent units, stock appreciation units, securities or debentures convertible into common stock or other forms determined by the Committee) in such amounts and subject to such terms and conditions as the Committee shall determine.&nbsp;&nbsp;Other Stock-Based Awards may be made available as a form of payment in the settlement of other Awards or as payment in lieu of compensation to which a Participant is otherwise entitled.&nbsp;&nbsp;Other Stock-Based Awards may involve the transfer of actual shares of Stock to Participants, or payment in cash or otherwise of amounts based on the value of Stock and may include, without limitation, Awards designed to comply with or take advantage of the applicable local laws of jurisdictions other than the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636215"></a>11.3&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Value of Cash-Based and Other Stock-Based Awards</font><font style="font-variant: normal;">.  Each Cash-Based Award shall specify a monetary payment amount or payment range as determined by the Committee.&nbsp;&nbsp;Each Other Stock-Based Award shall be expressed in terms of shares of Stock or units based on such shares of Stock, as determined by the Committee.&nbsp;&nbsp;The Committee may require the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section&#160;10.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award.&nbsp;&nbsp;If the Committee exercises its discretion to establish performance criteria, the final value of Cash-Based Awards or Other Stock-Based Awards that will be paid to the Participant will depend on the extent to which the performance criteria are met.&nbsp;&nbsp;If the grant of any Cash-Based Award or Other Stock-Based Award is intended to qualify as Performance-Based Compensation, the Committee shall follow procedures set forth in Sections&#160;10.3 through&#160;10.5(a) applicable to Awards intended to qualify as Performance-Based Compensation. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636216"></a><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">11.4&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;font-variant: normal;">Payment or Settlement of Cash-Based Awards and Other Stock-Based Awards</font><font style="font-variant: normal;">.&nbsp;&nbsp;Payment or settlement, if any, with respect to a Cash-Based Award or an Other Stock-Based Award shall </font><font style="font-variant: normal;">be made in accordance with the terms of the Award, in cash, shares of Stock or other securities or any combination thereof as the Committee determines.&nbsp;&nbsp;The determination and certification of the final value with respect to any Cash-Based Award or Other St</font><font style="font-variant: normal;">ock-Based Award intended to result in Performance-Based Compensation shall comply with the requirements applicable to Performance Awards set forth in Sections&#160;</font><font style="font-variant: normal;">10</font><font style="font-variant: normal;">.3 through 10.5 applicable to Awards intended to qualify as Performance-Based Compensation.&nbsp;&nbsp;To</font><font style="font-variant: normal;"> the extent applicable, payment or settlement with respect to each Cash-Based Award and Other Stock-Based Award shall be made in compliance with the requirements of Section 409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636217"></a>11.5&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Voting Rights; Dividend Equivalent Rights and Distributions.</font><font style="font-variant: normal;">&nbsp;&nbsp;Participants shall have no voting rights with respect to shares of Stock represented by Other Stock-Based Awards until the date of the issuance of such shares of Stock (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), if any, in settlement of such Award.&nbsp;&nbsp;However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Other Stock-Based Award that the Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Stock during the period beginning on the date such Award is granted and ending, with respect to each share subject to the Award, on the earlier of the date the Award is settled or the date on which it is terminated.&nbsp;&nbsp;Such Dividend Equivalent Rights, if any, shall be subject to the same Vesting Conditions and performance criteria, if any, as are applicable to the underlying Award and shall be paid in accordance with the provisions set forth in Section9.4.&nbsp;&nbsp;Dividend Equivalent Rights shall not be granted with respect to Cash-Based Awards.&nbsp;&nbsp;In the event of a dividend or distribution paid in shares of Stock or other property or any other adjustment made upon a change in the capital structure of the Company as described in Section&#160;4.3, appropriate adjustments shall be made in the Participant&#8217;s Other Stock-Based Award so that it represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant would be entitled by reason of the shares of Stock issuable upon settlement of such Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same Vesting Conditions and performance criteria, if any, as are applicable to the Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636218"></a>11.6&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Termination of Service</font><font style="font-variant: normal;">.&nbsp;&nbsp;Each Award Agreement evidencing a Cash-Based Award or Other Stock-Based Award shall set forth the extent to which the Participant shall have the right to retain such Award following termination of the Participant&#8217;s Service.&nbsp;&nbsp;Such provisions shall be determined in the discretion of the Committee, need not be uniform among all Cash-Based Awards or Other Stock-Based Awards, and may reflect distinctions based on the reasons for termination, subject to the requirements of Section&#160;409A, if applicable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636219"></a><a name="_AEIOULastRenderedPageBreakAEIOU78"></a>11.7&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Nontransferability of Cash-Based Awards and Other Stock-Based Awards.&nbsp;&nbsp;</font><font style="font-variant: normal;">Prior to the payment or settlement of a Cash-Based Award or Other Stock-Based Award, the Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except transfer by will or by the laws of descent and distribution.&nbsp;&nbsp;The Committee may impose such additional restrictions on any shares of Stock issued in settlement </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">of Cash-Based Awards and Other Stock-Based Awards as it may deem advisable, including, without limitation, minimum</font><font style="font-variant: normal;"> holding period requirements, restrictions under applicable federal securities laws, under the requirements of any stock exchange or market upon which such shares of Stock are then listed and/or traded, or under any state securities laws or foreign law app</font><font style="font-variant: normal;">licable to such shares of Stock.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref255644055"></a><a name="_Toc384636220"></a>12.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Deferred Compensation Awards</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636221"></a>12.1&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Establishment of Deferred Compensation Award Programs</font><font style="font-variant: normal;">.&nbsp;&nbsp;This Section&#160;12 shall not be effective unless and until the Committee determines to establish a program pursuant to this Section.&nbsp;&nbsp;If the Committee determines that any such program may constitute an &#8220;employee pension benefit plan&#8221; within the meaning of Section&#160;3(2) of ERISA, the Committee shall adopt and implement such program through a separate subplan to this Plan.&nbsp;&nbsp;Eligibility to participate in such subplan shall be limited to Directors and a select group of management or highly compensated employees, and the Committee shall take all additional actions required to qualify such subplan as a &#8220;top-hat&#8221; unfunded deferred compensation plan, including filing with the U.S. Department of Labor within 120 days following the adoption of such subplan a notice pursuant to Department of Labor Regulations Section&#160;2520.104-23.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636222"></a>12.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Terms and Conditions of Deferred Compensation Awards</font><font style="font-variant: normal;">.&nbsp;&nbsp;Deferred Compensation Awards shall be evidenced by Award Agreements in such form as the Committee shall from time to time establish.&nbsp;&nbsp;Award Agreements evidencing Deferred Compensation Awards may incorporate all or any of the terms of the Plan by reference and, except as provided below, shall comply with and be subject to the terms and conditions applicable to the appropriate form of Award as set forth in the applicable section of this Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:bold;font-style:italic;">Limitation on Elections.</font><font style="font-weight:bold;">&nbsp;&nbsp;</font>Notwithstanding any Participant&#8217;s prior election to reduce cash compensation pursuant to a program established in accordance with this Section&#160;12, no Deferred Compensation Award may be granted to the Participant after termination of the Plan or termination of the Participant&#8217;s Service, and any such cash compensation shall be paid at the normal time and in accordance with the terms of the applicable cash compensation arrangement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:bold;font-style:italic;">Election Irrevocable.</font><font style="font-weight:bold;">&nbsp;&nbsp;</font>A Participant&#8217;s election to reduce cash compensation pursuant to a program established in accordance with this Section&#160;12 shall become irrevocable on the last day of the calendar year prior to the year in which the services are to be rendered with respect to which such cash compensation would otherwise become payable, or at the time otherwise required by Section&#160;409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:bold;font-style:italic;">Vesting.</font><font style="font-weight:bold;">&nbsp;&nbsp;</font>Deferred Compensation Awards may be fully vested at grant or may be subject to such Vesting Conditions as the Committee determines.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636223"></a>13.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Standard Forms of Award Agreement</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636224"></a><a name="_AEIOULastRenderedPageBreakAEIOU79"></a>13.1&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Award Agreements</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;Each Award shall comply with and be subject to the terms and conditions set forth in the appropriate form of Award Agreement approved by the Committee and as amended from time to time.&nbsp;&nbsp;No Award or purported Award shall be a valid </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">and binding obligation </font><font style="font-variant: normal;">of the Company unless evidenced by a fully executed Award Agreement, which execution may be evidenced by electronic means.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636225"></a>13.2&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Authority to Vary Terms</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Committee shall have the authority from time to time to vary the terms of any standard form of Award Agreement either in connection with the grant or amendment of an individual Award or in connection with the authorization of a new standard form or forms; provided, however, that the terms and conditions of any such new, revised or amended standard form or forms of Award Agreement are not inconsistent with the terms of the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref77762719"></a><a name="_Toc384636226"></a>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-weight:bold;text-decoration:underline;">Change in Control</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636227"></a>14.1&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Effect of Change in Control on Awards.&nbsp;&nbsp;</font><font style="font-variant: normal;">Subject to the requirements and limitations of Section 409A, if applicable, the Committee may provide for any one or more of the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:bold;font-style:italic;">Accelerated Vesting.</font>&nbsp;&nbsp;In its discretion, the Committee may provide in the grant of any Award or at any other time may take such action as it deems appropriate to provide for acceleration of the exercisability, vesting and/or settlement in connection with a Change in Control of each or any outstanding Award or portion thereof and shares acquired pursuant thereto upon such conditions, including termination of the Participant&#8217;s Service prior to, upon, or following such Change in Control, and to such extent as the Committee shall determine.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref132107749"></a>(b) <font style="font-weight:bold;font-style:italic;">Assumption, Continuation or Substitution.</font>&nbsp;&nbsp;In the event of a Change in Control, the surviving, continuing, successor, or purchasing corporation or other business entity or parent thereof, as the case may be (the <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Acquiror</font><font style="font-style:italic;">&#8221;</font>), may, without the consent of any Participant, assume or continue the Company&#8217;s rights and obligations under each or any Award or portion thereof outstanding immediately prior to the Change in Control or substitute for each or any such outstanding Award or portion thereof a substantially equivalent award with respect to the Acquiror&#8217;s stock, as applicable.&nbsp;&nbsp;<font style="color:#000000;">For purposes of this Section, if so determined by the Committee in its discretion, an </font>Award denominated in shares of Stock<font style="color:#000000;"> shall be deemed assumed if, following the Change in Control, the </font>Award <font style="color:#000000;">confers the right to receive, subject to the terms and conditions of the Plan and the applicable Award Agreement, for each share of Stock subject to the </font>Award <font style="color:#000000;">immediately prior to the Change in Control, the consideration (whether stock, cash, other securities or property or a combination thereof) to which a holder of a share of Stock on the effective date of the Change in Control was entitled (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Stock); provided, however, that if such consideration is not solely common stock of the Acquiror, the Committee may, with the consent of the Acquiror, provide for the consideration to be received upon the exercise or settlement of the </font>Award<font style="color:#000000;">, for each share of Stock subject to the </font>Award<font style="color:#000000;">, to consist solely of common stock of the Acquiror equal in Fair Market Value to the per share consideration received by holders of Stock pursuant to the Change in Control.</font>&nbsp;&nbsp;Any Award or portion thereof which is not assumed, substituted for, or otherwise continued by the Acquiror in connection with the Change in Control nor exercised or settled as of the time of consummation of the Change in Control shall terminate and cease to be outstanding effective as of the time of consummation of the Change in Control.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) </font><font style="font-weight:bold;font-style:italic;">Cash-Out of Outstanding Stock-Based Awards.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;The Committee may, in its discretion and without the con</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sent of any Participant, determine that, upon the occurrence of a Change in Control, each or any Award denominated in shares of Stock or portion thereof outstanding immediately prior to the Change in Control and not previously exercised or settled shall be</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> canceled in exchange for a payment with respect to each vested share (and each unvested share, if so determined by the Committee) of Stock subject to such canceled Award in (i)&#160;cash, (ii)&#160;stock of the Company or of a corporation or other business entity a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> party to the Change in Control, or (iii)&#160;other property which, in any such case, shall be in an amount having a Fair Market Value equal to the Fair Market Value of the consideration to be paid per share of Stock in the Change in Control, reduced (but not </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below zero) by the exercise or purchase price per share, if any, under such Award.&nbsp;&nbsp;In the event such determination is made by the Committee, an Award having an exercise or purchase price per share equal to or greater than the Fair Market Value of the cons</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ideration to be paid per share of Stock in the Change in Control may be canceled without payment of consideration to the holder thereof.&nbsp;&nbsp;Except as otherwise provided by the Committee, payment pursuant to this Section (reduced by applicable withholding tax</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es, if any) shall be made to Participants in respect of the vested portions of their canceled Awards as soon as practicable following the date of the Change in Control and in respect of the unvested portions of their canceled Awards in accordance with the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vesting schedules applicable to such Awards.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636228"></a>14.2&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Federal Excise Tax Under Section 4999 of the Code.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref132108469"></a>(a) <font style="font-weight:bold;font-style:italic;">Excess Parachute Payment.</font>&nbsp;&nbsp;In the event that any acceleration of vesting pursuant to an Award and any other payment or benefit received or to be received by a Participant would subject the Participant to any excise tax pursuant to Section 4999 of the Code due to the characterization of such acceleration of vesting, payment or benefit as an &#8220;excess parachute payment&#8221; under Section 280G of the Code, the Participant, subject to compliance with applicable law (including, but not limited to the rules imposed by Section 409A), may elect to reduce the amount of any acceleration of vesting called for under the Award in order to avoid such characterization.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:bold;font-style:italic;">Determination by Independent Accountants.</font>&nbsp;&nbsp;To aid the Participant in making any election called for under Section&#160;14.2(a), no later than the date of the occurrence of any event that might reasonably be anticipated to result in an &#8220;excess parachute payment&#8221; to the Participant as described in Section&#160;14.2(a), the Company may request a determination in writing by independent public accountants selected by the Company (the <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Accountants</font><font style="font-style:italic;">&#8221;</font>).&nbsp;&nbsp;As soon as practicable thereafter, the Accountants shall determine and report to the Company and the Participant the amount of such acceleration of vesting, payments and benefits which would produce the greatest after-tax benefit to the Participant.&nbsp;&nbsp;For the purposes of such determination, the Accountants may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.&nbsp;&nbsp;The Company and the Participant shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make their required determination.&nbsp;&nbsp;The Company shall bear all fees and expenses the Accountants charge in connection with their services contemplated by this Section.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57607126"></a><a name="_Toc384636229"></a><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">15.&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-weight:bold;text-decoration:underline;">Compliance with Securities Law</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of Awards and the issuance of shares of Stock pursuant to any Award shall be subject to compliance with all applicable requirements of federal, state and foreign law with respect to such securities and the requirements of any stock exchange or market system upon which the Stock may then be listed.  In addition, no Award may be exercised or shares issued pursuant to an Award unless (a)&#160;a registration statement under the Securities Act shall at the time of such exercise or issuance be in effect with respect to the shares issuable pursuant to the Award, or (b)&#160;in the opinion of legal counsel to the Company, the shares issuable pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act.&nbsp;&nbsp;The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company&#8217;s legal counsel to be necessary to the lawful issuance and sale of any shares under the Plan shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained.&nbsp;&nbsp;As a condition to issuance of any Stock, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref97886349"></a><a name="_Toc384636230"></a>16.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Compliance with Section 409A</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref143244884"></a><a name="_Toc384636231"></a>16.1&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Awards Subject to Section&#160;409A.</font><font style="font-variant: normal;">&nbsp;&nbsp;</font><font style="color:#000000;font-variant: normal;">The Company intends that Awards granted pursuant to the Plan shall either be exempt from or comply with Section&#160;409A, and the Plan shall be so construed.&nbsp;&nbsp;</font><font style="font-variant: normal;">The provisions of this Section&#160;16 shall apply to any Award or portion thereof that constitutes or provides for payment of Section&#160;409A Deferred Compensation.&nbsp;&nbsp;To the extent that the Committee determines that any Award granted under the Plan is Section&#160;409A Deferred Compensation, the Plan, and the Award Agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A. In that regard, to the extent any Award under the Plan or any other compensatory plan or arrangement of the Company or any of the Participating Companies is Section&#160;409A Deferred Compensation, and such Award or other amount is payable on account of a Participant&#8217;s termination of Service (or any similarly defined term), then such Award or amount shall only be paid to the extent such termination of Service qualifies as a &#8220;separation from service&#8221; as defined in Section 409A,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref224391308"></a>16.2&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Installment Payments</font><font style="font-variant: normal;">.&nbsp;&nbsp;It is the intent of this Plan that any right of a Participant to receive installment payments (within the meaning of Section 409A) shall, for all purposes of Section 409A, be treated as a right to a series of separate payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref248047637"></a>16.3&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Required Delay in Payment to Specified Employee Pursuant to Separation from Service</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;Notwithstanding any provision of the Plan or an Award Agreement to the contrary, except as otherwise permitted by Section&#160;409A, no payment in settlement of an Award providing for Section&#160;409A Deferred Compensation may be made to a Participant who is a &#8220;specified employee&#8221; (as defined by Section&#160;409A) on account of his or her termination of Service (or any similarly defined term) before the date (the </font><font style="font-style:italic;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">Delayed Payment Date</font><font style="font-style:italic;font-variant: normal;">&#8221;</font><font style="font-variant: normal;">) that is six&#160;(6) months after the date of such Participant&#8217;s separation from service, or, if earlier, the date of the Participant&#8217;s death.&nbsp;&nbsp;All such amounts that would, but for this paragraph, become payable prior to the Delayed Payment Date shall be accumulated and paid on the Delayed Payment Date.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref224390831"></a><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">16.4&nbsp;&nbsp; </font><font style="font-weight:bold;font-variant: normal;">Payment Upon Change in Control</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;Notwithstanding any provision of the Plan or an Award Agreement to the contrary, to the extent that any amount constituting Section 409A Deferred Compensation would become payable under this Plan by reason of a Change in Control, such amount shall become</font><font style="font-variant: normal;"> payable only if the event constituting a Change in Control would also constitute a change in ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company within the meaning of Section 409</font><font style="font-variant: normal;">A.</font><font style="font-variant: normal;">&nbsp;&nbsp;Any Award which constitutes Section 409A Deferred Compensation and which would vest and otherwise become payable upon a Change in Control as a result of the failure of the Acquiror to assume, continue or substitute for such Award in accordance with Sec</font><font style="font-variant: normal;">tion&#160;14.1(b) shall vest to the extent provided by such Award but shall be converted automatically at the effective time of such Change in Control into a right to receive, in cash on the date or dates such award would have been settled in accordance with it</font><font style="font-variant: normal;">s then existing settlement schedule (or as required by Section 409A), an amount or amounts equal in the aggregate to the intrinsic value of the Award at the time of the Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">16.5&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Prohibition of Acceleration of Payments</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-weight:bold;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-variant: normal;">Notwithstanding any provision of the Plan or an Award Agreement to the contrary, this Plan does not permit the acceleration of the time or schedule of any payment under an Award providing Section&#160;409A Deferred Compensation, except as permitted by Section&#160;409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">16.6 <font style="font-weight:bold;font-variant: normal;">No Representation Regarding Section 409A Compliance</font><font style="font-variant: normal;">.&nbsp;&nbsp;Notwithstanding any other provision of the Plan, the Company makes no representation that Awards shall be exempt from or comply with Section 409A.&nbsp;&nbsp;No Participating Company shall be liable for any tax, penalty or interest imposed on a Participant by Section 409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636235"></a>17.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Tax Withholding</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636236"></a>17.1&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Tax Withholding in General.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Company shall have the right to deduct from any and all payments made under the Plan, or to require the Participant, through payroll withholding, cash payment or otherwise, to make adequate provision for, the federal, state, local and foreign taxes (including social insurance), if any, required by law to be withheld by any Participating Company with respect to an Award or the shares acquired pursuant thereto.&nbsp;&nbsp;The Company shall have no obligation to deliver shares of Stock, to release shares of Stock from an escrow established pursuant to an Award Agreement, or to make any payment in cash under the Plan until the Participating Company Group&#8217;s tax withholding obligations have been satisfied by the Participant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref57606983"></a><a name="_Toc384636237"></a><a name="_AEIOULastRenderedPageBreakAEIOU83"></a>17.2&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Withholding in or Directed Sale of Shares.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Company shall have the right, but not the obligation, to deduct from the shares of Stock issuable to a Participant upon the exercise or settlement of an Award, or to accept from the Participant the tender of, a number of whole shares of Stock having a Fair Market Value, as determined by the Company, equal to all or any part of the tax withholding obligations of any Participating Company.&nbsp;&nbsp;The Fair Market Value of any shares of Stock withheld or tendered to satisfy any such tax withholding obligations shall not exceed the amount determined by the applicable minimum statutory withholding rates.&nbsp;&nbsp;The Company may require a Participant to direct a broker, upon the vesting, exercise or settlement of an Award, to sell a portion of the shares subject to the Award determined by the Company in its discretion to be sufficient to cover the tax withholding obligations of any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Participating Company and</font><font style="font-variant: normal;"> to remit an amount equal to such tax withholding obligations to such Participating Company in cash.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636238"></a>18.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;font-family:Times New Roman Bold;">Amendment, Suspension</font><font style="font-weight:bold;text-decoration:underline;"> or Termination of Plan</font><font style="font-weight:bold;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Committee may amend, suspend or terminate the Plan at any time.&nbsp;&nbsp;However, without the approval of the Company&#8217;s stockholders, there shall be (a)&#160;no increase in the maximum aggregate number of shares of Stock that may be issued under the Plan (except by operation of the provisions of Section&#160;4.3), (b)&#160;no change in the class of persons eligible to receive Incentive Stock Options, (c)&#160;any amendment to Section 3.6, and (d)&#160;no other amendment of the Plan that would require approval of the Company&#8217;s stockholders under any applicable law, regulation or rule, including the rules of any stock exchange or quotation system upon which the Stock may then be listed or quoted.&nbsp;&nbsp;No amendment, suspension or termination of the Plan shall affect any then outstanding Award unless expressly provided by the Committee.&nbsp;&nbsp;Except as provided by the next sentence, no amendment, suspension or termination of the Plan may adversely affect any then outstanding Award without the consent of the Participant.&nbsp;&nbsp;Notwithstanding any other provision of the Plan to the contrary, the Committee may, in its sole and absolute discretion and without the consent of any Participant, amend the Plan or any Award Agreement, to take effect retroactively or otherwise, as it deems necessary or advisable for the purpose of conforming the Plan or such Award Agreement to any present or future law, regulation or rule applicable to the Plan, including, but not limited to, Section&#160;409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Ref97885665"></a><a name="_Toc384636239"></a>19.&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:underline;">Miscellaneous Provisions</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636240"></a>19.1&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Repurchase Rights</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">.</font><font style="font-variant: normal;">&nbsp;&nbsp;Shares issued under the Plan may be subject to one or more repurchase options, or other conditions and restrictions as determined by the Committee in its discretion at the time the Award is granted.&nbsp;&nbsp;The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company.&nbsp;&nbsp;Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to the Company any and all certificates representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636241"></a>19.2&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Forfeiture Events.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The Committee may specify in an Award Agreement that the Participant&#8217;s rights, payments, and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an Award.&nbsp;&nbsp;Such events may include, but shall not be limited to, termination of Service for Cause or any act by a Participant, whether before or after termination of Service, that would constitute Cause for termination of Service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a>(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, any Participant who knowingly or through gross </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-37</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negligence engaged in the misconduct, or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> who knowingly or through gross negligence failed to prevent the misconduct, and any Participant who is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002, shall reimburse the Company for (i)&#160;the amou</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt of any payment in settlement of an Award received by such Participant during the twelve- (12-) month period following the first public issuance or filing with the United States Securities and Exchange Commission (whichever first occurred) of the financi</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al document embodying such </font>financial reporting<font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> requirement, and (ii)&#160;any profits realized by such Participant from the sale of securities of the Company during such twelve- (12-) month period.&nbsp;&nbsp;In addition, to the extent claw-back or similar provisions app</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licable to Awards are required by applicable law, listing standards and/or policies adopted by the Company, Awards granted under the Plan shall be subject to such provisions.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636242"></a>19.3&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Provision of Information.</font><font style="font-variant: normal;">&nbsp;&nbsp;Each Participant shall be given access to information concerning the Company equivalent to that information generally made available to the Company&#8217;s common stockholders.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636243"></a>19.4&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Rights as Employee, Consultant or Director.</font><font style="font-variant: normal;">&nbsp;&nbsp;No person, even though eligible pursuant to Section&#160;5, shall have a right to be selected as a Participant, or, having been so selected, to be selected again as a Participant.&nbsp;&nbsp;Nothing in the Plan or any Award granted under the Plan shall confer on any Participant a right to remain an Employee, Consultant or Director or interfere with or limit in any way any right of a Participating Company to terminate the Participant&#8217;s Service at any time.&nbsp;&nbsp;To the extent that an Employee of a Participating Company other than the Company receives an Award under the Plan, that Award shall in no event be understood or interpreted to mean that the Company is the Employee&#8217;s employer or that the Employee has an employment relationship with the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636244"></a>19.5&nbsp;&nbsp;<font style="font-weight:bold;font-variant: normal;">Rights as a Stockholder.</font><font style="font-variant: normal;">&nbsp;&nbsp;A Participant shall have no rights as a stockholder with respect to any shares covered by an Award until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).&nbsp;&nbsp;No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section&#160;4.3 or another provision of the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636245"></a>19.6&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Delivery of Title to Shares.</font><font style="font-variant: normal;">&nbsp;&nbsp;Subject to any governing rules or regulations, the Company shall issue or cause to be issued the shares of Stock acquired pursuant to an Award and shall deliver such shares to or for the benefit of the Participant by means of one or more of the following: (a)&#160;by delivering to the Participant evidence of book entry shares of Stock credited to the account of the Participant, (b)&#160;by depositing such shares of Stock for the benefit of the Participant with any broker with which the Participant has an account relationship, or (c)&#160;by delivering such shares of Stock to the Participant in certificate form.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636246"></a>19.7&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Fractional Shares.</font><font style="font-variant: normal;">&nbsp;&nbsp;The Company shall not be required to issue fractional shares upon the exercise or settlement of any Award.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636247"></a><a name="_AEIOULastRenderedPageBreakAEIOU85"></a>19.8&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Retirement and Welfare Plans</font><font style="font-variant: normal;">.&nbsp;&nbsp;Neither Awards made under this Plan nor shares of Stock or cash paid pursuant to such Awards may be included as &#8220;compensation&#8221; for purposes of computing the benefits payable to any Participant under any Participating </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><font style="font-variant: normal;">Company&#8217;s retirement plans (both qualified and non-qualified) or welfare benefit plans unless suc</font><font style="font-variant: normal;">h other plan expressly provides that such compensation shall be taken into account in computing a Participant&#8217;s benefit.&nbsp;&nbsp;In addition, unless a written employment agreement or other service agreement references Awards, a general reference to &#8220;benefits&#8221; in </font><font style="font-variant: normal;">such agreement shall not be deemed to refer to Awards granted hereunder.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636248"></a>19.9&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Beneficiary Designation.</font><font style="font-variant: normal;">&nbsp;&nbsp;Subject to local laws and procedures, each Participant may file with the Company a written designation of a beneficiary who is to receive any benefit under the Plan to which the Participant is entitled in the event of such Participant&#8217;s death before he or she receives any or all of such benefit.&nbsp;&nbsp;Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Company, and will be effective only when filed by the Participant in writing with the Company during the Participant&#8217;s lifetime.&nbsp;&nbsp;If a married Participant designates a beneficiary other than the Participant&#8217;s spouse, the effectiveness of such designation may be subject to the consent of the Participant&#8217;s spouse.&nbsp;&nbsp;If a Participant dies without an effective designation of a beneficiary who is living at the time of the Participant&#8217;s death, the Company will pay any remaining unpaid benefits to the Participant&#8217;s legal representative.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636249"></a>19.10&nbsp;&nbsp; <font style="font-weight:bold;color:#000000;font-variant: normal;">Severability</font><font style="color:#000000;font-variant: normal;">.&nbsp;&nbsp;If any one or more of the provisions (or any part thereof) of this Plan shall be held invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan shall not in any way be affected or impaired thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636250"></a>19.11&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">No Constraint on Corporate Action.&nbsp;&nbsp;</font><font style="font-variant: normal;">Nothing in this Plan shall be construed to: (a)&#160;limit, impair, or otherwise affect the Company&#8217;s or another Participating Company&#8217;s right or power to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure, or to merge or consolidate, or dissolve, liquidate, sell, or transfer all or any part of its business or assets; or (b)&#160;limit the right or power of the Company or another Participating Company to take any action which such entity deems to be necessary or appropriate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636251"></a>19.12&nbsp;&nbsp; <font style="font-weight:bold;font-variant: normal;">Unfunded Obligation.</font><font style="font-variant: normal;">&nbsp;&nbsp;Participants shall have the status of general unsecured creditors of the Company.&nbsp;&nbsp;Any amounts payable to Participants pursuant to the Plan shall be considered unfunded and unsecured obligations for all purposes, including, without limitation, Title&#160;I of the Employee Retirement Income Security Act of 1974.&nbsp;&nbsp;No Participating Company shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.&nbsp;&nbsp;The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder.&nbsp;&nbsp;Any investments or the creation or maintenance of any trust or any Participant account shall not create or constitute a trust or fiduciary relationship between the Committee or any Participating Company and a Participant, or otherwise create any vested or beneficial interest in any Participant or the Participant&#8217;s creditors in any assets of any Participating Company.&nbsp;&nbsp;The Participants shall have no claim against any Participating Company for any changes in the value of any assets which may be invested or reinvested by the Company with respect to the Plan.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-39</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_Toc384636252"></a><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">19.13&nbsp;&nbsp; </font><font style="font-weight:bold;font-variant: normal;">Choice of Law.</font><font style="font-variant: normal;">&nbsp;&nbsp;Except to the e</font><font style="font-variant: normal;">xtent governed by applicable federal law, the validity, interpretation, construction and performance of the Plan and each Award Agreement shall be governed by the laws of the State of </font>Delaware<font style="font-variant: normal;">, without regard to its conflict of law rules.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A | Page A-40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><img src="g20170410210550933559.jpg" title="" alt="" style="width:623px;height:807px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date To withhold authority to vote for any individual nominee(s), mark &#8220;For All Except&#8221; and write the number(s) of the nominee(s) on the line below. 0 0 0 0 0 0 0 0 0 0 0 0 0 0000326725_1 R1.0.1.15 For Withhold For All All All Except The Board of Directors recommends you vote FOR the following: 1. Election of Directors Nominees 01 David M. Rickey 02 Richard J. Hawkins 03 Marc H. Hedrick, M.D. 04 Gary A. Lyons 05 Gail K. Naughton, Ph.D. 06 Ronald A. Martell 07 Gregg A. Lapointe C/O COMPUTERSHARE 250 ROYALL STREET CANTON, MA 02021 VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. The Board of Directors recommends you vote FOR proposals 2 and 3. For Against Abstain 2. To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of Cytori Therapeutics, Inc. for the fiscal year ending December 31, 2017. 3. To approve the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan. The Board of Directors recommends you vote 1 YEAR on the following proposal: 3 years 2 years 1 year Abstain 4 To approve, by non-binding vote, frequency of the advisory vote on executive compensation. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><img src="g20170410210550961560.jpg" title="" alt="" style="width:623px;height:807px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0000326725_2 R1.0.1.15 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Combined Document is available at www.proxyvote.com CYTORI THERAPEUTICS, INC. PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 22, 2017 The undersigned hereby appoints Marc H. Hedrick, M.D., Tiago Girao and Jeremy Hayden, or any of them, as proxy holders each with full power of substitution, to appear on behalf and to vote all shares of common stock of Cytori Therapeutics, Inc. (the "Company") that the undersigned is entitled to vote at the Annual Meeting of Stockholders of the Company to be held on May 22, 2017, and at any postponement thereof. When properly executed, this proxy will be voted as directed. If properly executed and no instructions are specified, this proxy will be voted FOR the election of the listed Nominees as Directors under Proposal 1, FOR Proposals 2 and 3, FOR one (1) year for Proposal 4, and at the discretion of the proxies with respect to such other business as may properly come before the meeting. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Director's recommendations. PLEASE COMPLETE, DATE AND SIGN THIS PROXY AND RETURN IT IN THE ACCOMPANYING ENVELOPE. Continued and to be signed on reverse side</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g20170410210550961560.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20170410210550961560.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW!:&YA=2)(=S!22&+/R!R5Q39].\7V^H1VH?4KF.*V>*:<S;X[G=:O\ -@L
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M=1T1G;_@%8VG>'_%6C'1]/L%O;;3K:21(E@P53_2Y&)E7>H*M%LQG=C)P :
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M!3*@D$J'+19\T8Z\!7P>^WMD9DD\61K!"Z:?-)+<PB:SA#+NG!8C ]#MPQ]
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M!M4=R?SK7K"HXN7N;#0F!Z4N***@8C*KJ5905(P01UH5%50JJ H&  .!2T4
M)@>E&!Z4M% "8'I1@>E+10 F!Z48'I2T4 )@>E"HJYVJ!DY.!U-+10 F!Z4M
M%% !BC HHH 145!A5"C.< 8HP/2EHH 3 ]*7 ]*** $P/2EP*** "C ]***
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M<)UQ5N-_$W]D2F6#21J>_P#=*LTGDE./O';NSUZ#TK9HH YCS/'?_/KX<_\
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ML_)UKI:* ,:%_$W]E7!GATD:D&'D+'-(82O&=Q*[@>O0'M5'S/'?_/KX<_\
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M-MHK1KVWNX[A8$"+(%C)&0.O7]!Z4 >JT444 %%%% 'EVE?\G(:]_P!@6/\
MG%7J->7:5_R<AKW_ &!8_P"<5>HT %%%% !1110 4444 %%%% !1110 4444
M %%%% !7%7FHZP_C:33_ +;>V=LS*EM'#IWG1S(8B6D:4C"%7XY/\(^4[J[6
MJLFI6$5RUM)>VR7"H7:)I5#!0,DXSG&.] '!&X\876B:==MJMQ:7,^J"TFBM
M[)"$A#^67PZ$C)0R9Z#?CH!65/XA\<L;F*V-XUV7V30_V>L:V;?:42,1R,I6
M0-&6))W ?>X'%>G_ -L:7]E6Z&HV?V=VV+-YZ["WH#G&?:I'U"RB?9)>6Z-O
M$85I5!WD9"]>N"#B@#C?".I>(=4>2VU.:XA/]G@^8]LJ/%.9IE.?E"LZJL><
M#:>H&#7.KK?CVULU=)9[UI+>621I[58VA*W(C&Q5C^8E,G:<<$G/ KU62^LX
MK>2>6Z@2&-BKR-( JD'!!/0'/%-&I6#311"]MC),GF1H)5RZ_P!X#/(]Q0!Y
M./$/C:<W\5O=7CW7]H>3#;I:JA6+SG7(9X @^4+@EG'.>*OVGBKQ8]WHS/:W
M<MD+1%U&9;+:!<2!MN0<,"A$8.T8^9LXP*]+DOK.*+S9+J!(]GF;VD &SCYL
M^G(Y]Q4<^KZ;;1++<:A:11MC:\DRJ#G.,$GO@_E0!Y))K7Q%LM$TNYOKQX?M
MK*Y86RO)&OD[B'V0-L!?&!L)'()KHK#5_$FH:K)I?GWL C^UN]U]A  C_=FV
M8%DVL2"_ YZY Q7:G7-(!E!U2Q!B&9?](3Y!D#)YXY('/K4TNI6$-HEW->VT
M=L^"DSRJ$;/3#9P<T >8Q:WXNAM+/[?J&H);S6EK/=7R:8KRVSR1RLR+&J<_
M.L:G()&1G&<U?L_$^N6?B\)JL]Y_9(MQ+(3IAC5%\E3O;@E27)'#-R=I48S7
MH:W=LSA%N(B[,4"AQDL!DCZ@<U!#JFEWS-#!?6=PP.&1)E<@^X!]C^5 '!>+
M=?\ %]AXEO(M'BFELX+<RB-;8-OQ"Y(5L<MNVD#N1CO5JSUW6$UV$:G=7T,*
M11O]GBTLR1S1?9P[R-(!E6$FX8!_A VG.:[5-5TY[I;5+^U:X=0RPK,I=@1D
M$#.<8Y^E(-5TTQSR"_M3';MMG;SEQ$?1CG@_6@"VC!T5UZ,,CC%+4"WEJ_E;
M;F%O.4O'AQ\ZCJ1ZCD=/6J_]N:1]E^U?VK8_9P_E^;]H39NQG;G.,X[4 7Z*
M@N+ZTM(EEN;J""-R KRR!0Q/0 FFKJ-E)>/9I>6[72#<T"R@NH]2N<]Q^= %
MFBJD.JZ=<QF2"_M98U8J6296 (&<9!ZX!/T%1G7=(6V6Y.JV(MV8HLIN$VEA
MU .<9H OT54?5=.B\[S+^U3R5#2[IE'E@]"W/ /O21:MIT[PI#J%K(\REHE2
M929 .I7!Y'!Z4 7**I+K&EM!-.NI69AA.V603KMC/HQSQ^-6XY$FC62)U=&
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M !1110 4444 %%%% !1110 4444 %><>+?\ DM/@'_KG??\ HJO1Z\X\6_\
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M+O2!V4B3'E@''+-N&%'/M3KGQ)90Z5!J2-FWDN4MW:7,7E$OL.X, 05/4'%
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M9FH:_I^ESI%=O*F_;EQ"[(F3M&Y@,+D^IJ!?%FCM,8C<2*1(T89X'5&97V,
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M)JNI+J'VE!.B)&JS0>;'@!@<KN!.=P/48V]\FM&;0B-+TZULITMI=/=7@?R
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M#$IO'7/&0^.G&,TRR\#?8+=?)O(8[J%HVM[B.S52-@(_>#=\^0Q!Y4<Y !H
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M$3!E52"F[)(VJ0=V>/3BK#>#%-M+:I>".V?E$2!5V$VQMSC!QC!# 8&",=^
M#07Q7HCQAENW)9@JQ^1)YC9!((3;N*X!.0,8!YJQ_;VEC28-3%T#9W&WR756
M)D+?="J!N)/H!FL76-&O[?5[?5]-66:Y6-8#L5&V* V25=E#9)'\0(('4$BK
M%EX=NU\+Z/:278AU&P*2K*$#KYFU@<KQD$.PX(]L4 3V'B2WU37#862--"ML
M+AKGY@HRS+M *]05.<D$=,<'&[BL;1= _LBXN)S=-/)<*/-9D"Y?S))&8 =
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M59!,L0C*@^6S!>7(;:2>. #Q7<>1#O9_*3<WWFVC)[<TJ0Q1JJQQHBJ,*%7
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ME]S72%5)!(!(Z'TJ*:UBGC1'0;4D60 <?,#D'\^: .1\;>)[S0IE6RN($>.
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MYOFR#C'R_,1CBK7_  DVHK.R/?Z6I,US;&-T8/!Y2N?.?YON$H"1@8#K@GN
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MBBB@ KSCQ;_R6GP#_P!<[[_T57H]><>+?^2T^ ?^N=]_Z*H ]'HHHH ****
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M+)$TD4<:X)49/R$DX'WC5>Y\"W#PK%;_ &*-/[.%H5 (!?R)8R< =,R+^ -
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MM076521G/[V2-Q\S $XV-D\<]O31N;6XL]7N=6@B69?L:0I A(9F#LQ[?[5
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MV[M$E8.K,SXC#,P"C'4C)) &?PK:NK'0[^&22ZAL+B%)?,D:0*P60 +DGL<
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MDW*6IC8OF)RF=K26[$.4158GRGYVCJH.>M.U?P7=SZA--:06YM'EEVVB2+$
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MU&Q+;AM^7' "E>#S7:^&- NM!N_$BF(PZ?<212VB><7'^H42'DD@EPW7KUH
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MT_50#8W(G!ACG#*IP4<$HP..<@5QWC?P[K&L+HYBLVU&W@MYH[BT^U^3^^9
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MU""&"[C@598H'9D1@.@+$DCZD_6@#5HHHH **** "O./%O\ R6GP#_USOO\
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MDMG?']HQV<S1YV,Q38&R2-H.0Q&&Y -7]-\1:MJPM[>U6S$DHDF6\>.01R0
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M:Y?>S*,X7L !D\ #J?6J47A*PC7RFFO);=(GB@@DG+) K*5.SO\ =) R3@'
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MM[Q5ZG0 4444 %%%% !@4444 %)@>E+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %><>+?^2T^ ?^N=]_Z*KT>O./%O\ R6GP#_USOO\
MT50!Z/1110 5BZRVJB7-IN\@1DX14.YN<ARS A>G*\]?:MJN4\1RHFJ0J\FJ
MC='M"VMUY,8)+$%NA_A()[97CF@#E=$S_P -$ZUNQN_L.+.WIUBKU6O+-&_Y
M.+US/_0$C[Y[Q5ZG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7G'BW_DM/@'_KG??^BJ]'KSCQ;_ ,EI\ _]
M<[[_ -%4 >CT444 %%%9E^NK&2273YH<)%\D$HXD?)SENJ]L'GOD&@#@=)_Y
M./U[_L"Q_P XJ]1KRCP_)YW[0FL2[@V_0HFW#H<F*O5Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\X\6_\
M):? /_7.^_\ 15>CUYQXM_Y+3X!_ZYWW_HJ@#T>BBB@ K U:\EAU!81J"6D9
MCWEBA)!^<#)VE<$[>"03M('6M^N:U^?R9YBTL;1O J/:O;B595RY;=T.  3P
M?7@Y% '&^'PH_:$U@+MVC08L;1@=8N@]*]7KRK0RK?M$:T4QL.AQ%<=,9BKU
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4$]G:W+*T]M#*5^Z9(PV/IF@#S'0CN_:(UIM^_.A1'=C&>8N<=J]5KR[2?\
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MF7<DB]"/Z'M@\BK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-J=P\ANIY[5'257"C CR N @QR>^<UZ310!S'B3P=%K^A6>EQW$5JEK@1O\
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MD_\ BZ/^$H^+?_0AZ?\ ^!R?_%UZE10!Y;_PE'Q;_P"A#T__ ,#D_P#BZ/\
MA*/BW_T(>G_^!R?_ !=>I44 >6_\)1\6_P#H0]/_ / Y/_BZ/^$H^+?_ $(>
MG_\ @<G_ ,77J5% 'EO_  E'Q;_Z$/3_ /P.3_XNC_A*/BW_ -"'I_\ X')_
M\77J5% 'EO\ PE'Q;_Z$/3__  .3_P"+H_X2CXM_]"'I_P#X')_\77J5% 'E
MO_"4?%O_ *$/3_\ P.3_ .+H_P"$H^+?_0AZ?_X')_\ %UZE10!Y;_PE'Q;_
M .A#T_\ \#D_^+H_X2CXM_\ 0AZ?_P"!R?\ Q=>I44 >6_\ "4?%O_H0]/\
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M_P#0AZ?_ .!R?_%UZE10!Y;_ ,)1\6_^A#T__P #D_\ BZ/^$H^+?_0AZ?\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20170410210550933559.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20170410210550933559.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD) !).
M .I-8-QXX\+VFKII4^NV*7SG B,HX/H3T!^IH WZ*165U#(P92,@@Y!I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2],ERY8(/)D"L5SG#%=I^ZV,'D*<=*Z"@ HHHH **** "BBB@ HHHH ****
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MKF0.2@DRTAR %P#ELR=!TR* *QM? RRS9CA,@AG@DQYI(BD($H./X21C/8Y
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M3^S(99G=&:XD*1O&5\S=UR. 58@ GE<8]:Z.UM(;*W6"!=L:DD+G.,DG^9H
MGHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEOPWXATR\^.U_K/
MC&=84AEG\C[1G9%(AVQJ?3:H./<#O7U)7'Z]\+_!WB2_:_U+1T>[<AI)HI&C
M,A_VMI - 'F7Q%^(W_"=HO@KP3#-?M>.!<7*H0I4-G:N?X<X)8\8%>D^#/AO
MH?ACP[86EQIMA=ZA"FZ:[>W5F:0\G#$9P#P/85MZ#X4T+PO;M#HNF6]FK??:
M-<N_U8Y)_$UL@8H 3 XXZ=*X/XS7<MI\*=::$D-(L<1(/\+2*#^8)'XUWM8O
MBW08_$_A/4M%DD$8NX2BN>BL.5/X,!0!P'[/NG6MM\/#>1QK]IN[J0ROCYB%
MP ,^@Z_B:]3>UMY+F*XD@C>>$$12,@+)GKM/49[U\P^#/B!K/P@N[[PYKNCR
M2V_FF3RMVQT;&"R'&&4X'Y=:ZS3OCEK_ (E\9:?9>'O#1ELBV)X"VZ5P?XM_
M1 O7GCU- 'JGCSPV/%7@C5-("@S2PEH">TJ_,GZ@#\:\F^"OC:/2/A]XBM;X
M@-H@>[C5CR48'Y1_P-?S>O?!T&>M?(_Q<T6Y\)?$#5H+-Y(K+6(Q/M7@.K,&
M9?H)%_E0!W'[/>BRZEK.M>+KT;Y2Q@C=N\CG?(?KC;_WT:[OXY_\DFU3_KI!
M_P"C5K;^&_AS_A%? 6EZ:Z;;@Q>=<<<^8_S$'Z9Q^%4?B_I5WK/PQU:UL86F
MG4)*(T&68(X8X'<X!./:@#,^ W_)*[/_ *^)O_0S7)_M+3N--\.P G8\T[L.
MQ(" ?^A'\Z9\!_'L(M[3P2;"47&Z:87.\;<?>P1USVKK/C?X-O?%?A&&?3(F
MFO-.E,PA49:1",,![\ X]C0!V?@ZS@LO!6B6]N@CC6QAP%]2H)/U))/XUX1J
M<$>F?M2VXLU$8DO8G8+ZR1C?^>X_G4GA7X_/H'ANWTG5=$DN;NRC$$<B2A-Z
MKP X(R"!QWZ4GPQTG6?'OQ1D\=ZE;F*RAD:;?M.UGV[4C3/7:,$GV'<T >K?
M&3_DDVO<'_5Q_P#HU*Y_]GJVBC^',LR(JRS7TGF.!RV%4#)]OZUO_&3_ ))-
MKW_7.+_T:E8O[/A_XMG]+Z7^2T >JU\V_%+_ ).#T+_KI8_^C:^DN@KYM^*7
M_)P>A?\ 72Q_]&T ?25%%% !1110 4444 %%%% !1110 4ULX&/6G4UNW)Z]
MJ ./^T^%/(V,LBQ1'<OF1RJ&+;1P3][.$_ Y[TR74?#$4;!3<7COC>4+NS!E
M8;B?99#D]MP]*0ZAX?>RBE?3[N(D@1*0RNIP",'. VU%;KG%337'A9DD2YEE
MA24JV9'D56((7<#GU&"?13VS0 7;>&;D+/*US^Z<RJR"4$$,S>9@#[H8O\W3
M\A4K#0-/U'RA'<&2WS)D;V1"FS)'JW*9_6JFM?V1YMG:>7>P+- '$T$3$>2=
M[%"<Y'&X]#[U;>;PWJ$E[>+OE:%E$K+(Z@%G"[@,XSE "?\ 9H J%_#>NPVE
MI%-<0,Y$5M@NFX1LVQO]H9#[2??N*N7IT)YTT2X,_FARFQ9&#.)%+OD@Y8'#
M9]ZJ17GAO3((I;.WOP0,1PIYN_!Y VD_]--P'^T3Q6E-J6AR))<21R_-*@(,
M3@NY#1I@=\X91]* *$DOA.XC:Z9Y L#"!TW.ISL  *]^ .?7WK6FU/19HFO9
M9@4DMMN[YOFB=B.!]1SW%94;>'XWFM_[/NU<%H]SHYD?[CDJ2<\8![8VU(UY
MH.HO8,SS2P*K00J\3GS!*"N[<>2I"L/>@">>_P!#$4<\T]TBVSI'Y7[W(8DA
M%9 ,D@J<<<'!]*4S:#9/'!+'*9+=]XWPNY\QU''0[GVL..H%5T30)[T026MX
M)HKK;F5I-K2*Y"NQ!P06) )]:2>]T1=6EN9A=S222AR &V1^6I&\ <$?NV!;
MVQ0!+<W?AW47\ZZ\UI=N4WHX8KM;E1Z;78\=N>W%RXETZXO+>3[1<F=7>)#;
ML_/W68';U4?+ST'2LNWO?#R1VMPMO/!*\2W%OYX?=&IP!M&>  1P.V1ZBK-B
M=%ATJQ3=.B6H8(S(\39VAV! _O AMO?\* *Z-X8WR1Q_:7>2;+Q*LK$LO 4@
M#C[XP/\ Z]$$GAZTM;<,+H1SVXG17+N0C*X+''3Y2Q)-+;GPRB3")+B)A&DI
M9C*K[-RJC*?3(4#'H?>II;CP_!;6[R03)&;(1Q[D<;8#\B@Y/!.[ SR<T 6)
M[W2+62[L)8IEVLDDAV,P9@BL,,.X" XXX4FJ1O/"YB<HLLRMN<!$D;S20CL%
M_O<*I('0?C4TU_X?U" W;QSR(\H=94209=4(W*1_=4'/IBJ,ESX76RM5%M=B
MWP?*=%E7:&0C.[.0&5,#U'US0!9FD\.C3%TZ664+L%PD'F,)/N@@ @]-K8].
M&]#1_:OANSNTOWDEM[B7+LK*X8Y^;YEQG/S\?45-J;>';%+:\OK8*'A"12^6
MQ(4*5 ]<X<@#KR/05&SZ#=WL4(M;DRS/Y+@!T"G:0!)R,<1G _QH 1[+PVMG
MYTC31P@.W[QY/E$75"IZ!<?=]C[TZS319M+M[#S9OW#!EP'B?=(2O(ZX;S.A
M['/O0MSI&L6]JC)/;Q>:;QHYHB,M@N5)YP<-NQZ&H7F\.6BQ3217:;!'*I?S
M1GYL1ALG!Y3@'LM $JKX<M'DTY/.62$[1$-^Z('!!4#HHV9SVQFD67PU;M:1
MAY(G+-/$6,@9MW)8]\,4S[XJM<W_ (8AO6D:&Z,KL&>1#(-JD,P[C"L688[[
MN>*NR7&@6-A:ZFSW"6S(427S)#A>>&YZ#)QZ=J &RMX?NH[TLDUP)H#=2Q?/
M\R [OE';)&<=ZB_M?P\D,'VB2\@\AG5/.61';H7!_O#H2.W%2&Y\.VM@MW()
MDB.ZVVR[PWSC>WRD]2I+9Z\U"MUX:>2* K/]HMPYC(=S)RV",@Y); Z]<^^*
M )9X_#&F73Q74H,HC^>*=V?<N%P<'T 7&.F&]#2Z9<>'WU"$VGGO/P(YWWL,
MD,NTGH" I SV I);W0-1N'FN=+N3<+F'$EL^YAN>, ?7Y\#KQ["FP7_AWSH+
MN(W,C+]QV,A\S;OP0#]XABX!]30!!<GPR]RLCI=R"61P65I-J!27;([)G))]
MZN6LOAVVL3J,4LK6T@-N[,78<#'S>F  .>V*==P^'H-\UU',LC8D;S&DWL'R
M,8ZD84@CL.*J'4-!NX#836VHM%!,T05UDW.Y"Y48Y/W\$'IB@"S9ZKH6F-*U
MH;AYIBBL2DC,X#>6K<_P@G;GVKJ:YFVAT'5+N*."&4ND64D7S%1T5@V,]&PS
M@X]?I734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44$X&365
M/K]G!>3VY\]OLZDRR)$61&"AMA(Z,5(('?([X% &K165:Z]9W>KOID3R&XC1
MG/R?*=K!6 ;H2I8 CW]C5*Y\9:5:LQD>?R@Q E6$F-E#A&8-T*JQ )]QV(-
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M@@@TO4KHS/!&IB$0"M,GF(#N<?PY^F*@O/B7I-E96UT\%V4N8HI4!,4>!(9
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MG)!RI-;ZVWBR[U&0RM<6MM-<QNODM&A5"^'#'!8[4C ![F7V&*HM_&TNK1S
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M' QUWP,# [4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.X!\MBK2*8P5&5)!RH V\< =1T-3_P!H>'C,8VMWVQ1FW\U8VV)%]T<CL=^
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MQ+%)9AHUSA"[8QD'&,],@8'08XK-TK4M#BMYKC36DD#S1QRREV8MGY5;+$\
M# [X%2/XTTN&11(+E4:/>'>$J/4#GN5.X>WO0!HRZ#ID]Q)/):AI),[SN;!!
MQD8SC!P,COCG-:58DGBO2H0[R23+"F2TQ@<( &VYSCIN&!ZFIM+URUU2:6.U
M69EB56+LF%))(P#W(VG- &K1110 4444 %%%% !1110 4444 %%%% !1110
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MS%S)<>=-N"G<[!@G/&"S= .1GK@UG^9H%C9:89=,O/-(,1*2-OAV@*Q+!AD
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MYOL_VI$EDEW;#(3N&/FXPSG.,#)S4ZZGH<[VT;).WDEY())5<[B@WL02<G&
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M4;..,@&JFBV<5Y;W,42QF NR(H &Y@ 6]<X %/71[!$V+:1*#N! '9@ WY@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUX6N=2,"6BIJ$CM$T31E9 <@D?0'GC@8)'2ML>'M*"[?L49'/#$M@<# R>
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M1[$=J -@'(!Z9]:6CH,"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1NP]^OI2TA&: ./&JZ9-8?:9]#!5!N@B2,LS! Q
MZ%5& !V)'-3/X@T**]@'V*;[0 6A9+<'*EB"RXZC<3QUR>G-:Y\.Z283";0&
M(G.PNV!UZ#/ .3D#KFH[;PUI]M>RW85WED8$$M@* 2=HQCC)Z'V]* ,BSO\
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M* "BBB@ HHHH ***YK5_&VG:->WUI-#=22V5NMS,(T7 C.?FR6'<8^K#MD@
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M N8]5AOG^SVR)(&-K;,?*"A9!_=&6_> YX'6@"G_ &7KUUH5Y]NM-'35C*3
MEO>SB%@61FWOM# Y7. .P]36;!9^.8KR:XBL/"S3NA1]VIW3[58[B "GR@GG
MBK&I>"M2OKR^NENK827;22_.IS#*J.D# X^;"N W3@<9JWX5\*7FA7S27#6K
M(JL T.XN^Y8AAL@# \LD=?O=L<@%35-)U==-TJRTNP\/&VM;06\L5Q?3HBG
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M5_(_X5:^SP_\\8_^^12_9X?^>2?]\B@"I_;.G_\ /ROY'_"C^V=/_P"?E?\
MOD_X5;^SP_\ /&/_ +Y%'V>'_GDG_?(H J?VSI__ #\K^1_PH_MG3_\ GY7_
M +Y/^%6_L\/_ #QC_P"^11]GA_YXQ_\ ?(H J?VSI_\ S\K^1_PH_MG3_P#G
MY7\C_A5O[/#_ ,\D_P"^11]GA_YXQ_\ ?(H J?VSI_7[2OY'_"IK>^M[HGR)
M5?;]X#K^M2_9X?\ GE'_ -\BLJXC2#7[1HE"^8"& [_A_GI0!LT444 %%%%
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M<42VSPLXXDPH //7*L>><L?2I]9@$=_%=MJWV1G*Q0B1F"%@&)4\@?-QGO\
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M\\XZ<#(.* .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2&'%:]S:6]Y 8;F".:,G.R101D<@_G44>EVB&4M"LAEF$S&10?F  7'I@
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M:_\ (Q2?]<!_.M2LQ/\ D8G!_P"> _G6G0 45&\\<;A&=%8\X9@.*>&RI.*
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MTK.%QGO[T .HI"<=J7M0 44T-][VZ\TN[ 8G@#WH 6LB^_Y#MCQV/:M8'/\
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MYW!2&;.!\NX@[<D$=N,5Z9'/%+(ZQR(S+C<%8$C/3-5[S5+*PB:2>=% D6+
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MNHM'%:1.JVK0*ZEV&/,R>0PZ CMD=S6I"LD5NJRR>;(J@,^ N\XY..@S4M%
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M8;G8*3M[;0&'X_2M>*QMH,>3;PQ@+L 2,#"YR1QVSVJ5(D0@A5&!M&!C ]*
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M)')(X&[*QMC';_6H*U'MHI%*R1HP*[2&0'(].>U'V6'_ )Y1XX_@'M_@/R%
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M!57J2< 4 +61??\ (=L>.Q[5KUD7W_(=L>.Q[4 :]%%% !1110!F+D^(I/\
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M=.HP&'MUJXMC:+%Y2VT(CV[-HC&-N,8QCICBI%@BC!$<:H"<D*H&3Q_@/RH
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MRV<$9/&!D<]^U;=SIUG>1LD]O&X8!3E1D@,& ^F1TZ4\6=LK!EMX@P  (09
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LB^_P"0[8\=CVK7K(OO^0[8\=CVH UZ*** "BBJ%S'J9G'V66T2'9R94=FW
M<^C#C&/UH B3'_"12=,>0/YUJ5C6=PEUK'VB-MR/; J0"._H?>MF@!"3G %
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MB#<(R&)TP4#?/PV#C9CW#>M7##J"-9FYEFE+74KE3C"</Y0^4?=^[USSUYH
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M_#*W>K75S/,5@DC942,\AF7:S'(]/\CG.Q/9I<" .S#R95E7!ZD9P#^=6:*
M*.FZ7!IBR+"SMOVYWD'H,"JG_".6^^V83SCR(?) !&' 5U&>,\"1NF.OM6S1
M0!2@TV*WGCE1W+1VZVXS_=!SGZU5N- @N+F2X,LJ2,_F#;CY7*A689'=0!@\
M<9Z\UKT4 84WAF!_)CBE>*!7=I4&"65HQ'M!(X&!UZ^]36_AZUMG1TDFW(I1
M#D?*I4(!T[*  >OKFM>B@#"B\+6D=I]F,]P\3+,LH9AF02'+9( QS@@C!^M7
M(=&@@TE=/227:K^8)"06W[]X;I@G=S6C10!2T[2X-+C>.W+;7?>=QR<[0O\
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MLNK_ /02M?\ P#/_ ,<H^RZO_P!!*U_\ S_\76E10!F_9=6_Z"-I_P" 9_\
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M:6150VI; 5V4<[QGI5G[+JW_ $$+3_P#/_QSWI-!_P"04/\ KO/_ .C7K3H
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MB@#"U,ZO8Z?-<K?6;%!G:;,\Y./^>GO5O[+JW_00M/\ P#/_ ,<_SFF^(O\
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MP)SB@#UJBO'+GPEX3M[F.-?#>E2EY8X1")IP[G8CNP.2,;7. >N!SS@0G1/
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MM&K_ //E#_W\_P#KUIT4 9$W]HW$9CGTVVEC/5'<,#Z<&JU[87&H6?V2XTJ
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MN:U:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g20170410210550394558.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20170410210550394558.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% /\# 2(  A$! Q$!_\0
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g20170410210544195557.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20170410210544195557.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% /\# 2(  A$! Q$!_\0
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g20170410210543884557.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20170410210543884557.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" 20# 2(  A$! Q$!_\0
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M7AS2;JWOVF$DDWF+Y<>X8P!_2NETW[+;4Y%47MGKH>OT5%;7"7=K%<19\N5
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M_#5KH=JJ@!Y\?,_^%>,?&#2)[?Q(][&C/!-R2HSM/'6O>KV^@T^V:>=PJ@<
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MR]DI7U,53BZSC;0[FSMA96-O:JQ988UC#'J<#&:Q?&7B ^'= DN8@#<R-Y4
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MY966,.D8:3_?/)_4UKT45Y[=W<]-*RLCR7XM_P#(7TW_ *X-_P"A5M?"7_D
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
